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Abstract 
The emergence and spread of drug resistant (DR) tuberculosis (TB) strains in the form of 
multidrug resistant (MDR)- and extensively drug resistant (XDR)-TB is a major threat to the 
global fight against TB. Treatment for these forms of TB is prolonged, up to 24 months, and 
involves the use of a combination of highly toxic, less potent anti TB drugs. In 2015 alone, 
the World Health Organisation (WHO) estimated 580,000 new MDR-TB cases across the 
world. Nine African countries are listed as high MDR-TB burden countries by the WHO.  
A review of published research revealed that diverse genotypes are associated with DR TB in 
Africa, and demonstrated that DR TB strains are associated with community and nosocomial 
outbreaks. Furthermore, the role of migration in the transmission of DR TB strains has been 
demonstrated in certain parts of Africa. Of concern is the under-use of molecular 
epidemiological tools, resulting in gaps in knowledge of the transmission dynamics of DR TB 
on the continent. This study aims to address some of these gaps by describing the molecular 
epidemiology of DR TB in regions of the Copperbelt province and Northern regions of 
Zambia. 
We used molecular strain typing tools of whole genome sequencing (WGS), Sanger (targeted 
gene) sequencing, insertion sequence 6110-restriction fragment length polymorphism 
(IS6110-RFLP) and spoligotyping to describe the genotypes of DR Mycobacterium 
tuberculosis (M.tb) strains circulating within parts of Zambia. We demonstrated that a variety 
of genotypes are associated with DR TB in Zambia. The predominant genotype was lineage 
4, with majority of strains belonging to Latin American Mediterranean (LAM). Other 
lineages belonged to 2 and 3. The genotyping analysis showed clustering of strains among 
patients being from different regions of the country thereby suggesting that DR TB is 
possibly widespread across the country. In addition, this analysis also identified household 
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transmission of MDR-TB between two household contacts, placing emphasis on the need for 
routine tracing of MDR-TB patient contacts in Zambia. 
Further analysis of WGS and Sanger sequencing data identified 8 pre-XDR-TB cases. These 
belonged to lineage 4.6.1 (Uganda lineage), lineage 2.2 (Beijing genotype) and lineage 4.3 
(LAM), giving a preliminary first insight into the genotypes associated with pre-XDR-TB in 
Zambia. Alarmingly, transmission of these pre-XDR-TB strains was demonstrated, with 
clustered strains sharing identical drug resistance-conferring mutations and low nucleotide 
variance differences. This finding emphasises the need for more comprehensive drug 
susceptibility testing, as failing to identify second line resistance may place the patient at risk 
of acquisition of additional resistance when treated with a standardised MDR-TB regimen. 
Nosocomial transmission of DR TB has not been described in Zambia, despite the high risk 
of transmission in health care facilities. Assessment of the knowledge, attitudes and practices 
of health care workers at MDR-TB health care facilities in Ndola district revealed knowledge 
gaps and administrative deficiencies which could be placing these critical personnel at risk of 
acquiring DR TB at the work place. Findings highlighted continuous infection prevention and 
control trainings and provision of adequate personal protective equipment (PPE) as key areas 
of improvement. 
The current study provides a first insight into the genetics of DR TB strains circulating in 
Zambia. These findings address knowledge gaps and contribute to our understanding of DR 
TB in Africa. To address the DR TB epidemic in Zambia, the TB control program need to 
expand the Xpert test-and-treat diagnostic strategy to all people entering healthcare facilities 
with symptoms of TB. More comprehensive drug susceptibility testing needs to be done to 
ensure patients are adequately treated. Following diagnosis of DR TB patients need to be 
counselled to initiate treatment and families and close contacts should be screened for TB.  
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Opsomming 
Die opkoms en verspreiding van middelweerstandige (DR) tuberkulose (TB), spesifiek die 
multi weerstandige (MDR-TB) en uiters weerstandige (XDR-TB) vorme van TB is 'n groot 
bedreiging vir die globale stryd teen TB. Behandeling vir hierdie vorms van DR TB word 
verleng, tot 24 maande, en behels die gebruik van 'n kombinasie van hoogs toksiese en 
swakker anti-TB-middels. In 2015 het die Wêreldgesondheidsorganisasie (WGO) beraamd 
daar is 580,000 nuwe MDR / rifampisien weerstande (RR) -TB gevalle regoor die wêreld. 
Nege Afrika-lande word deur die WGO as hoë MDR-TB lande gelys. 
'n Literatuuroorsig het aan die lig gebring dat diverse genotipes met DR TB op die vasteland 
geassosieer word, en getoon dat DR TB-stamme geassosieer word met gemeenskaps- en 
hospitaal uitbrake. Verder is die rol van migrasie in die oordrag van DR TB-stamme in 
spesifieke dele van Afrika gedemonstreer. Daar is kommerwekkend min molekulêre 
epidemiologiese studies, met ‘n gevolglike gebrek in kennis oor die transmissie dinamika van 
DR TB op die vasteland. Die doel van hierdie studie is om sommige van hierdie leemtes aan 
te spreek deur die transmissie dinamika van DR TB in dele van Zambië te beskryf. 
Ons het genotipiese onderskeidings tegnieke, spoligotipering, IS6110-restriksie 
fragmentlengte polimorfisme (IS6110-RFLP), heel genoomvolgorde bepaling (WGS) en 
Sanger volgordebepaling gebruik om die genotipes van DR Mycobacterium tuberculosis te 
beskryf wat in dele van Zambië sirkuleer. Ons het gewys dat 'n wye verskeidenheid genotipes 
geassosieer word met DR TB in Zambië. Drie van die vernaamste stamme is gevind (linie 2, 
3 en 4) met die oorheersende genotipes wat behoort in linie 4 (Latyns-Amerikaanse 
Mediterreens (LAM)). Groepering van stamme onder pasiënte uit verskillende streke van die 
land is getoon, wat daarop dui dat DR TB moontlik wydverspreid oor die land voorkom. 
Hierdie analise het ook huishoudelike oordrag van MDR-TB geïdentifiseer, wat klem lê op 
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die behoefte aan roetine opsporing van MDR-TB-pasiënt kontakte in Zambië.  
Verdere analise van WGS en Sanger volgorde bepalingsdata het 8 pre-XDR-TB gevalle 
geïdentifiseer, wat aan linie 4.6.1 (T1 genotipe), linie 2.2 (Beijing genotipe) en linie 4.3 
(LAM) behoort. Dit is die eerste beskrywing van genotipes wat verband hou met pre-XDR-
TB in Zambië. Oordrag van hierdie stamme is gedemonstreer, deurdat groepe dieselfde 
weerstandsmutasies het, asook beperkte variasie in die heelgenoomdata toon. Hierdie 
kommerwekkende bevinding beklemtoon die behoefte aan meer omvattende 
middelweerstandigheidstoetse, aangesien versuim om tweede-linie weerstand te diagnoseer, 
die pasiënt se risiko verhoog om addisionele weerstand op te bou, indien ‘n 
gestandaardiseerde MDR-TB-regimen gebruik word. 
Hospitaaloordrag van DR TB is nog nie voorheen in Zambië beskryf nie, ten spyte van die 
hoë risiko van oordrag in gesondheidsorgfasiliteite. Assessering van die kennis, houdings en 
praktyke van gesondheidswerkers by MDR-TB gesondheidsorgfasiliteite in Ndola-distrik, het 
gebrekkige kennis en administratiewe tekortkominge onthul, wat hierdie kritieke personeel in 
gevaar sou stel om DR TB in die werkplek op te doen. Ons bevindings beklemtoon die 
belang van deurlopende infeksie voorkomings- en beheerpraktyke en die voorsiening van 
voldoende persoonlike beskermingstoerusting (PPE) as sleutelareas van verbetering. 
Hierdie studie is die eerste beskrywing van die genetika van DR TB-stamme in omloop in 
Zambië. Hierdie bevindings vul ons kennis aan en dra by tot ons begrip van DR TB in Afrika. 
Om die DR TB -epidemie in Zambië aan te spreek, moet die TB-beheerprogram die Xpert 
toets-en-behandel strategie uitbrei sodat alle mense met TB simptome bereik word. Meer 
omvattende middelweerstandigheidstoetsing moet gedoen word om te verseker dat pasiënte 
effektief behandel word. Na die diagnose van DR TB by pasiënte moet beraadslaag word om 
behandeling te begin en gesinne en naby kontakte moet vir TB gesif word. 
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Chapter 1: General Introduction 
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1.1 Global burden of drug resistant tuberculosis 
Tuberculosis (TB) caused by Mycobacterium tuberculosis (M.tb) remains a major cause of 
death worldwide and it is the number one cause of death amongst HIV infected individuals 
(1). The global TB epidemic is driven by factors such as development of drug resistance, the 
HIV epidemic, poverty and weak health care systems (1). In 2015 alone, the World Health 
Organisation (WHO) estimated that there were 10.4 million new TB cases of which the 
highest burden (60%) was seen in just six countries; India, Indonesia, China, Nigeria, 
Pakistan and South Africa (1). An estimated 2.7 million TB patients live in Africa where 16 
of the 30 high TB burden countries are found (1). This region continues to experience high 
HIV/TB co-infection rates, with some regions in Southern Africa experiencing co-infection 
rates higher than 50% (1). Zambia has recently (2016) been included amongst the top 30 high 
TB burden countries, other countries recently included are Angola, Central African Republic, 
Congo, Democratic People’s Republic (DPR) of Korea, Lesotho, Liberia, Namibia, Papua 
New Guinea and Sierra Leone (2). Of concern is that 9 out of 10 countries recently included 
amongst the high TB burden list are found within the WHO Africa region (2). 
Exposure to M.tb has varying outcomes dependent on host genetic and immunological 
factors, the pathogen strain and environmental factors (1, 3). Exposure to M.tb, defined as 
contact with aerosolized bacilli, can result in either active infection, latency or no infection. 
Latent TB infection (LTBI) is described as the presence of M. tuberculosis in the body 
without clinical signs and symptoms, or radiographic or bacteriologic evidence of TB disease 
(4). Exposure to M.tb results in infection in approximately 20-50% of individuals. From these 
infected individuals, 2-10% will develop active disease while 90-98% remain latently 
infected with a lifetime reactivation risk of 5% (4, 5). Infection with M.tb can result in 
pulmonary and/or extra-pulmonary TB (1). 
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Treatment must be guided by the phenotypic drug susceptibility pattern of the infecting strain 
(Table 1.1), however globally most treatment is started without phenotypic drug 
susceptibility testing (DST) data. Treatment of drug susceptible TB relies upon a daily 
combination of anti-TB drugs over a period of 6 months, with a 2 month intensive phase 
followed by a 4 month continuation phase (6). Multidrug resistant (MDR)- and extensively 
drug resistant (XDR)-TB are treated over longer periods of time with a daily combination of 
anti-TB drugs which are less potent and more toxic than first line anti-TB drugs (Table 1.1) 
(7). Treatment adherence is a challenge due to the length of the treatment regimens, 
especially in the absence of a fully functioning TB control program. Strains resistant to all 
currently recommended anti-TB drugs, termed as “totally drug resistant” (TDR) TB and 
“extremely drug resistant” (XXDR) TB, have been described in various parts of the world, 
with initial cases identified in Italy and later described in Iran, India and South Africa (8-11). 
However, currently WHO does not recommend the use of the terms “TDR-TB” and “XXDR-
TB” to describe strains showing in vitro resistance to all first and second line anti-TB drugs 
(12). This is due to the technical challenges of phenotypic DST for some second line anti-TB 
drugs and there is not enough data supporting a correlation between phenotypic DST results 
and the clinical response/outcome to treatment (12). Furthermore, the initial cellular and 
molecular classification of TDR-TB isolates, which was based on microscopic findings, is 
unclear and untestable (13). 
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Table 1.1: WHO recommendations for treatment of active drug sensitive and drug 
resistant TB, subject to phenotypic DST results (6, 7). 
Regimen Anti-TB drugs Duration of treatment 
Drug susceptible TB 
(first line treatment) 
H, R, E, Z or S 6 months  
2 months intensive phase (RHZE) followed 
by 4 months continuation phase (RH) 
8 months retreatment; 3 months intensive 
phase 2 months S(RHZE)/ 1 month (RHZE) 
followed by 5 months continuation phase 
(RHE) 
Longer WHO approved 
MDR-TB regimen 
(second line treatment) 
Injectable drugs: Km or Am or Cm 
FQs: Lfx or Mfx or Gfx 
Other core agents: Eto, Cs, Pto, Trd, 
PAS, PAS-Na, Cfz 
Add on agents: Z, E, high-dose H, 
Bdq, Dlm, Ipm, Mpm, Amx-Clv 
20 months  
8 months intensive phase e.g. (Km-Lfx-Eto-
Cs-Z) and 12 months continuation phase e.g. 
(Lfx-Eto-Cs-Z) 
Short WHO approved MDR-
TB regimen 
Gfx or Mfx, Km, Pto, Cfz, high-dose 
H, Z and E. 
 
9-12 months 
4/6 months intensive phase (Gfx or Mfx, 
Km, Pto, Cfz, high-dose H, Z, E) and 5 
months continuation phase (Gfx or Mfx, 
Cfz, Z, E) 
XDR-TB treatment    
 
Km, or Am or Cm, Lfx or Mfx or 
Gfx. 
Eto, Cs, Pto, Trd, PAS, PAS-Na, Cfz. 
Z, E, high-dose H, Bdq, Dlm, Ipm, 
Mpm, Amx-Clv 
24 months  
Drug combination is subject to DST results 
Abbreviations: Am, amikacin; Amx-Clv, amoxicillin-clavulanate; Bdq, bedaquiline; Cm, 
capreomycin; Cfz, Clofazimine; Cs, cycloserine; Dlm, delamanid; E, Ethambutol; Eto, 
ethionamide; FQs, Fluoroquinolones; Gfx, gatifloxacin; H, Isoniazid; Ipm, imipenem-
cilastain; Km, kanamycin; Lfx, levofloxacin; Mpm, meropenem; Mfx, moxifloxacin; PAS, 
para-aminosalicylic acid; PAS-Na, para-aminosalicylate sodium; Pto, prothionamide; Z, 
pyrazinamide; R, rifampicin; S, streptomycin; Trd, terizidone. 
 
Drug resistant TB can either be as a result of infection with an already drug resistant strain, 
termed primary resistance, or can be acquired during the course of treatment, termed 
secondary resistance (1, 14). Drug resistant TB, in the forms of MDR/rifampicin resistant 
(RR)- and XDR-TB, continues to be a major public health concern globally (1). MDR-TB is 
defined as resistance to isoniazid and rifampicin, the most potent anti-TB drugs, while XDR-
TB is defined as MDR-TB with added resistance to any of the second line injectable drugs 
(aminoglycosides) and any fluoroquinolone (FQ) (1, 14). Rifampicin resistance is defined as 
a proxy for MDR-TB and rapid detection of resistant strains is recommended (1). There were 
an estimated 480,000 new MDR-TB cases and 100,000 new RR-TB cases reported across the 
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world in 2015 with China, India and Russia accounting for 45% of cases (1). Nine additional 
countries, 7 of which are found within the WHO Africa region, were included in the high 
MDR-TB burden list namely; Angola, DPR Korea, Kenya, Mozambique, Papua New Guinea, 
Peru, Somalia, Thailand and Zimbabwe (14). A total of 117 countries have reported XDR-TB 
globally (1). It has been estimated that 9.5% of MDR-TB cases are XDR-TB, however the 
case detection rates for both MDR-TB and XDR-TB remain poor (1). Co-morbidity with HIV 
and other diseases such as diabetes mellitus worsens the progression of these diseases (1). 
However the molecular epidemiology of both TB and HIV are not well characterised in 
Zambia (1). The TB epidemic in Zambia is largely driven by the HIV epidemic, with a 
HIV/TB co-infection rate as high as 60% (1).  
 
1.2 Mycobacterium tuberculosis genetics 
The genus M.tb belongs to the M.tb complex (MTBC), a genospecies with a high level of 
homology. The other members of the complex are Mycobacterium africanum, 
Mycobacterium bovis (including the Bacillus Calmette–Guérin (BCG) strain), 
Mycobacterium caprae, Mycobacterium microti, Mycobacterium mungi, Mycobacterium 
orygis, Mycobacterium pinnipedii, Mycobacterium suricattae and the dassie bacilli (15, 16). 
A former member of the MTBC, Mycobacterium canettii, which is part of the ‘smooth 
tubercle bacilli’ has been described as sharing the most recent common ancestry with species 
of the MTBC (17). Species of the complex share 99.9% similarity at genome level (15, 18). 
However, there are differences in host range, pathogenicity and phenotypes (15). Exclusive 
human pathogens are M.tb, M. africanum and M. canettii (15, 19), it is however likely that 
other members of the complex are yet undiscovered. 
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Phylogenetic markers have been identified and whole genome sequencing (WGS) of M.tb has 
enabled better understanding of the organism (18). Knowledge of phylogenetic markers 
coupled with molecular typing tools is beneficial in investigating M.tb evolutionary and 
transmission events (18, 20, 21, 22). Molecular epidemiological studies of MDR- and XDR-
TB reveal the major genotypes in circulation across the globe to be the Euro-American 
(Haarlem, LAM and T), East Asian (Beijing, Beijing-like) and East African-Indian (CAS) 
(Figure 1.1) (11, 19, 23, 24, 25). Genotypes such as the Beijing family are widespread across 
the world from its initial origin in Far-East Asia (26, 27, 28). Furthermore, the Beijing 
genotype family has been widely associated with MDR- and XDR-TB outbreaks across the 
globe (11, 26, 27, 29). 
 
 
Figure 1.1: The global distribution of extensively drug resistant TB genotypes (24). 
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Since mid-1990s, several techniques have been validated for use in molecular 
epidemiological investigations of M.tb strain diversity and clustering including spacer 
oligonucleotide typing (spoligotyping), insertion sequence 6110-based restriction fragment 
length polymorphism (IS6110-RFLP) and Mycobacterial Interspersed Repetitive Units – 
Variable Number Of Tandem Repeats (MIRU-VNTR) (20, 21, 22). Furthermore, next 
generation WGS of M.tb clinical isolates provides invaluable knowledge on genetic diversity 
and microevolution of the M.tb genomes in circulation (18). Whole genome sequencing is 
preferred to other typing techniques due to the robustness and high resolution offered by the 
technique (18). It however does not negate the usefulness of other typing tools due to 
limitations experienced in resource limited countries such as Zambia. These include the lack 
of expertise to set up libraries and to analyse sequencing data, the cost of equipment and the 
general running cost. 
The burden of DR-TB and drug susceptible TB is highest in resource constrained 
communities across the world. It is in these regions that the molecular epidemiology as well 
as the transmission dynamics of M.tb is largely unknown. Genetic diversity has been 
demonstrated amongst isolates associated with DR-TB across the world with certain 
genotypes being more predominant in particular regions and population groups (19. 24). Six 
major global lineages have been described, with varying distributions across the world (Table 
1.2). Treatment success of DR-TB has also been associated with the infecting genotype of 
M.tb, with particular genotypes being strongly associated with high rates of resistance as well 
as development of MDR- and XDR-TB (30, 31).  
Knowledge of DR-TB strains in circulation within a population group is particularly 
important for the national TB control program as it gives a better understanding of 
transmission dynamics, whether drug resistant TB is being acquired or transmitted, and 
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allows for better management of outbreaks in the population (11, 27, 29).  The usefulness of a 
standard TB regimen can be guided through molecular investigations by identifying 
resistance-conferring mutations in key drugs. Furthermore, findings will guide diagnostic 
developers and drug/vaccine development efforts by defining strains present in the study 
population. 
 
Table 1.2: the major global MTBC lineages and families (19). 
Linage number Lineage name Family 
1 Indo-Oceanic EAI 
2 East Asian Beijing, none-Beijing 
3 East-African-Indian CAS, CAS1-Kili, CAS1-Delhi 
4 Euro-American LAM, Haarlem, S, Uganda, 
Cameroon, H37Rv-like, X 
5 West-African 1 AFRI_2, AFRI_3 
6 West-African 2 AFRI_1 
Abbreviations: CAS, Central Asian; EAI, East African Indian; LAM, Latin American 
Mediterranean.
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1.3 The global epidemiology of drug resistant TB 
Case detection of DR TB remains low across the world. Of the 580,000 incident cases of 
MDR/RR-TB estimated in 2015, only half were started on treatment, falling short of the 
WHO target of 75% of MDR-TB cases being started on treatment (1). Trends in drug 
resistance are poorly characterised as there is very limited drug resistance surveillance in 
countries across the world. From the 30 high TB and high MDR-TB burden countries, only 
50% had repeated a drug resistance survey to assess MDR-TB trends (1). Resistance trends 
for XDR-TB are even more poorly evaluated with only 6 out 30 (20%) high TB and MDR-
TB burden countries establishing continuous national surveillance for XDR-TB (1). It has 
further been demonstrated that as high as 51% of MDR-TB cases are resistant to at least one 
fluoroquinolone or injectable agent or both (1), reinforcing the need to improve efforts in 
case detection and treatment of MDR/RR- and XDR-TB globally. 
The global spread of MDR- and XDR-TB has been attributed to several factors including 
transmission within the community and inadequate infection control measures (1). 
Transmission of drug resistant TB has been described in vulnerable population groups 
including HIV positive individuals and hospital transmission has been described amongst 
patients as well as health care workers (HCWs) (31, 32). It is estimated that over 50% of new 
MDR-TB cases occur among individuals without prior TB infection and treatment (1). In 
some modelling studies estimates are as high as 95% (33, 34), implying that a large 
proportion of drug resistant TB is being transmitted. 
According to WHO, the continents and countries with the highest burden of MDR- and XDR-
TB burden are Africa (DR Congo, Ethiopia, South Africa, Nigeria), Asia/Eurasia (Armenia, 
Azerbaijan, Bangladesh, China, India, Indonesia, Kazakhstan, Kyrgyzstan, Myanmar, 
Pakistan, Philippines, Tajikistan, Uzbekistan, Viet Nam) and Europe (Belarus, Bulgaria, 
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Estonia, Georgia, Latvia, Lithuania, Moldova, Russia, Ukraine) (1). The global spread of 
specific M.tb genotypes is attributed largely to immigration and travel (19, 35). Drug resistant 
TB strains are mainly introduced to developed countries by economic migrants from 
developing nations (36, 37, 38). Molecular epidemiological investigations have revealed a 
strong association between M.tb genotype and geographical distribution/population groups 
(19, 30).  
In parts of Africa, with an exception of South Africa were the population structure and 
transmission dynamics of drug resistant TB have been extensively described (11, 32, 37, 38), 
there is very limited knowledge on the molecular epidemiology of DR-TB. For instance, 
currently there is no published data on the genotypes associated with DR-TB in Zambia. This 
is concerning as it means that the transmission dynamics of drug resistant TB are largely 
unknown for Africa as a whole. This research aims to bridge some of the gaps in knowledge, 
with a specific focus on Zambia. 
 
1.4 National TB and Leprosy Control Program (NTLP) Zambia  
In the first national prevalence survey, conducted in 2013-2014, the prevalence of all forms 
of TB was estimated to be 455/100,000 population (39). In 2015, WHO estimated 1,500 
MDR/RR-TB cases (1). From the estimated MDR/RR-TB cases, only 196 (13%) laboratory-
confirmed cases were reported and only 50% of the laboratory confirmed cases were started 
on treatment (1). These statistics are similar to trends seen in previous years with only 13% of 
the estimated MDR-TB cases being notified in 2012 for Zambia (40). A review of national 
TB laboratory records over a period of 11 years showed that the incidence of MDR-TB is 
steadily rising with 18 cases notified in 2000 compared to 85 cases in 2011 (41). These 
statistics also highlight a poor case detection rate of MDR/RR-TB in Zambia with detected 
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cases falling short of WHO estimates (1, 40). This places emphasis on the likely presence of a 
large pool of undiagnosed and untreated MDR/RR-TB cases across the country and calls for 
improved case detection efforts. 
The country experienced an increase in TB incidence in the 1990s to early 2000 due to the 
HIV epidemic (40). The National TB and Leprosy control programme (NTLP) and the 
Ministry of Health (MoH) recommend that patients with signs and symptoms of pulmonary 
TB provide sputum for smear microscopy for the diagnosis of TB (40). Zambia has over 360 
diagnostic laboratories with the capacity to provide TB smear microscopy services for 
diagnosis and monitoring of treatment outcome, and 2000 treatment centres offering first line 
directly observed treatment short-course (DOTS) at no cost to the patient (40, 42). Zambia 
implemented the WHO recommended DOTS strategy in 2001 and has since attained a 
reported 100% coverage in all government-run health facilities (40). All new and retreatment 
TB patients diagnosed by smear microscopy, Xpert MTB/RIF, culture or chest x-ray are 
treated with the first line drugs rifampicin, isoniazid, ethambutol and pyrazinamide or 
streptomycin (Table 1.1), according to WHO recommendations (40).  
There are 10 provinces in Zambia which are serviced by three TB reference laboratories 
providing culture and first line DST, namely Chest Diseases Laboratory (CDL; Lusaka 
district, Lusaka province), University Teaching Hospital (UTH; Lusaka district, Lusaka 
province) and Tropical Diseases Research Centre (TDRC; Ndola district, Copperbelt 
province), (Figure 1.2) (40, 42). The country is further serviced by two specialist MDR-TB 
wards at UTH and Ndola Teaching Hospital (NTH; Ndola district) where confirmed 
MDR/RR-TB patients are admitted for some part of second line treatment and treatment 
response is monitored (40). The standard first choice MDR/RR-TB regimen prescribed by the 
NTLP in Zambia is administered for a minimum of 20 months, 8-Km-Lfx-Eto-Cs-Z/12-Lfx-
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Eto-Cs-Z (Table 1.1) (40). Currently, second line phenotypic DST is not routinely performed 
in Zambia, however there are two centres with the capacity of offering first and second line 
molecular line probe assay (LPA) and CDL TB reference laboratory has the capacity to 
perform DST on capreomycin, kanamycin and ofloxacin for MDR-TB patients (40). 
 
 
Figure 1.2: The map of Zambia highlighting patient residences by province 
(Copperbelt, Luapula, Muchinga, Northern and North-Western provinces) and the sites 
of the 3 national TB reference laboratories; Copperbelt (TDRC TB reference 
laboratory; Ndola district) and Lusaka province (CDL and UTH; Lusaka District). 
Abbreviations: CDL, Chest Diseases Laboratory; TB, tuberculosis; TDRC, Tropical Diseases 
Research Laboratory; UTH, University Teaching Hospital.  
 
The 10 provinces in Zambia are further subdivided into administrative districts. Diagnosis at 
district level is limited to smear microscopy with some designated TB diagnostic centres 
offering the Xpert MTB/RIF assay for simultaneous detection of M.tb and rifampicin 
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resistance (40). Due to the increased likelihood of HIV-positive patients having a smear 
negative TB result, the MoH in Zambia recommends the use of the Xpert MTB/RIF assay for 
high risk patients as in the case of HIV-positive individuals suspected of having TB, patients 
that have failed retreatment and for diagnosis of TB in children (40). 
Culture based phenotypic DST is recommended for diagnosis of MDR-TB by the MoH and 
NTLP based on suspicion of MDR-TB (Figure 1.3) (40). According to the MoH and NTLP, 
TB patients who fail the WHO category II/retreatment regimen as well as TB patients from 
high MDR-TB burden facilities such as prisons have a high suspicion of MDR-TB while TB 
patients who remain smear positive at the end of treatment have a low suspicion of MDR-TB 
(40). However, the capacity to perform DST on all MDR-TB suspects is currently not 
available. For instance, TB in new cases is diagnosed by smear microscopy and it is only in 
the case that a patient remains smear positive after re/treatment that Xpert MTB/RIF assay 
and first line DST is performed. 
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Figure 1.3: Recommended algorithm for the management of MDR/RR-TB patients in 
Zambia (40). Abbreviations: DR-TB, drug resistant tuberculosis; HCWs, health care 
workers; IPT, isoniazid preventative therapy; LTBI, latent TB infection; MTB, M. 
tuberculosis; RIF, rifampicin. 
 
Ndola district is the provincial headquarters for the Copperbelt province and is the site for the 
TDRC TB reference laboratory and the NTH MDR-TB ward (40). The TDRC TB reference 
laboratory provides culture and first line DST to 3 provinces out of the 10 provinces, namely; 
Copperbelt, North-Western and Luapula provinces (Figure 1.2) (40). The three provinces 
have a combined population of 4.1 million out of the national population of 16 million (43).  
The molecular epidemiology, that is the transmission and genotypes, of DR TB and drug 
susceptible TB in Zambia is poorly understood, with few reported studies. Only 3 molecular 
epidemiological studies have been published and these were largely focused on drug 
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susceptible TB in Ndola district, Namwala district (animal to human transmission was 
investigated) and one study collected samples from across Zambia (44, 45, 46). The main 
molecular typing tools used in these studies were a combination of spoligotyping, MIRU-
VNTR, LPA and targeted gene sequencing (44, 45, 46, 47, 48). From these studies, the major 
genotypes were LAM (predominately LAM11_ZWE), T, CAS, M. bovis and X (44, 45, 46). 
Genotypic susceptibility testing to second line anti-TB drugs, with LPA, in one study in 
Zambia identified 1 XDR-TB and 1 pre-XDR-TB case out of 113 evaluated cases, however 
the associated genotypes were not described (47). In another study evaluating 16 samples 
from the capital city, Lusaka, one isolate was found to have variation at codon 73 in gyrA 
(which has not been associated with FQ drug resistance), however 13 out of 16 isolates had 
mutations in the “quinolone-resistance-determining region” (QRDR) of the gyrA gene (48). 
In these studies, the genotypes associated with drug resistance were not described and the 
studies are further disadvantaged by poor sampling coverage (44, 45, 46, 47, 48). The 
usefulness of WGS in understanding transmission dynamics has been demonstrated in 
Zambia (49), with one study using WGS data to differentiate relapses and re-infection 
through single nucleotide variant (SNV) analysis (49). The study found that 33 out of the 36 
patients (92%) had TB due to relapse, that is recurrence of disease due to endogenous strains 
(49).  
 
1.5 Rationale, aims and objectives of this study 
1.5.1 Rationale 
In Zambia, management and treatment of DR-TB remains in its infancy (1). By advancing 
knowledge of DR-TB epidemiology, it is anticipated that findings from this study will better 
inform the national TB control program on the M.tb genotypes that are circulating within the 
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Copperbelt province and Northern regions of Zambia. This study will provide a measure of 
the efficacy of the TB control program and guide intervention, to make better use of limited 
resources and will likely provide a better understanding of the transmission dynamics of drug 
resistant TB as well as the genetic mechanisms of resistance. Further, the findings will add to 
national, regional and global data on drug resistant TB genotypes that are in circulation. 
 
1.5.2 Aim 
This research aims to describe the molecular epidemiology of drug resistant M.tb clinical 
isolates circulating within the Copperbelt province and Northern regions of Zambia, 
diagnosed at the TDRC TB reference laboratory in Ndola district.  
 
1.5.3 Objectives: 
Objective 1 - To describe the genotypes and distribution of drug resistant M.tb clinical 
isolates circulating within the Copperbelt province and Northern regions of Zambia. 
Zambia is amongst the top 30 high TB and high HIV burden countries in the world, however 
there is a lack of knowledge on the molecular epidemiology (transmission dynamics and 
genotypes) of TB with no data on the genotypes associated with DR TB in the country. The 
findings of this study will inform the national TB control program on the population structure 
and distribution of DR TB isolates from the Copperbelt province and northern regions of 
Zambia, molecular typing findings will be correlated to patient demographic data, including 
residential township. (Addressed in chapter 4.) 
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Objective 2 - To describe the transmission dynamics of drug resistant TB within the 
Copperbelt province and Northern regions of Zambia, in terms of acquisition vs. 
transmission. 
Drug resistant TB can either be acquired during the course of treatment (secondary 
resistance) or it can be transmitted (primary resistance) (1). There is no data on the 
transmission dynamics of drug resistant TB for Zambia. Therefore molecular typing tools 
will be used to investigate clustering amongst clinical isolates. This will be analysed in 
conjunction with the clinical data. Clustering and primary drug resistance would be 
suggestive of recent transmission while unique patterns and secondary resistance would 
suggest acquired resistance. (Addressed in chapter 4 and 5.) 
 
Objective 3 - To analyse the transmission of drug resistant M.tb using whole genome 
sequence analysis 
Alongside using spoligotyping and IS6110 DNA fingerprinting, next generation WGS data 
for 86 DR TB isolates will be used to investigate genetic diversity and transmission. A 
phylogenetic tree will be constructed using WGS data, this will be used to investigate strain 
relatedness and the evolution of drug resistant isolates from the Copperbelt province and 
northern regions of Zambia. (Addressed in chapter 5.) 
 
Objective 4 - To compare genotypes of drug resistant M.tb from the Copperbelt 
province and northern regions of Zambia with isolates circulating within a high TB-
incidence area of Cape Town, South Africa. 
The molecular epidemiology of DR-TB in Cape Town has been systematically described and 
particular strains have been associated with MDR- and XDR-TB (11, 50). WGS data 
conveniently available at Stellenbosch University for strains that have previously been 
Stellenbosch University  https://scholar.sun.ac.za
18 | P a g e  
 
described in Cape Town will be compared to WGS data for strains of the same lineage from 
this study. Migration has been documented within the region, mainly due to political 
instability, for instance cross border movement between South Africa, Zimbabwe and Zambia 
has been described (51). There however is very limited data on the role of migration on the 
transmission of TB within the region. In this study, we anticipate that strain relatedness 
would suggest that migration is playing a role in the transmission of drug resistant TB strains 
within the region and the continent (52). (Addressed in chapter 5.) 
 
Objective 5 - To investigate the distribution and transmission of XDR-TB amongst M. 
tuberculosis isolates circulating within the Copperbelt province and northern regions of 
Zambia. 
A case of XDR-TB and one case of pre-XDR-TB have previously been described in one 
study in Zambia (47). The lack of routine in-country second line DST could imply that a pool 
of XDR-TB cases remain undetected and is a potential source of future XDR-TB cases in 
Zambia and the surrounding region. In order to investigate the presence of XDR-TB in the 
Copperbelt province and northern regions of Zambia, WGS and targeted gene sequencing 
(TGS) will be used to determine the presence of mutations conferring resistance to second 
line anti TB drugs. This will give a first insight into the genotypes associated with XDR-TB 
in Zambia. (Addressed in chapter 6.) 
 
Objective 6 - To describe the genetic mechanisms of resistance and relationship to 
phenotype. 
Using TGS and next generation WGS, mutations conferring resistance will be investigated 
and findings will be compared to phenotypic DST results. (Addressed in chapter 6.) 
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Objective 7 - To determine the knowledge, attitudes and practices (KAPs) of health care 
workers, in MDR-TB diagnostic and treatment facilities, toward TB infection, 
prevention and control (IPC) practices. 
Health care workers (HCWs) have an increased risk of acquiring TB due to exposure at the 
work place and in the community. HCWs play an important role in the transmission and the 
control of MDR-TB. During sample collection and initial processing, observations were 
made of HCWs not always adhering to TB IPC practices. The barriers in adhering to TB IPC 
practices in HCWs working at the Ndola Teaching Hospital (NTH) MDR-TB ward and the 
TDRC TB reference laboratory have not been evaluated. This research will provide an insight 
into the knowledge, attitudes and practices (KAPs) of this group of HCWs and the barriers to 
adhering to IPC practices and policies. The findings will identify key areas of training and 
safety and guide IPC practices in this at risk population group. (Addressed in chapter 7.)   
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1.5.4 Thesis structure 
Chapter 1. Introduction 
The general introduction chapter sets the tone for the thesis by introducing the background to 
the study. The chapter highlights the growing global concerns over the emergence and spread 
of drug resistant TB in the form of MDR- and XDR-TB. It further highlights the knowledge 
gaps on the genotypes that are associated with drug resistant TB in Zambia. 
 
Chapter 2. Molecular epidemiology of drug resistant Mycobacterium tuberculosis in 
Africa 
This chapter in the form of literature review summarises the molecular epidemiology of drug 
resistant TB across Africa. It further highlights the gaps in knowledge and the deficiencies in 
management of drug resistant TB across the continent. 
 
Chapter 3. Materials and Methods 
This chapter describes the study design, the materials and methods used to meet the 
objectives of this research. The study population group and ethical considerations are defined 
in this chapter. 
 
Chapter 4. Drug resistant Mycobacterium tuberculosis clinical isolates collected from the 
TDRC TB reference laboratory in Ndola district: Genetic diversity, demographic and 
clinical characteristics 
The genetic diversity observed in drug resistant clinical isolates of M. tuberculosis diagnosed 
at the TDRC TB reference laboratory is described in this chapter as part of the results. These 
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findings are significant as they give a first insight into the genotypes that are associated with 
drug resistant TB in parts of Zambia. This chapter addresses Objectives 1. 
 
Chapter 5. Molecular analysis of transmission 
This chapter describes the transmission of drug resistant clinical isolates of M. tuberculosis 
diagnosed at the TDRC TB reference laboratory using WGS analysis. Further, the chapter 
describes strain relatedness between strains of the same lineage from the study population 
and strains associated with drug resistance in Cape Town South Africa, whose WGS data is 
conveniently available at Stellenbosch University, to assess the impact of migration on 
transmission of drug resistant TB strains in the region. This chapter addresses Objectives 2, 3 
and 4. 
 
Chapter 6. Genetic mechanisms of drug resistance 
In this chapter the genetic mechanisms of drug resistance in relation to the phenotype, are 
described in the study population. Further, the chapter gives a first insight into genotypes 
associated with pre-XDR and XDR-TB in Zambia. This chapter addresses Objectives 6. 
 
Chapter 7. Occupational risk of transmission of drug resistant TB in healthcare 
workers: knowledge, attitudes and practices 
This chapter describes the knowledge, attitude and practices of health care workers toward 
TB IPC practices. Health care workers are at an increased risk of acquiring drug resistant TB 
and TB in general due to increased exposure. The findings in this chapter were gathered 
through literature review and self-administered questionnaires to health care workers from 
MDR-TB health care facilities in Ndola district, Zambia. This chapter addresses Objective 7. 
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Chapter 8. General conclusion 
The general conclusion brings the thesis together by describing the genotypes of drug 
resistant TB diagnosed at the TDRC TB reference laboratory. It further sums up factors that 
are driving drug resistant TB and the deficiencies in management of drug resistant TB in 
Zambia. 
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Chapter 2: Molecular epidemiology of drug resistant Mycobacterium 
tuberculosis in Africa 
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2.1 Burden of drug resistant tuberculosis in Africa 
The WHO reports that globally, of the 6.4 million global TB patients, 1.3 million (20%) live 
in Africa and 16 out of the 30 high TB burden countries are in this continent (1). In Africa, 
countries with the highest burden of MDR-TB are; Angola, Democratic Republic (DR) 
Congo, Ethiopia, Kenya, Nigeria, Mozambique, Somalia, South Africa and Zimbabwe (1). In 
2015, the incidence of MDR/RR-TB in Africa was estimated to be 42,000 (1). Of the 
estimated cases only 26,929 (64%) MDR-TB and 1,100 XDR-TB cases had laboratory 
confirmation with a further 69% MDR-TB and 72% XDR-TB laboratory confirmed cases 
being started on second line treatment (1). The highest proportion of TB/HIV co-infection is 
also seen in this region (31% on average), with some regions having co-infection rates higher 
than 50% (1, 3). It is therefore important to identify TB/HIV co-morbidity in these high risk 
areas. A further factor driving the TB epidemic in Africa is non-communicable “lifestyle 
diseases”, such as diabetes mellitus, which are on the rise within the continent and pose a 
potential source of at-risk individuals in high TB burden settings (4). It is in this light that 
recommendations have been made to screen for diabetes in TB patients in Africa (4).   
The gold standard for the diagnosis of drug resistant TB is the use of culture-based 
phenotypic drug susceptibility testing (DST) which has been recommended by the WHO 
since 2007 (1, 5). Other WHO approved methods include nucleic acid tests (NATs) such as 
the Xpert MTB/RIF assay and the molecular line probe assay (LPA), which provide a more 
rapid diagnosis but are limited in the range of drug susceptibility that can be detected (1). The 
molecular LPA and Xpert MTB/RIF assay were recommended for rapid screening of patients 
at risk of drug resistant TB by the WHO in 2008 and 2010, respectively (1). More recently, in 
2017, WHO endorsed the use of the next-generation Xpert MTB/RIF Ultra assay, which is 
said to have increased sensitivity in detecting MTB compared to the Xpert MTB/RIF assay 
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(6). The running costs associated with these techniques, the need for expertise and the lack of 
availability at point of care could however result in low uptake of these rapid diagnostic tools 
across Africa. 
The recommended treatment regimen for drug susceptible TB, which includes streptomycin, 
isoniazid, rifampicin, ethambutol, or pyrazinamide, differs from the treatment regimen of 
MDR- and XDR-TB. The WHO recommends that MDR-TB be treated with a standard 
regimen of second line anti-TB drugs which includes a combination of an injectable drug, a 
fluoroquinolone, other core anti-TB agents as well as the first line anti-TB drugs 
pyrazinamide and ethambutol, subject to DST results (Table 1.1, page 4) (7). These drugs are 
however less potent, more toxic and require a prolonged treatment period of up to 24 months. 
More recently however, the WHO has endorsed a shorter 9-12 month regimen which has 
been demonstrated to be more effective in the treatment of MDR-TB and consists of a 
combination of anti-TB agents (Table 1.1, page 4) (8, 9). The initial phase of the newly 
endorsed regimen involves treatment with kanamycin, moxifloxacin, prothionamide, 
clofazimine, pyrazinamide and high dose isoniazid, for 4 to 6 months, followed by a 5 month 
continuation phase with moxifloxacin, clofazimine, pyrazinamide and ethambutol (9). The 
usefulness of including the first line drugs pyrazinamide and ethambutol in treatment of drug 
resistant TB is however challenged by the high association of some of these anti-TB drugs 
with MDR-TB (10, 11), placing emphasis on the need for routine DST prior to MDR-TB 
treatment. 
Since 2014, at least 12 countries have introduced this short MDR-TB regimen in Africa (9). 
Inappropriate implementation of the shorter MDR-TB treatment regimen however poses a 
risk of acquiring additional resistance in affected patients, as currently observed for the 
longer MDR-TB treatment regimen (8, 9). It is in this light that the WHO recommends DST 
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before commencement of treatment and that the shorter regimen only be made available to 
patients that have not received prior MDR-TB treatment (9). 
The molecular mechanisms of drug resistance as well as the evolution of drug resistant strains 
have been widely studied using a combination of genotyping tools (12, 13). This has given a 
better insight into the transmission dynamics of drug resistant TB. Most studies under review 
have used spacer oligonucleotide typing (spoligotyping) to describe the molecular 
epidemiology of drug resistant TB in Africa although there are a number of studies which 
have used highly discriminatory methods which include insertion sequence 6110-restriction 
fragment length polymorphism (IS6110-RFLP), Mycobacterial interspersed repeat units-
variable number of tandem repeats (MIRU-VNTR) and whole genome sequencing (WGS).  
There is no existing review on the molecular epidemiology of drug resistant TB in Africa. 
This review aims to synthesise available knowledge of drug resistant TB in Africa, with a 
particular focus on molecular epidemiological studies. 
 
2.2 Drug resistance tuberculosis surveillance 
Routine and frequent epidemiological surveillance is critical for understanding the burden of 
drug resistant TB in a given region and for planning and policy development and 
implementation. The major drug resistance TB surveillance methods that have been used in 
Africa include case notifications combined with expert opinions, prevalence surveys, and 
capture-recapture to estimate incidence (1, 2). However, the most effective drug resistance 
monitoring tool has been demonstrated to be continuous surveillance of TB patients through 
DST and systemic analysis of routinely collected data (1). It is a concern that there is scanty 
data on the prevalence of drug resistant TB across Africa (Figure 2.1 and Table 2.1) (2).  
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Figure 2.1: An illustration of the year of the most recent drug resistance survey for 
African countries. Adapted from WHO (1). 
 
Between 2010 and 2015, only 16 of 54 African countries (30%) completed national drug 
resistance prevalence surveys namely; Benin, Djibouti, Egypt, Kenya, Lesotho, Malawi, 
Morocco, Namibia, Nigeria, Senegal, Somalia, South Africa, Rwanda, Togo, Tunisia, and 
Uganda (1, 2). Older drug resistance survey data is available from 8 countries for the period 
2005 and 2009, namely Botswana, Central African Republic (CAR), Ethiopia, Madagascar, 
Mozambique, Tanzania, and Zambia (1). Since 2016, there were drug resistance TB surveys 
on-going in Burkina Faso, Cote D’Ivoire, DR Congo, Ghana, North-Sudan, Swaziland, and 
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Zimbabwe (1). Fourteen countries in Africa currently do not have any survey data (Figure 
2.1). From the countries with repeat drug resistance survey data (Table 2.1), some countries 
have reported an increase in the prevalence of MDR-TB and drug resistant TB in general (14, 
17). Other countries have demonstrated no significant changes in prevalence rates of drug 
resistant TB (15, 16, 18). 
 
Table 2.1: Repeat drug resistance survey trends for African countries with published 
data.  
Country Survey periods Trends Ref 
Botswana 1995-1996, 1999, 
2002 and  2007-2008 
 The proportion of new cases with MDR-TB tripled since 
the previous survey in 2002, from 0.8% to 2.5%. 
 There was a rise in R, H, E & S resistance in new cases in 
2007 compared to 2002. 
 Prevalence of MDR-TB in retreatment cases was lower in 
2007-2008 at 6.6% compared to 10.4% in 2002.  
14 
Mozambique 1998 and 2007-2008  The prevalence of MDR-TB amongst new and previously 
treated cases was 3.5% and 11.2% during the 2007-2008 
survey.  
 No significant differences in prevalence with the first 
survey.  
15 
South Africa 2001-2002 and 2012-
2014 
 National prevalence rate of MDR-TB was estimated to be 
2.8% 
o  2.1% in new and 4.6% in retreatment cases.  
 MDR-TB prevalence has remained stable over a period of 
10 years. 
 A doubling in R resistance from 1.8% in 2001-2002 to 
3.4% in 2012-2014 survey.  
 Highest MDR-TB rate, 5.1%, seen in Mpumalanga 
province in both surveys  
16 
Swaziland 1995 and 2009-2010  An 8.5- and 3.5-fold increment in previously treated cases 
and new MDR-TB cases, respectively, between the two 
surveys.  
 0.9% in new cases and 9.1% in retreatment cases in 1995 
compared to 15.3% and 33.8% in 2009-2010. 
17 
Zambia 2001 and 2008  In 2001 the prevalence of MDR-TB in new cases and 
previously treated cases was 1.2% and 1.8%, respectively 
compared to 0 and 6.5% in 2008  
 There was no significant increase in the prevalence of 
MDR-TB over a period of 8 years. 
18 
Abbreviations: MDR-TB, multidrug resistant tuberculosis; R, rifampicin; H, isoniazid; E, 
ethambutol; S, streptomycin. 
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High rates of resistance have been documented with some studies reporting over 50% of all 
cases as having some form of resistance with the majority of cases being MDR-TB (19, 20, 
21, 22). This has been attributed to factors such as inadequate therapy due to lack of 
adherence to a combination therapy (20). The high rates of drug resistance observed pose a 
serious public health threat across the continent. There are however countries that have 
reported low levels of primary drug resistance, as low as 4.9% in Burkina Faso (3.3% 
isoniazid mono-resistant and 1.6% MDR-TB) (23), implying that the current treatment 
regimen is effective in managing drug resistant TB. Further, there is limited clustering of 
drug resistant isolates in parts of Africa, suggesting that drug resistance is largely acquired in 
some regions (24, 25). It is however worth noting that drug resistant isolates could possibly 
be under-estimated due to poor surveillance and low case detection rates seen across Africa. 
African countries share similar challenges in the management of drug resistant TB mainly 
due to poorly funded TB programs and weak health care systems (1, 2). This is reflected by 
the poor surveillance and the poor treatment outcomes that are seen across the continent (1). 
The average MDR/RR-TB case detection rate for the 47 WHO African member states is 64% 
(1). From all laboratory confirmed MDR/RR-TB and XDR-TB cases 69% and 72% are 
started on treatment, respectively, across Africa. There is an average treatment success rate of 
54% for MDR/RR-TB and 24% for XDR-TB (1), however there are variations from region to 
region (1). Across Africa, the MDR/RR-TB case detection rates range from 7% to 87% (1). 
This implies that drug resistant TB cases are perhaps underreported in the region.  
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2.3 Population structure of drug resistant TB genotypes 
Sporadic molecular mycobacteriological studies have been conducted within Africa (Figure 
2.2, Figure 2.3), with South Africa having the vast majority of data in the continent. Diverse 
genotypes have been associated with drug resistant TB (Figure 2.2, Table 2.2), with particular 
genotypes being more predominant (26, 27, 28, 29). For instance, the Beijing genotype is 
widespread across parts of Africa (30, 31, 32, 33, 34). The population structure of drug 
resistant TB is however not homogeneous, with certain strains being more predominant in 
specific population groups (35, 36, 37). For instance, the Haarlem and CAS genotypes are 
predominantly associated with drug resistance including MDR-TB in parts of North and East 
Africa while in Southern and West Africa the Beijing and LAM genotypes are highly 
associated with drug resistance (38, 39, 40, 41). 
Associations between drug resistant TB strains and HIV have been noted, with high mortality 
rates being observed in these population groups (33, 42, 43, 44). Genotypes such as Beijing, 
Haarlem and LAM have been associated with high levels of drug resistance and high 
mortality rates in both HIV seropositive and seronegative individuals (38, 45, 46, 47). A clear 
distinction has been observed in the population structure of genotypes associated with mono-
resistance, MDR- and XDR-TB (Table 2.2). In parts of South Africa the F15/LAM4/KZN 
and Beijing genotypes have been associated with XDR-TB while LAM11_ZWE is associated 
with MDR-TB in parts of Zimbabwe (41, 48, 49). The genetic diversity observed across the 
continent could be influenced by host genetics and migration, which is discussed further in 
section 3.4 (50). 
High cluster rates of drug resistant TB isolates have been observed in parts of Africa (19, 51, 
52), this is of great concern as it implies that there is recent and ongoing transmission of drug 
resistant TB strains within the region. Further, a correlation between the adult population and 
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children has been demonstrated (53), suggestive of adult to child transmission. There is 
however very limited molecular typing data on drug resistant TB amongst children and 
household contacts of drug resistant TB patients in Africa to confirm this. 
 
Figure 2.2: Genotypic distribution of drug resistant Mycobacterium tuberculosis isolates 
characterised across Africa. Varying genotyping tools were used to characterise isolates 
including spoligotyping, MIRU-VNTR, PCR typing, and WGS, further described in 
Table 2.3. Figure generated in Microsoft PowerPoint from references listed in Table 2.3. 
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Figure 2.3: Distribution of M. tuberculosis strains according to the 7 major lineages. 
Figure generated from references listed in Table 2.3. 
 
The appearance of modern lineages (East Asian, EAI and Euro American) has resulted in a 
shift in genotypes associated with resistance in Central and West Africa (22), regions 
predominantly associated with Mycobacterium africanum (MAF) (19, 54, 55). In North and 
East Africa, the most predominant genotypes associated with drug resistance are T, CAS and 
Haarlem (44, 56, 57, 58, 59) while in central and Southern Africa the lineages East Asian, 
Euro-American and East African Indian are more prevalent. Lineage 5 (West-Africa 1) and 6 
(West-Africa 2) continue to predominate in West Africa and are not associated with drug 
resistance. However, modern strains are being observed in the region and are associated with 
drug resistance (60, 61, 62, 63). Overall, there is a high degree of diversity in the genotypes 
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associated with drug resistant TB across Africa with certain genotypes being more prevalent 
in specific regions (24, 56). Further, clustering of these strains has been observed, implying 
that there is ongoing transmission of multiple drug resistant TB strains within the continent. 
Additional studies are required to better understand the epidemiology and associated factors 
of drug resistant TB in Africa as a whole. 
 
Table 2.2: Genotypes associated with drug resistant TB across Africa.  
Country Province DST phenotype Genotype Genotyping 
method 
Ref 
Angola Luanda MDR-TB, mono-  
& poly-resistant 
T1, T2, LAM9, 
LAM1, LAM2, LAM6 
Spoligotyping, 
MIRU-VNTR 
64 
Benin  Cotonou S mono resistant Beijing MIRU-VNTR 65 
Burkina Faso Ouagadougou MDR-TB, mono-  
& poly-resistant 
T, Haarlem Spoligotyping, 
MIRU-VNTR 
23 
CAR Bangui MDR-TB T, Cameroon, H, EAI Spoligotyping 54 
Chad N’Djame´na I mono-, E mono-, 
P mono-, I & E 
poly-resistant 
T, Cameroon, H37Rv,  
undefined 
Spoligotyping 63 
Congo 
Brazzaville 
Brazzavile & 
Pointe Noire 
MDR-TB, mono-
resistant 
T, Beijing, LAM MIRU-VNTR, 
DNA sequencing 
19 
Djibouti  Countrywide MDR-TB T, Beijing  WGS, MLVA, 
Spoligotyping, 
MIRU-VNTR, 
IS6110-RFLP 
22 
66 
Djibouti city XDR- Pre XDR-,  
MDR-TB, mono-  
& poly-resistant 
T, Beijing, CASKILI-
1, CAS-Delhi, LAM, 
EAI 
Egypt Suez canal region  MDR-TB, I & S 
mono resistant 
T, LAM, M. bovis, 
CAS, S, undefined 
IS6110-RFLP, 
Spoligotyping, 
DNA sequencing 
25 
56
 
Assiut 
Ethiopia Jimma I mono resistant T3_ETH Spoligotyping, 
DNA 
sequencing, 
MLPA assay, 
MIRU-VNTR  
57 
67 
68 
Meskenena 
Mareko district 
I mono resistant Haarlem 
Oromia, 
SNNRPS, Harari 
MDR-TB, mono-  
& poly-resistant 
Ethiopia_3 
CAS1_Delhi, EA, 
ETH_H37Rv like,  
lineage 7, H, Ural, X, 
EAI 
Ghana South-west Ghana MDR-TB, mono-  
& poly-resistant 
Cameroon, MAF, 
undefined 
Spoligotyping, 
IS6110-RFLP, 
DNA sequencing 
61 
Guinea Conakry MDR-TB, mono-  
& poly-resistant 
T, H, LAM, Beijing, 
EAI, S,  Cameroon, 
MAF WA2,  
Spoligotyping 55 
Kenya North west MDR-TB CAS1, Beijing Spoligotyping 28 
34 
Mono  & poly 
resistant 
CAS1, S, LAM, T2 
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Country Province DST phenotype Genotype Genotyping 
method 
Ref 
Malawi Karonga district R & I mono 
resistant 
EAI WGS 43 
51 
Mali Bamako MDR-TB, mono-  
& poly-resistant 
T, MAF2, LAM10 Spoligotyping 37 
Morocco Casablanca MDR-TB, mono-  
& poly-resistant 
H, LAM9, EAI, 
Beijing, T  
Spoligotyping, 
MIRU-VNTR 
69 
70 
Countrywide 
Mozambique Countrywide MDR-TB Beijing Spoligotyping, 
MIRU-VNTR, 
IS6110-RFLP 
33 
Nigeria Ibadan, Nnewi 
and Abuja 
MDR-TB, mono-  
& poly-resistant 
Cameroon, T, LAM, 
MAF 
Spoligotyping, 
MIRU-VNTR 
40 
60 
Cross river state MDR-TB & S 
mono-resistant  
Cameroon 
Rwanda Countrywide  MDR-TB, R 
mono-, I mono-
resistant 
T2, CAS1_Delhi RD analysis, 
Spoligotyping  
21 
Sierra Leone Western area & 
kenema district 
MDR-TB, mono-  
& poly-resistant 
MAF, LAM, H, Sierra 
Leone1/2, Beijing, S 
Spoligotyping, 
IS6110-RFLP, 
MIRU-VNTR 
62 
South Africa  Eastern Cape XDR-TB Beijing, LAM, 
MANU, S 
Spoligotyping, 
IS6110-RFLP, 
DNA sequencing 
45 
46 
Pre- XDR TB Beijing, LAM4 
MDR-TB Beijing, LAM, H, 
MANU, S, T, U, X 
Gauteng XDR-TB Beijing, LAM, T, H, 
EAI_SOM, X 
Spoligotyping, 
MIRU-VNTR 
27 
35 
48 
71 
Pre-XDR-TB Beijing, LAM, S, H, 
EAI_SOM 
MDR-TB and 
mono-resistant 
Beijing, LAM, T, H, 
S, EAI_SOM, X 
KZN XDR-TB & Pre-
XDR-TB 
LAM4 
(F15/LAM/KZN), S, T 
Spoligotyping, 
WGS, targeted 
gene sequencing, 
IS6110-RFLP 
13 
42 
47 
71 
 
MDR-TB LAM4 
(F15/LAM/KZN), 
Beijing, S, T 
Mono- & poly- 
resistant 
LAM4 
(F15/LAM/KZN) 
Limpopo XDR-TB LAM4, X1 Spoligotyping, 
MIRU-VNTR 
27 
Pre-XDR Undefined genotype 
MDR-TB Beijing, EAI1_SOM, 
T, S, LAM9, LAM10, 
X3, T2,  
Mpumalanga XDR-TB None reported Spoligotyping, 
MIRU-VNTR 
27 
Pre-XDR Beijing, EAI_SOM, T, 
S, LAM,  X, H, T  
MDR-TB Beijing, EAI1_SOM, 
T, S, LAM, X, H, 
MANU  
North-West XDR-TB None reported Spoligotyping, 
MIRU-VNTR 
27 
Pre-XDR EAI1_SOM 
MDR-TB Beijing, EAI1_SOM, 
T, S, LAM  
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Western Cape XDR-TB Beijing, T Spoligotyping, 
IS6110-RFLP, 
targeted gene 
sequencing 
30 
31 
32 
41 
53 
 
Pre- XDR-TB Beijing, LAM4, S, T, 
X 
MDR-TB Beijing, Haarlem, 
LAM, X. 
mono-  & poly-
resistant 
Beijing 
Sudan Omdurman, 
Khartoum & Port 
Sudan 
MDR-TB, mono 
resistant 
CAS1_Delhi, T, 
Beijing, H, CAS, 
LAM7_TUR, U, T2, 
S, LAM9 
Spoligotyping, 
MIRU-VNTR 
 
72 
Tanzania Chagga and 
Masai tribes 
MDR-TB, mono-  
& poly-resistant 
CAS, LAM, T, EAI, 
MANU, Beijing 
Spoligotyping  44 
Tunisia Bizerte MDR-TB Haarlem3, undefined Spoligotyping, 
MIRU-VNTR, 
PCR typing 
38 
73 
Bizerte, Tunis, 
Zaghouan 
MDR-TB, mono-  
& poly-resistant 
H3, T1, H1, LAM9, U, 
unknown 
Uganda Mubende district R mono-, E mono-, 
I mono-resistant 
T2, Uganda, LAM3 & 
S, CAS, CAS1_Delhi, 
LAM11_ZWE, 
undefined 
Spoligotyping, 
MIRU-VNTR, 
RD analysis 
29 
58 
59 
74 
Mbabara district MDR-TB, R 
mono-, I mono-
resistant 
T2, Uganda, 
CAS_Delhi 
Kampala district MDR-TB,  R 
mono-, I mono-
resistant  
T2, Uganda, LAM9, 
Beijing 
Zimbabwe Countrywide Pre-XDR Undefined Spoligotyping   
49 MDR-TB LAM11_ZWE, LAM 
other, Beijing, CAS1 
KILI, CAS1 Delhi, T, 
S, MANU 
Abbreviations: XDR-TB, extensively drug resistant tuberculosis; MDR-TB, multidrug 
resistant tuberculosis; R, rifampicin; H, isoniazid; E, ethambutol; S, streptomycin; WGS, 
whole genome sequencing; MLVA, Multiple loci VNTR analysis; IS6110-RFLP, Insertion 
Sequence 6110-Restriction Fragment Length Polymorphism; Spoligotyping, Spacer 
oligonucleotide typing; MIRU-VNTR, Mycobacterial interspaced repeat units-variable 
number of tandem repeats; CAS, Central Asian; EAI_SOM, East African Indian_Somalia; 
KZN, KwaZulu-Natal; LAM, Latin American Mediterranean; MAF, Mycobacterium 
africanum; H, Haarlem; ETH, Ethiopia; SNNRPS, Southern Nations, Nationalists and 
Peoples Regional State. 
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2.4 Application of molecular methods to describe transmission dynamics of drug 
resistant tuberculosis in Africa 
2.4.1 Acquired MDR- and XDR-TB  
Although there are few molecular epidemiological studies from Africa, evidence suggests 
that to an extent drug resistant strains endemic in parts of Africa are as a result of ongoing 
and recent transmission (75, 76). These methods have also been demonstrated however that 
acquisition of MDR-and XDR-TB also plays an important role in the burden of drug resistant 
TB in endemic regions of Africa (76, 77). Inadequate treatment has been shown to be a 
significant driving force in the development of drug resistant TB, driven by factors such as 
poor adherence to treatment, diagnosis delay and low quality anti-TB drugs (78, 79). 
The WHO recommends the use of a standardized TB treatment regimen which has been 
adopted by most countries in the region (7). In the absence of laboratory monitoring and 
surveillance, mainly due to poor infrastructure and lack of resources, the risk of acquiring 
resistance is heightened in high TB burden settings (78,
 
80). Further, standardized TB 
treatment has been shown to be unsuccessful in preventing the spread of drug resistant TB 
(79, 81). Therefore, there is a need to implement routine DST and surveillance, supported by 
molecular epidemiology, in order to guide effective TB treatment in high risk population 
groups. 
 
2.4.2 Outbreaks 
Drug resistant strains of M. tuberculosis have been linked with outbreaks in parts of Africa 
(31, 42, 63, 65). Outbreaks are characterised by sporadic spread of a particular strain of drug 
resistant TB unlike ongoing transmission which is characterised by constant spread of strains 
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over a longer period of time. In Africa, there is very limited information on outbreaks of drug 
resistant TB; this is largely due to poor surveillance and monitoring systems. 
A prominent outbreak in Tugela Ferry KZN (mostly amongst HIV positive individuals) 
involving the F15/LAM4/KZN lineage, brought global focus onto XDR-TB and revealed that 
XDR-TB strains are transmissible (42). The main factors associated with the outbreak were 
an inadequate TB control program coupled with a high HIV prevalence in the affected 
population (42). This stresses the need for improved TB infection prevention and control 
(IPC) measures, together with rapid diagnostics in the successful control of XDR-TB and TB 
in general. Outbreaks in vulnerable population groups of institutionalized and HIV positive 
individuals have been documented (13, 42) (and are further discussed in section 2.3.3). High 
clustering rates of drug resistant isolates was observed in a mining community which had a 
high rate of HIV sero-positive individuals (78). The outbreak was as a result of an inefficient 
TB control program and diagnosis delay with the biannual chest radiography screening only 
diagnosing 30% of TB cases in this group of miners (78). Recommendations have since been 
made to improve detection and to promote parallel treatment of TB and HIV in high risk 
groups (78). 
Community outbreaks of MDR-TB in HIV sero-negative, non-institutionalized individuals 
have also been reported (31, 65). Molecular investigations have revealed diversity in 
genotypes associated with outbreaks of drug resistant TB. For instance the Beijing genotype 
was associated with an outbreak in parts of South Africa, while the Haarlem genotype was 
linked with outbreaks in Tunisia (31, 82). Genotypes initially identified to be responsible for 
drug resistant TB outbreaks have been demonstrated to re-emerge in communities as was the 
case in Tunisia (82). A subsequent MDR-TB Haarlem strain outbreak was reported amongst 
the post-outbreak patients’ population group in which the same strain was identified as the 
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progenitor (82). Inefficient treatment and lack of effective control measures of outbreaks pose 
a major threat as outbreak strains are likely to become endemic in parts of Africa. The 
findings of these drug resistant TB outbreak studies emphasise that MDR-TB and indeed 
other drug resistant TB outbreaks are not limited to specific population groups such as the 
immunocompromised and the institutionalized (32, 82). 
There is some evidence that particular bacterial genotypes are associated with outbreaks. The 
Beijing genotype for instance, which is endemic in parts of South Africa, was linked to an 
outbreak of MDR-TB at a school in the Western Cape Province (31). Molecular 
characterization confirmed that all isolates belonged to cluster R220 (31). The genotype was 
further associated with a streptomycin-resistance outbreak in Benin and an MDR-TB 
outbreak in Djibouti (65, 66). The occurrence of an outbreak caused by the Beijing genotype 
in East and West Africa further highlights the emergence of “modern” strains in this region 
which appear highly virulent and pose a potential threat to TB control efforts in the region. 
Further, lineage 4 has been demonstrated to be widespread across Africa. Genotypes from 
this lineage have been associated with drug resistant TB and have been implicated in ongoing 
outbreaks of MDR-TB in parts of East Africa (29). 
While host and strain genetics may play a role in driving outbreaks, inappropriate treatment, 
non-compliance to treatment and delays in diagnosis are amongst risk factors that have been 
linked to outbreaks within the continent (28, 31, 32, 42, 65). This highlights the urgent need 
for development and implementation of TB IPC policies in high-risk population groups and 
also calls for strengthening of outbreak response measures. 
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2.4.3 Nosocomial transmission 
Hospital-acquired drug resistant TB has been reported in Africa. An outbreak of the XDR-TB 
F15/LAM4/KZN strain was described in a district hospital in Tugela Ferry, KZN, South 
Africa (83). Epidemiological links for 82% of the patients were made and clustering was 
observed in 92% of strains (83). The major risk factors that have been associated with 
hospital-acquired drug resistant TB are lack of proper IPC measures such as overcrowded 
wards, poor ventilation and delayed diagnosis (83). This coupled with the high HIV 
prevalence experienced in most TB endemic regions makes nosocomial transmission a 
significant driving force in the transmission of drug resistant TB strains. 
Rather than a single point-source outbreak, social network analysis has revealed that patients 
linked to nosocomial transmissions have a high degree of community interconnectedness (83, 
84). This implies that transmission is occurring both in the community and in the health care 
facilities. Prolonged exposure to patients with drug resistant TB and frequent, concurrent 
hospital admissions were common in most XDR-TB patients providing strong evidence that 
nosocomial transmission had occurred (83, 84). 
Transmission of TB and drug resistant TB in particular is not only limited to patients 
receiving care and treatment in health care facilities but has been described in healthcare 
workers (HCWs)  (85). Healthcare workers are at an increased risk of acquiring drug resistant 
TB at the work place, especially in the absence of effective IPC measures (86). It has been 
demonstrated that diabetes mellitus and HIV infection are common co-morbidities in HCWs 
that were infected with MDR-TB in a teaching hospital in South Africa (85). Other factors 
that have been associated with occupational acquisition of drug resistant TB and TB in 
general include: increased contact with patients who typically present to the health care 
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facility when they are highly infectious, complacency and low awareness of self-risk 
typically seen in longer-serving HCWs (85, 86). 
Recommendations made towards improved control measures are to prevent transmission 
through early diagnosis of resistant TB, minimize congregation areas in hospitals by 
redesigning wards and out-patient areas and use of personal protective equipment (84, 85, 
86). The highly limited data on nosocomial transmission of drug resistant TB in Africa is 
alarming and places emphasis on the need for molecular epidemiological studies in these high 
risk settings. 
2.4.4 Migration  
Migration has been demonstrated to play a critical role in the spread of drug resistant TB 
strains globally, with the majority of cases being reported in high-income countries 
originating from economic migrants from high TB burden countries (87). There is abundant 
literature from high-income countries owing to excellent TB surveillance and monitoring 
(87). In Africa however, there is very limited information on the impact of migration on 
transmission of drug resistant TB; this is mainly due to poor surveillance and monitoring. 
Further, migrant populations have poor access to health care and social structures. 
Lineages and strains that had previously not been described in particular population groups 
have been hypothesised to have been introduced to various regions by immigrants (50, 81, 
87). However, the absence of baseline data makes it rather difficult to prove this hypothesis 
as there is very limited data on genotypes that are in circulation within Africa. On the other 
hand, migration is rife in Africa, mainly due to political instability, civil wars and poverty, 
and it poses a major concern in the fight against TB and drug resistant TB in particular (88). 
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Drug resistant strains with streptomycin resistance were detected in a refugee camp in Kenya 
(50). Upon comparison to strains in the general populace, the refugee strains were unique to 
the camp (50). The nomadic nature of refugees means that they are highly capable of 
spreading drug resistant strains. There is a higher possibility of refugees failing to complete 
treatment due to their drifting nature and instability. Further, there is a possibility that the 
transmission of drug resistant strains is facilitated by a poor TB control program in the 
country of origin and/or in the refugee camp (50, 88). 
Migration is not only an important factor in transmission of drug resistant TB across country 
borders and across continents, it has also been demonstrated to be an important means of 
transmission within countries as a result of movement to new cities and provinces in search 
of better employment opportunities and better health care facilities (89). For instance, the 
F15/LAM4/KZN has been shown to be widespread both in districts of KZN and in 
surrounding areas (89). Further, transmission of drug resistant TB strains has been 
demonstrated between provinces and districts in South Africa (77, 90, 91). This stresses a 
need for rigorous screening of migrants coming from high TB endemic regions and also calls 
for development and implementation of TB IPC polices in congregate settings in high TB 
burden regions. 
 
2.5 Summary and discussion 
The emergence and spread of drug resistant TB strains in the form of MDR-and XDR-TB 
continue to hinder global efforts to curb the disease. The application of molecular 
epidemiological tools has enabled a better understanding of the global phylogeography of TB 
(12). In Africa however, there is very limited and sporadic data for the genotypes associated 
with drug resistant TB. Knowledge of the lineages that are driving drug resistant TB gives a 
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better understanding of whether drug resistant TB is being acquired or transmitted within 
specific populations. Further, routine surveillance better informs TB control programs on the 
incidence of drug resistant TB in a given population. It is important for African countries to 
implement rigorous drug resistant TB surveillance systems as it has been demonstrated that 
16 out of the 30 global high TB and MDR-TB burden countries are found within the 
continent (1). 
Genetic diversity of M. tuberculosis strains has been demonstrated across Africa implying 
that diverse genotypes are driving the epidemiology of drug resistant TB across the continent. 
The diverse genotypes seen in parts of Africa suggest that drug resistant strains are possibly 
being introduced to the region. There are variations from region to region and particular 
genotypes have been demonstrated to be more predominant in certain countries and regions. 
There is a high degree of genetic diversity in the predominant strains in West Africa with 
both ancient and modern strains being associated with drug resistant TB (37, 40, 55).  
The Beijing and LAM genotypes are widespread across Africa demonstrating the ability of 
these “modern strains” to adapt and spread easily (28, 31, 49, 64). It is however worth noting 
that the strain relatedness or transmission dynamics of these genotypes are not fully 
understood due to the lack of highly discriminatory tools of WGS in the reviewed studies. In 
contrast, the “ancient strains” such as the Cameroon and MAF strains are largely restricted to 
West Africa where these strains are mostly associated with drug susceptible TB (37, 40, 60). 
A similar observation is made with the Haarlem genotype which is associated with drug 
resistant TB in North and East Africa (22, 38). 
The drug resistant TB epidemic in Africa has been attributed to several drivers, including 
socio-economic factors (poverty, overcrowded living conditions) and inefficient TB IPC 
policies (inappropriate treatment, lack of surveillance, diagnostic and treatment delay). MDR-
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TB case finding and treatment remain a challenge in Africa with high MDR-TB burden 
countries, such as Nigeria, falling short on treatment enrolment of new MDR-TB cases, 
mainly due to the lack of adequate DST (1).  
There remains a large pool of MDR- and XDR-TB cases that are untreated and are a potential 
source of drug resistant TB in the various communities (1). There is a need for united efforts 
from the continent to improve case detection and treatment for prevention and control of drug 
resistant TB. Further, high mortality rates have been observed in MDR- and XDR-TB 
patients and this is worsened by co-infection with HIV (42). This places emphasis on the 
need to strengthen the integration of HIV/TB screening and treatment in Africa.  
The main challenge for TB activities across the continent is the lack of adequate funding. The 
majority of countries receive limited funding toward the national TB program with almost a 
third of the budget being unfunded on average in Africa (1). Addressing this shortcoming will 
require collaborative efforts from global funders as well as domestic support from local 
government. Concerns regarding international funding have arisen following the proposed 
budget cuts after the election of Donald Trump as the president of the USA and after the 
”Brexit” vote in the UK (92, 93). These changes from the major global TB funders could 
result in the disintegration of already weak TB control programs in developing countries 
across the world.  
Political instability is a source for concern as it leads to failing of health care infrastructure 
which in turn results in poor surveillance and treatment efforts. This has been demonstrated 
in migrant population groups with high rates of untreated drug resistant TB being found in 
these groups (88). There is a need to develop and implement rigorous TB screening and 
treatment of migrants and TB suspects across Africa. This is however made difficult by the 
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poor laboratory infrastructure such as lack of rapid diagnostic techniques for these highly 
mobile population groups. 
Through molecular epidemiology, it has been demonstrated that drug resistant TB which is 
endemic in parts of Africa is both acquired and transmitted. Acquired drug resistant TB is 
largely driven by inadequate treatment, as seen in the case of standardized treatment in the 
absence of DST results, and non-adherence to treatment. On the other hand, drug resistant TB 
has been demonstrated to be transmitted in communities and hospital outbreaks have been 
reported mainly due to poor IPC measures. On average, the treatment success rates for MDR- 
and XDR-TB are low for Africa, 54% and 28% respectively. There are lessons to be learnt 
from model countries on the continent that report higher than average treatment success rates, 
as high as 80%, in Tunisia (1). 
The gap in knowledge on the transmission dynamics and molecular epidemiology of drug 
resistant TB across the continent is a hindrance in the management of drug resistant TB and 
calls for improved surveillance efforts. Molecular epidemiological studies play an important 
role in understanding the transmission dynamics of drug resistant TB across Africa, and will 
play a part in addressing this knowledge gap. 
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Chapter 3: Materials and methods 
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3.1 Study setting 
This study involved molecular characterisation of drug resistant clinical strains of 
Mycobacterium tuberculosis (M.tb) collected from the Tropical Diseases Research Centre 
(TDRC) tuberculosis (TB) reference laboratory in Ndola district on the Copperbelt province 
of Zambia (Figure 1.2, page 12). The TDRC TB reference laboratory has a catchment of 3 
out of 10 provinces; Copperbelt, Luapula and North-Western provinces (Figure 1.2, page 12). 
The centre provides culture-based first line drug susceptibility testing (DST) for all 
presumptive multidrug resistant (MDR)-TB cases (approximately 50 cultures per month); 
these are confirmed TB cases suspected of having MDR-TB either due to treatment failure or 
contact with a confirmed MDR-TB patient (Figure 1.3, page 14). The centre offers diagnostic 
services to government and privately run clinics and hospitals that are within the catchment 
area at no cost to the patient (1). 
Ndola district is also the site for one of the two national MDR-TB wards at Ndola Teaching 
Hospital (NTH) where laboratory confirmed MDR/rifampicin resistant (RR)-TB patients are 
quarantined for part of their second line treatment, until culture negative, and treatment 
response is monitored (1). Similar to the TDRC TB reference laboratory, the NTH MDR-TB 
ward has a catchment of 3 provinces namely; Copperbelt, Luapula and North-Western 
provinces (Figure 1.2, page 12) (1). 
All drug resistant samples for patients diagnosed at the TDRC TB reference laboratory were 
included as part of the study. This included samples from the TDRC TB reference laboratory 
catchment area and samples from outside the catchment area; Muchinga and Northern 
provinces (Figure 1.2, page 12). Samples from children (15 years and below) were excluded. 
Initial sample processing of culture and first line DST to streptomycin, isoniazid, rifampicin 
and ethambutol (SIRE) was conducted at the TDRC TB reference laboratory, a level 2 
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biosafety laboratory with level 3 practices, as per routine. In the recent past, TDRC TB 
reference laboratory has been involved in national surveillance of both drug susceptible and 
drug resistant TB. Molecular typing methods including whole genome sequencing (WGS) 
and Sanger targeted gene sequencing (TGS), insertion sequence 6110-restriction fragment 
length polymorphism (IS6110-RFLP), spacer oligonucleotide typing (spoligotyping), 
described in sections 3.5 and 3.6, and all respective data analysis were performed at the 
Division of Molecular Biology and Human Genetics Stellenbosch University. 
 
3.2 Ethical considerations 
Permission to access clinical specimens and patient records was sought from the Ministry of 
Community Development, Mother and Child Health, and Ministry of Health in Zambia. 
Ethical approval was obtained from the TDRC ethics committee, ethics number: TDRC STC 
2015/9, and the Stellenbosch University Health Research Ethics Committee (HREC), ethics 
number: S15/08/172. Informed consent was obtained from all study participants that were 
followed up for sputum collection by community health workers (CHW) and consent was 
obtained from health care workers (HCWs) that participated in the TB infection prevention 
and control (IPC) knowledge, attitude and practices questionnaire. A waiver of consent was 
obtained for the analysis of samples collected through programmatic diagnosis from the 
TDRC TB reference laboratory. 
In order to uphold patient anonymity, patients were assigned a unique study identification 
(ID) number and were not identified by their name during data analysis and presentation of 
findings. 
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3.3 Organism selection and data collection 
Based on convenience sampling a sample size of 170 out of 184 (92%) drug resistant clinical 
isolates were available following culture based phenotypic DST of 581 samples over a period 
of 15 months from January 2016 to April 2017, including samples stored at the TDRC TB 
reference laboratory. Samples found to be phenotypically drug susceptible were not 
processed further as part of this study. Fourteen samples either did not yield positive cultures 
during subsequent re-culturing at Stellenbosch University (6 samples) or were cultured at the 
University Teaching Hospital in Lusaka and isolates were not available for this study (8 
samples). Primary diagnostic cultures for samples found to be resistant to any first line drugs 
(mono-resistant, poly-resistant and MDR-TB) through phenotypic DST at the TDRC TB 
reference laboratory were collected (Figure 3.1), and stored for subsequent processing. 
Twenty samples previously archived at the TDRC TB reference laboratory, from August 
2014 to December 2015, which had corresponding clinical data were revived through culture. 
To increase the number of samples captured, smear positive sputum samples were collected 
from the busiest TB diagnostic centres in Ndola district namely; New Masala clinic and 
NTH. Community health workers were hired to follow up known MDR-TB patients that were 
lost to follow up by the national TB program and did not have a sample stored at the TDRC 
TB reference laboratory or whose archived sample had no growth after culture revival. 
Samples collected from consenting patients were cultured as described in section 3.4 as per 
routine at the TDRC TB reference laboratory.  
Following approval of waiver of consent to access patient records, clinical and demographic 
data were collected from TB registers at the various TB diagnostic sites and in the case of 
patient follow up, through one-on-one interviews with patients with the aid of CHWs. The 
data collected included; patient name, TB number, age, gender, address, referring 
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clinic/hospital, TB history, Patient type (new, failure, treatment after interruption, relapse, re-
treatment, and defaulter), treatment status and HIV status. 
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Figure 3.1: sample collection strategy used in the study. Abbreviations: NTH, Ndola 
Teaching Hospital; NMC, New Masala Clinic; TDRC, Tropical Diseases Research Centre. 
 
3.4 Mycobacterium tuberculosis Culturing; phenotypic drug susceptibility testing and 
DNA extraction 
A bacteriologic confirmation of M. tuberculosis was made at the various TB diagnostic 
centres through fluorescence smear microscopy using Auramine O staining and grading was 
done according to the National TB and Leprosy Control Program (NTLP) and World Health 
Organisation (WHO) recommendations (1). This was followed by digestion and 
decontamination of sputum using 1% N-acetyl-L-cysteine (NALC) sodium hydroxide 
(NaOH) reagent as per manufacturer’s instructions (BD BBL MycoPrep kit). Decontaminated 
sputum samples were then inoculated into Mycobacteria Growth Indicator Tubes (MGIT) 
culture media and incubated in the BACTEC MGIT 960 culture system (Becton Dickinson 
Diagnostic Instrument Systems, Towson, Maryland, USA) until a culture flagged either 
positive or negative (no growth detected after 42 days of culture). Positive cultures were 
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confirmed to be M. tuberculosis complex using Capilia TB assay (TAUN, Numazu, Japan) 
and cultures found to be positive for M. tuberculosis were subjected to phenotypic DST. 
Phenotypic drug susceptibility testing to the first line drugs streptomycin, isoniazid, 
rifampicin and ethambutol (SIRE) was performed using the BACTEC MGIT 960 SIRE kit, as 
per manufacturer’s instructions, at the TDRC TB reference laboratory and for some isolates 
(70 isolates) at the Division of Molecular Biology and Human Genetics, Stellenbosch 
University, as per routine. A sample volume of 1 mL was stored at -80ºC for any sample that 
showed resistance to any of the first line drugs. DNA extraction and molecular typing was 
done at the Division of Molecular Biology and Human Genetics. 
DNA extraction was performed as per routine and according to published methods (3). 
Briefly, MGIT cultures were grown from stock and positive cultures were re-grown in 7H9 
Middlebrook broth (Becton, Dickinson and Company, Sparks, USA) supplemented with 
glycerol and oleic albumin dextrose catalase (OADC) for approximately 7 days or until 
opaque. One millilitre of the culture was transferred onto 7H11 Middlebrook (Becton, 
Dickinson and Company, Sparks, USA) agar plates for approximately 2-3 weeks or until a 
confluent lawn of M. tuberculosis culture was obtained. The M. tuberculosis cultures on 
7H11 agar plates were heat killed at 80ºC for 2 hours. Bacilli were carefully scraped off the 
media into 6 mL of extraction buffer (50 mM Tris-HCl, 25 mM EDTA, 5% mono-sodium 
glutamate, pH 7.4) in a 50 mL polypropylene tube containing approximately 20 glass beads 
(5 mm diameter) and vortexed for approximately 2 minutes or until homogenous. To degrade 
the cell wall, lysozyme (50 mg Roche, Germany) was added to each bacterial suspension and 
incubated at 37ºC for 2 hours after which 300 μl of a 10 mg/mL stock solution Proteinase K 
(Sigma-Aldrich, St. Louis, USA) and a 10X Proteinase K buffer (100 mM Tris-HCl, 50 mM 
EDTA, 5% SDS, pH 7.8) was added and incubated at 45ºC overnight (16 hours). In order to 
obtain pure DNA, the suspension was treated with 5 mL phenol/chloroform/isoamylalcohol 
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(ration 25:24:1) and incubated at room temperature for 2 hours with gentle mixing every 30 
minutes. The suspension was centrifuged at 3000 x g for 20 minutes and the upper aqueous 
phase was aspirated into a new polypropylene tube containing 5 mL 
chloroform/isoamylalcohol (24:1). The suspension was gently mixed and centrifuged at 3000 
x g for 20 minutes, after which the upper aqueous phase was aspirated into a new 
polypropylene tube containing 700 µl 3M sodium acetate pH 5.2. DNA was precipitated with 
7 mL ice cold isopropanol, collected on a glass rod and washed in 70% ethanol for 10 
minutes after which it was air dried overnight. The air-dried DNA was resuspended in 300 µl 
TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and allowed to redissolve overnight at 
4ºC after which it was stored at -20ºC until further use. The DNA concentration for 
individual samples was quantified using a NanoDrop spectrophotometer (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA). 
 
3.5 Spoligotype analysis 
In order to determine the genotypes associated with drug resistant TB and whether isolates 
were clustered, spoligotyping and IS6110-RFLP were applied in parallel for all 170 drug 
resistant isolates, as per routine at the Division of Molecular Biology and Human Genetics, 
Stellenbosch University, as previously described (4, 5). Spoligotyping is a polymerase chain 
reaction (PCR) based technique that detects variations in the direct repeat (DR) region of M. 
tuberculosis, which consists of multiple 36 bp repetitive sequences interspersed by non-
conserved sequences of about 35-41 bp in length (4). Primers used for spoligotyping were 
DRa (biotin-labelled) and DRb (Appendix 1) which amplify the DR region of the M. 
tuberculosis genomic DNA. The PCR reaction mix for individual samples consisted of 12.5 
µl Kapa Taq PCR ReadyMix (Kapa Biosystem, Wilmington, Massachusetts, United States), 2 
µl of each primer (DRa and DRb), 6.5 µl PCR grade water and 2 µl of template DNA (20 
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ng/µl) making a final volume of 25 µl. The PCR mix with genomic DNA was amplified in a 
thermal cycler with the PCR conditions listed in Table 3.2. 
Table 3.1: Spoligotyping PCR reaction mix 
Component  Volume 
Kapa Taq ReadyMix 12.5 µl 
DRa (biotin-labelled) 2 µl 
DRb 2 µl 
PCR grade water 6.5 µl 
Template DNA (20 ng/µl) 2 µl 
Final volume 25 µl 
 
Table 3.2: Spoligotyping PCR conditions 
Step  Temperature (ºC) Time (minutes, unless 
stated) 
Cycles 
Initial denaturation 95 3 1 
Denaturation 94 1 30 
Annealing 55 1 30 
Extension 72 30 seconds 30 
Final extension 72 10 1 
Hold 4 ∞ 1 
 
M. tuberculosis H37Rv and M. bovis Bacillus Calmette–Guérin (BCG) were amplified as 
positive controls, and negative controls consisted of the PCR mix with PCR grade water. 
Following amplification of the M. tuberculosis DR region for individual samples, 150 µl 
2xSSPE/0.1%SDS was added to 25 µl of the PCR product. This was followed by heat 
denaturation at 99ºC for 10 minutes and immediate cooling on ice. In parallel a nylon 
membrane consisting of 43 immobilized spacer oligonucleotide sequences 
(mapmygenome.in, Hyderabad, India) was washed in 2xSSPE/0.1%SDS at 60ºC for 5 
minutes. The washed nylon membrane was placed on a support cushion in a mini-blotter with 
40 sample slots. Residual fluid was aspirated out of the slots and slots were filled with the 
diluted denatured PCR product, with care to avoid bubbles. The genomic DNA was 
hybridized to the nylon membrane by incubating at 60ºC for 60 minutes. Following 
hybridization, samples were aspirated from the mini-blotter and washed twice in 
2xSSPE/0.5%SDS at 60ºC for 10 minutes. Subsequently, the nylon membrane was incubated 
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in 40 mL of 2xSSPE/0.5%SDS containing 10 µl Strepavidin-peroxidase (Roche, Basel 
Switzerland) at 42ºC for 60 minutes. The nylon membrane was washed twice in 
2xSSPE/0.5%SDS for 5 minutes at 42ºC, followed by a final 5 minute wash in 2xSSPE at 
room temperature.  
To detect the presence of spacers, the nylon membrane was incubated with the ECL-detection 
system (Amersham GE Healthcare, Chicago USA) for 90 seconds. The nylon membrane was 
exposed to an x-ray film for 5 minutes and developed to identify the presence of spacers. 
Black squares on the x-ray film represent the presence of a spacer at that particular position 
while a clear area represents the absence of spacers in the particular position. Spoligotyping 
data was compared to the SITVIT database to determine the lineage and spoligo international 
type (SIT) based on existing patterns in the online SITVIT database (http://www.pasteur-
guadeloupe.fr:8081/SITVIT_ONLINE/). Spoligotype patterns that matched with existing 
patterns on the online SITVIT database were assigned the corresponding SIT and clade while 
patterns that did not exist on the database were defined as orphans, not in SITVIT. 
 
3.6 IS6110-RFLP analysis 
Following DNA extraction and purification, genomic DNA for individual isolates (6 µg) was 
digested using the restriction enzyme PvuII (30 units). To test that the PvuII digestion was 
complete, gel electrophoresis was set up using 1% agarose gel (3g agarose in 300 mL 1x 
Tris-borate-EDTA (TBE), pH 8.3) and 8 µl of PvuII-digested genomic DNA was aliquoted 
into a 0.5 mL tube containing 4 µl 6x loading buffer. The PvuII-digested DNA was separated 
by electrophoresis at 120V for 4 hours after which it was stained by shaking for 30 minutes at 
room temperature in 500 mL 1xTBE containing 1 µg/ml ethidium bromide. The stained gel 
was visualized by trans-illumination at 245nm using a UV light box and the image was 
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captured by photography. Upon confirmation of complete digestion (DNA appeared as 
smears with evident banding patterns on the test gel), the intensity of the test gel was scored 
for each sample, from 12 (faintest bands) to 20 (brightest). This score was used to facilitate 
even loading on the final gel (see below).  
For the final gel to be used in the Southern transfer, the remaining PvuII digested DNA was 
precipitated by adding 10 µl 3M sodium acetate pH5.2 and 300 µl ice cold 100% ethanol, 
mixed and incubated at -20ºC for 16 hours. The DNA was then pelleted by centrifugation at 
14 000xg for 30 minutes at 4ºC. The supernatant was aspirated without disturbing the DNA 
pellet and 500 µl ice cold 70% ethanol was used to wash the DNA followed by a final 
centrifugation step at 14 000xg for 30 minutes at 4ºC. The supernatant was aspirated without 
disturbing the DNA pellet after which the DNA was allowed to dry for 16 hours (overnight). 
The DNA was resuspended with an internal molecular weight marker (IMWM) (volume 
dependent on the intensity of bands in the PvuII digestion test gel, to achieve even loading) 
and incubated at 65ºC for 4 hours with mixing every hour. A final gel (up to 20 samples per 
gel) was set up, the steps followed are as described for the test gel above with minor changes. 
Changes to the final gel included the use of 0.8% agarose gel (2.4g agarose in 300 mL 1x 
TBE, pH 8.3), the loading of 10µl of the PvuII-digested DNA for each sample with an 
external marker M. tuberculosis reference strain Mtb14323 (4), and separation by 
electrophoresis at 65V for 16 hours. The DNA was Southern transferred onto a nylon 
membrane (Hybond N+, GE Healthcare Amersham, Chicago USA). To fix the DNA to the 
nylon membrane, the membrane was baked at 80C for 2 hours. To identify IS6110 elements 
in the genomic DNA, the nylon membrane was hybridized with a horseradish peroxidase 
(HRP) nucleic acid labelling system (GE Healthcare Amersham, Chicago USA) labelled 
IS6110 probe (3), to allow visualisation of the IS6110 element following chemiluminescence. 
Briefly, to label the probe, 200 ng probe DNA was added to a 0.5 mL eppendorf tube and 15 
Stellenbosch University  https://scholar.sun.ac.za
75 | P a g e  
 
µl nuclease free water was added. This was followed by a 5 minute incubation step at 100ºC 
to denature the probe DNA, and DNA was snap cooled on ice for 5 minutes. To label the 
probe, 15 µl of the HRP labelling mix was added to the probe DNA and mixed, after which 
15 µl of gluteraldehyde solution was added and mixed, to aid in conjugation of HRP. This 
was followed by a 10 minute incubation step at 37ºC. To enhance visualisation the probe was 
used immediately. Hybridisation was done using the ECL Gold hybridization buffer 
according to manufactures instructions (GE Healthcare Amersham, Chicago USA). 
To visualise the IS6110 fingerprints, the probe hybridized DNA was detected using the ECL 
detection system (Amersham GE Healthcare, Chicago USA) and subsequently exposed to an 
x-ray film. The presence of bands in the developed films represents the presence of an IS6110 
element in the particular position while a clear region (lack of bands) represents the absence 
of an IS6110 element in the specific position. Similar probe labelling, hybridization and 
visualisation steps were followed for the internal molecular weight marker, which is used to 
obtain accurate and standardized IS6110 RFLP results during computer assisted analysis.  
The resulting autoradiographs were analysed using gel-analysis computer software, 
Gelcompar (Applied Maths, Kortrijk, Belgium). Fingerprints were assigned an IS6110 cluster 
number, based on the positions and copy numbers of IS6110 element, and strains were further 
assigned to an existing family that shared identical IS6110 patterns. Dendograms were 
constructed based on similarity coefficients (6), that is according to the number and position 
of the IS6110 elements identified. Strains sharing identical patterns were defined as clustered, 
suggestive of recent transmission. 
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3.7 Whole genome sequencing 
To determine whether recent transmission had occurred, all 91 strains with purified genomic 
DNA at the window of opportunity for sequencing were sent for WGS. Due to financial 
constraints, not all strains could be analysed using WGS, the remainder of isolates without 
WGS data (84 isolates) were characterised using TGS, described in section 3.8. Whole 
genome sequencing, using the next generation sequencing (NGS) platform Illumina HiSeq 
2000, was performed at the Centers for Disease Control and Prevention (CDC) Atlanta 
Georgia (90 strains) or Beijing Genomics Institute (BGI) Tech Solutions Hong Kong (12 
strains) using the Illumina HiSeq 2500/4000 NGS platform as per routine. For validation and 
quality control (QC) purposes 11 strains were sequenced both at CDC and BGI. 
 
3.7.1 Data analysis 
WGS data were analysed using a data analysis pipeline developed in the Stellenbosch 
University Division of Molecular Biology and Human Genetics, Universal Sequence 
Analysis Pipeline (USAP) (Figure 3.2).  
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Figure 3.2: Universal Sequence Analysis Pipeline (USAP) genome sequence data 
analysis process (7). Abbreviations: BWA, Burrows-Wheeler Aligner; GATK, Genome 
Analysis Tool Kit; in/del, insertions/deletions; PCR, polymerase chain reaction; SAMTools, 
Sequence Alignment/Map tools; SMALT, Sequence Mapping and Alignment Tool. 
 
3.7.2 Alignment and variant detection 
The NGS data analysis pipeline is comprised of various open-source NGS analysis tools 
combined with in-house Python scripts (7). Briefly, as depicted in Figure 3.2, quality 
assessment was performed using FastQC after which reads were pre-processed by removing 
adapters and low quality (phred quality < 20, sliding window of 4 bases) bases using 
Trimmomatic (8). In order to identify genomic variants, high quality reads were aligned to 
the reference M. tuberculosis genome, H37Rv (GenBank NC000962.2), using a combination 
of 3 alignment tools; Burrows-Wheeler Aligner (BWA), Novoalign and Sequence Mapping 
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and Alignment Tool (SMALT) (9, 10). The alignments were validated with Picard tools and 
SAMtools was used to retrieve alignment statistics. The Genome Analysis Tool Kit (GATK) 
was used to detect single nucleotide variants (SNVs) and insertions and deletions (indels) 
according to the GATK Best-Practices and only variants identified in all 3 alignments were 
considered for downstream analyses (7, 11). 
A high confidence variant file was generated for SNVs that were identified in all 3 alignment 
tools by GATK and the file was used for further analysis. 
Using USAP, known mutations conferring resistance to any of the first and second line drugs 
were investigated. Isolates were classified according to lineage and in order to investigate 
strain relatedness (12), the number of SNVs between clustered isolates was determined using 
pairwise comparisons for isolates that were clustered following phylogenetic analysis 
(described further in 3.7.3). Upon pairwise comparison of strains sharing the same terminal 
branches, genomic clusters were defined as strains separated by 12 or fewer SNVs suggestive 
of recent transmission, as previously described (13, 14). 
 
3.7.3 Phylogenetic analysis 
A phylogenetic tree was generated to investigate the evolution and relatedness of 86 isolates 
that were sequenced, 5 failed sequencing and were not included in analysis. Previously 
described M. tuberculosis isolates, representative of the M. tuberculosis complex, were 
included in the phylogenetic tree for reference purposes (Appendix 2). Variants identified in 
repetitive regions, including the pe/ppe and pe_pgrs genes, were excluded for phylogenetic 
analysis. To determine the phylogenetic relationship between the sequenced isolates, high 
confidence variable coding and non-coding SNV sites were used with Randomized 
Axelerated Maximum Likelihood (RaxML), as previously described (7, 15). The general time 
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reversal model of nucleotide substitution (determined with ModelGenerator) was applied to 
construct a maximum likelihood phylogeny with RaxML with 1000 bootstrap pseudo-
replicates. 
 
3.8 Sanger (targeted gene) sequencing and analysis 
Sanger sequencing was performed to identify resistance-conferring mutations to the first line 
drugs rifampicin (rpoB locus), isoniazid (katG and inhA; mutations in these genes results in 
high level and low level resistance, respectively), ethambutol (embB), streptomycin (rrs) and 
pyrazinamide (pncA). To investigate the presence of XDR-TB in the study population, Sanger 
sequencing was performed to identify mutations conferring resistance to fluoroquinolones 
(gyrA) and second line injectable drugs (rrs and tlyA). In total 8 loci associated with drug 
resistance in M. tuberculosis were sequenced and analysed. We performed targeted Sanger 
sequencing for 84 strains (and an additional 6 strains which had both WGS and Sanger 
sequencing performed, for validation purposes). Genomic DNA, either crude or purified 
DNA (25ng/µl), was used to amplify up to 8 genes associated with drug resistance using the 
CFX96 real-time PCR system (Bio-Rad, California, USA), as previously described (16, 17). 
The PCR reaction mix and conditions for individual genes are listed in appendix 1. Briefly, a 
25 µl PCR mix was set up for each sample (90 samples by 8 loci). The reaction mix consisted 
of nuclease free water (making up 25 µl), 2.5 µl of 10x PCR buffer, 0.5 µl magnesium 
chloride (MgCl2), dNTPs (2.5 mM each), forward and reverse primers specific for each loci 
(0.05 mM per primer), Taq polymerase (0.625 U; Qiagen, Germany), 1 µl Syto 9 green 
fluorescent nucleic acid stain (0.05 mM; Thermal Fisher Scientific, Waltham, Massachusetts, 
USA) and either 2.5 µl crude DNA or 1 µl purified DNA (25 ng/µl) was added. Q solution 
(Qiagen, Germany) was added to the PCR mix for amplification of gyrA, rrs and tlyA, to 
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facilitate amplification of G-C rich templates. The M. tuberculosis genome, H37Rv, was used 
as a positive control and nuclease free water was added to the negative control. The PCR 
products were sequenced at the Central Analytical Facilities (CAF), Stellenbosch University, 
as per routine, using the corresponding primers and amplification conditions listed in 
Appendix 1.  
To identify single nucleotide variants (SNVs) and indels, ABI Sanger sequence data was 
aligned to the M. tuberculosis H37Rv (GenBank NC000962.2) reference genome using the 
sequence alignment editor BioEdit (http://www.mbio.ncsu.edu/bioedit/bioedit.html) and 
chromatograms were viewed in Chromas (http://www.technelysium.com.au) in relation to the 
reference genome. To verify the findings, 6 strains were sequenced with both WGS and 
Sanger (targeted gene) sequencing. Mutations identified as resistance-conferring through 
sequencing were validated through comparisons with mutations listed on the TBdream 
database (https://tbdreamdb.ki.se/Info/Default.aspx). 
 
3.9 Knowledge, attitudes and practices of health care workers on TB IPC measures 
A cross sectional study was conducted to assess the knowledge, attitudes and practices 
(KAPs) of HCWs at the NTH MDR-TB ward and the TDRC-TB reference laboratory in 
Ndola district. A self-administered questionnaire (appendix 3) was developed, in consultation 
with an IPC expert, which captured demographic data and KAPs of the HCWs at the named 
facilities. The target population included clinicians, laboratory personnel (technologists and 
scientists), nurses, students, data entry clerks and cleaners who were directly involved in 
sputum collection and processing and/or had contact with MDR/RR-TB patients. Eleven out 
of 17 health care workers, 5 from the NTH MDR-TB ward and 6 from the TDRC TB 
reference laboratory, gave consent to participate in the survey in September 2017.  
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Participants were required to provide consent before filling out the questionnaire and 
questionnaires were anonymised to encourage participants to be forthcoming in their 
responses and for confidentiality. The survey was designed using previously described 
methods from published studies and based on guidelines from the WHO and the NTLP of 
Zambia (18, 19, 20, 21). The questionnaire included 34 questions based on demographics 
(age, gender, profession and highest education level), knowledge of TB transmission, attitude 
towards IPC policies and IPC practices. Ethical approval for this study was obtained from the 
TDRC ethics committee, ethics number: TDRC STC 2015/9. 
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Chapter 4: Drug resistant tuberculosis cases from the Copperbelt province 
and Northern regions of Zambia: Genetic diversity, demographic and 
clinical characteristics. 
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4.1 Introduction 
This chapter describes the genotypes associated with drug resistant TB within the Copperbelt 
province and Northern regions of Zambia diagnosed at the Tropical Diseases Research Centre 
(TDRC) TB reference laboratory in Ndola district as well as the demographic and clinical 
characteristics of patients. Currently, there is very limited knowledge on the genotypes and 
transmission dynamics of TB in Zambia as a whole with no published studies describing the 
genotypes associated with drug resistant TB in the country. Therefore this study aims to 
bridge the gaps in knowledge by describing the genetics and transmission dynamics of drug 
resistant TB for isolates collected from the TDRC TB reference laboratory in Ndola district, 
which has a catchment of 4.1 million (25% of the national population). Understanding the 
genotypes associated with drug resistant TB will be beneficial to the national TB control 
program as it provides a better insight into the population structure of drug resistant TB, 
transmission of these strains and associated risk factors. 
Overall, 170 out of 184 (92%) phenotypically resistant isolates (any form of drug resistance) 
were available for genotyping using spacer oligonucleotide typing (spoligotyping) and 
insertion sequence 6110-based restriction fragment length polymorphism (IS6110-RFLP) as 
described in sections 3.5 and 3.6.  
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4.2 Demographic and clinical characteristics of patients included in the study 
Demographic and clinical data was directly captured into a study register and included age, 
gender, TB history, HIV status, DST results, residential address and treatment status, as 
described in section 3.3. As indicated in Table 4.1, over half of the cases were male (57%) 
and the age range was between 16-63 years old, with 50% of patients falling within the 30 to 
49 years age group. The HIV-TB co-infection rate for patients with a known HIV status was 
64% (79/123); comparable to the WHO estimate of 60% for Zambia, and 47 (28%) patients 
had an unknown HIV status. Close to half of the cases (49%) had failed prior first line 
treatment (either first or retreatment), and a large proportion were new cases (24%), that is 
patients without prior TB treatment or patients with prior TB treatment for less than 1 month. 
The majority of patients (78%) were residents of the Copperbelt province while the 
remainder were diagnosed and/or treated in Ndola, but resided outside the Copperbelt 
province, Ndola district specifically (Figure 4.1). 
Less than half (35%) of the cases included in the current study were still receiving second 
line treatment at the time of sample analysis, while 23% of patients were not started on 
second line treatment, since these cases were not diagnosed with MDR/RR-TB prior to this 
study. A further 12% had completed treatment while close to 3% were lost to follow up and 
9% had died during the course of treatment. The treatment status for 18% of patients was 
unknown, as data was not recorded in the registers.  
Missing clinical and demographic data were observed for all the variables included in the 
current study. The largest gaps were seen in the HIV status (28% of patients had an unknown 
HIV status), TB history (15% of patients had an unknown TB history), and treatment status 
(18% of patients had an unknown treatment status). Gaps in the TB registers observed during 
data collection at the TDRC TB reference laboratory and the NTH MDR-TB ward are 
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concerning and point towards a poor health care system resulting from insufficient resources 
and staff to accurately record routine notification and follow up of MDR-TB cases.  
The drug resistant profiles for isolates included in the study are illustrated in Figure 4.2. From 
these strains 93 were MDR-TB, 32 had added resistance to ethambutol and streptomycin, 
while 13 had added resistance to ethambutol only and 18 to streptomycin only (Figure 4.2). 
There were 12 rifampicin and 23 isoniazid mono resistant cases and 5 streptomycin and 3 
ethambutol mono resistant TB cases. 
Table 4.1: Basic demographic and clinical characteristics of patients with drug resistant 
TB diagnosed at the TDRC TB reference laboratory in Ndola district.  
Variable  Number of patients 
(total=170) 
% 
Gender Male 97 57 
Female  67 39 
Unknown*  6 4 
Age 16-29 49 29 
30-49 85 50 
50-63 13 8 
Unknown*  22 13 
HIV status Positive 79 46 
Negative 44 26 
Unknown* 47 28 
TB history New 41 24 
Relapse 15 10 
After failure of 1
st
 line treatment 45 26 
After failure of 1
st
 line retreatment 43 25 
Unknown* 26 15 
Treatment status Treatment completed 21 12 
Treatment ongoing 60 35 
Lost to follow up (Defaulter)  5 3 
Died  15 9 
2
nd
 line treatment not started 39 23 
Unknown*  30 18 
Residence by Province Copperbelt  133 78 
Luapula  16 9 
Northern  11 6 
North-Western 3 2 
Muchinga  1 1 
Unknown* 6 4 
Abbreviations: TDRC, Tropical Diseases Research Centre; TB, tuberculosis. *not 
indicated in the TB register. 
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Figure 4.1: Distribution of drug resistant TB cases diagnosed at the TDRC TB reference 
laboratory in Ndola district Copperbelt province (highlighted in blue). The distribution 
of cases is according to Province of patient origin and does not include the 6 patients 
with an unknown residence.  
 
 
Figure 4.2: First line drug resistance patterns for individual isolates in the order SIRE 
(Streptomycin, S; Isoniazid, I; Rifampicin, R; Ethambutol, E). Abbreviations: R, resistant 
S, sensitive. 
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4.3 Analysis of spoligotype patterns 
Spoligotype results were compared to existing patterns in the online SITVIT database (1) and 
isolates that shared identical patterns were assigned the existing spoligo international type 
(SIT) number while isolates that had a unique pattern not previously described in the SITVIT 
database were defined as orphans, not in SITVIT. Spoligotype analysis reveals that diverse 
genotypes are associated with drug resistant TB in the study population (Table 4.2 and Figure 
4.2). Three major lineages (lineages 2, 3 and 4) were described with the major clades 
belonging to LAM, T and X (Figure 4.3). There were a total of 18 clusters, with 2 to 26 
strains per cluster; the largest clusters belonged to LAM11_ZWE, SIT 815 (24 strains).  
Previous molecular studies in this region demonstrated that the LAM11_ZWE, T, CAS and X 
were driving the epidemiology of drug susceptible TB in Ndola (2). The findings of the 
current study imply that genotypes associated with drug susceptible TB are evolving to 
become drug resistant in this population. In addition, genotypes not previously described in 
Zambia but other countries such as South Africa, have been identified amongst drug resistant 
M.tb clinical isolates in the study population (3). For instance, lineage 2 isolates belonging to 
the Beijing clade designated SIT 1 (4 strains) and an undefined non-Beijing lineage 2 with 
the SIT 955 (3 strains) were described in the current study. Nine strains (6%) did not exist on 
the online SITVIT database and were therefore defined as orphans. 
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Table 4.2: Summary of the M. tuberculosis spoligotype patterns for drug resistant TB 
cases diagnosed at the TDRC TB reference laboratory (total number of patients=170). 
Clade SIT Spoligotype pattern (spacers 1-43) n *Strains 
from a 
previous 
study (2) 
LAM11_ZWE 815 

 26 25 
LAM11_ZWE 59 

 24 61 
LAM11_ZWE 2173 

 2 None  
LAM11_ZWE 2490 

 1 None 
LAM11_ZWE 2488 

 1 None 
LAM11_ZWE 2385 

 1 None 
LAM9 42 

 12 7 
LAM1 20 

 6 4 
LAM1 961 

 4 None 
LAM1 2522 

 1 None 
LAM4 811 

 3 2 
LAM3 1685 

 1 None 
LAM3 719 

 1 None 
T1 53 

 11 22 
T1 244 

 9 None 
T1 52 

 6 1 
T1 1926 

 4 None 
T1 926 

 2 None 
T1 291 

 1 None 
T1 306 

 1 None 
T3 T2 73 

 3 1 
T1 Orphan 

 1 None 
T1 Orphan 

 1 None 
X1 1080 

 1 None 
X2 137 

 13 12 
X2 476 

 1 None 
CAS1_KILI 21 

 7 1 
Manu3 Orphan 

 1 None 
Beijing 1 

 5 None 
Undefined 955 

 3 None 
Not in SITVIT Orphan 

 2 None 
Not in SITVIT Orphan 

 1 None 
Not in SITVIT Orphan 

 1 None 
Not in SITVIT Orphan 

 1 None 
Not in SITVIT Orphan 

 1 None 
Not in SITVIT Orphan 

 1 None 
Not in SITVIT Orphan 



1 None 
Not in SITVIT Orphan 



1 None 
Abbreviations: CAS, Central Asian; LAM, Latin American Mediterranean; SIT, spoligo 
international type. Orphans are defined as patterns that are not found in the SITVIT database. 
*The number of strains described for spoligotyping findings in a previous study are listed in 
comparison with findings from this study. 
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Figure 4.3: Proportion of strains identified through spoligotype analysis. 
 
4.4 Analysis of IS6110-RFLP fingerprints 
DNA fingerprinting using IS6110-RFLP has been demonstrated to have superior 
discriminatory power over spoligotyping (4, 5). We therefore applied IS6110-RFLP 
fingerprinting in parallel with spoligotyping in order to further differentiate strains. 
Fingerprints were assigned an IS6110 cluster number, based on the positions and copy 
numbers of IS6110 element, and strains were further assigned to an existing family that 
shared identical IS6110 patterns (4), based on those existing on the Stellenbosch University 
Division of Molecular Biology Gelcompar database. Cluster numbers without an existing 
family on the Stellenbosch University Division of Molecular Biology Gelcompar database 
were left blank in the family assignment. 
Similar to spoligotyping findings, IS6110-RFLP demonstrates that diverse genotypes are 
associated with drug resistant TB in the sampled regions of Zambia, implying that various 
strains are driving drug resistance in Zambia (Figure 4.4). According to IS6110-RFLP, 11 
LAM11_ZWE 
LAM other 
T 
X 
BEIJING 
ORPHANS 
Other 
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clusters with 2-5 strains per cluster were identified (Figure 4.4), where clusters were defined 
as strains sharing identical IS6110-RFLP patterns (in terms of band number and position).  
The clustering of strains suggests that drug resistant TB is being transmitted in the study 
population; however there is a need for more detailed analysis and classical epidemiological 
links to support these findings. In contrast, 79 strains had unique patterns that were not 
clustered (Figure 4.4). This implies that drug resistant TB is both acquired and is being 
transmitted in the study population. The presence of unique patterns however could also be 
attributed to the poor case detection rate observed in Zambia, resulting in some cases being 
missed thereby impacting the estimate of transmission.  
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 IS6110-RFLP          ID       Family    IS6110          Spoligotype pattern                      SIT 
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IS6110 RFLP          ID      Family   IS6110          Spoligotype pattern                 SIT 
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Figure 4.4: IS6110-RFLP dendogram for M. tuberculosis strains showing strain 
relatedness. Sample IDs begin with N (starting with N41). The external marker MTB14323 (N 577) 
was included as reference. Highlighted in red are strains with no resistance-conferring mutations 
identified (further discussed in section 6.5). Strains were assigned IS6110 cluster numbers based on 
the positions and copy numbers of IS6110 element, and strains were further assigned to an 
existing family that shared identical IS6110 patterns. Cluster numbers without an existing family 
on Gelcompar were left blank in the family assignment. 
IS6110 RFLP                 ID     Family   IS6110      Spoligotype pattern                         SIT 
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4.5 Comparison of RFLP- IS6110 clusters and spoligotyping clusters 
Comparison of IS6110 clusters revealed that 9 out of 11 clusters were in agreement with 
spoligotyping results (Table 4.3). Strains belonging to low copy clades (LCC) were poorly 
differentiated by IS6110-RFLP (Figure 4.4 and Table 4.3). For instance, strains belonging to 
family 140 (assigned according to an existing family on the Stellenbosch University Division 
of Molecular Biology Gelcompar database) and cluster number 29696 were clustered 
according to IS6110-RFLP, and were better differentiated by spoligotyping (Figure 4.4), 
confirming the low discriminatory power of IS6110-RFLP in differentiating LCCs and the 
superiority of spoligotyping in differentiating these clades (6). From the IS6110-RFLP 
clustered strains, 14 out of 30 (47%) of patients were residents of Ndola district, which would 
be suggestive of a higher transmission rate in this district, however the majority of strains in 
the study were from Ndola district. In total 57% of patients with clustered strains had failed 
treatment, either retreatment or first treatment, while 13% of cases were relapses (Table 4.3).  
Compared to spoligotype clusters (18 clusters), IS6110-RFLP identified fewer clusters 
demonstrating the higher resolution of IS6110-RFLP. This illustrates the importance of 
combining spoligotyping with a higher discriminatory molecular technique for samples 
originating from this population.  
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Table 4.3: Comparison of RFLP-IS6110 clusters with spoligotyping clades and 
characteristics of patients with clustered strains.  
Sample 
ID 
IS6110 SIT number TB history Year 
of 
diagno
sis 
Patient address 
(district/province) 
N341 29695 1926 After failure of 1
st
  treatment 2016 Ndola/CB 
N359 29695 1926 After failure of re- treatment 2016 Samfya/LP 
N422 29695 1926 After failure of re- treatment 2014 unknown/LP  
N307 140 Not in SITVIT After failure of 1
st
  treatment 2016 Ndola/CB 
N225 140 1926 Relapse 2016 Ndola/CB 
N3A 29622 961 After failure of 1
st
  treatment 2015 Kitwe/CB 
N39 29622 961 Relapse  2015 Ndola/CB 
N464  29696 137 New 2017 Kitwe/CB 
N66 29696 137 Unknown 2016 Ndola/CB 
N407 29696 137 New 2016 Ndola/CB 
N482 29696 137 After failure of re- treatment 2016 Kitwe/CB 
N89 29696 137 After failure of 1
st
  treatment 2014 Ndola/CB 
N338 29696 52 After failure of 1
st
  treatment 2016 Ndola/CB 
N430 29696 Not in SITVIT After failure of re- treatment 2016 Chililabombwe/CB 
N352 29696 244 New  2016 Ndola/CB 
N332 29696 244 After failure of 1
st
  treatment 2016 Mpongwe/CB 
N176 29765 52 Relapse 2016 Ndola/CB 
N339 29765 52 New 2016 Ndola/CB 
N63 29765 52 Relapse 2016 Kitwe/CB 
N75 29685 815 Relapse 2016 Kitwe/CB 
N119 29685 815 Unknown 2014 Luanshya/CB 
N56 29685 815 After failure of 1
st
  treatment 2015 Masaiti/CB 
N369 29682 815 After failure of 1
st
 treatment 2015 Kitwe/CB 
N370 29682 815 After failure of re- treatment 2016 Chililabombwe/CB 
N477 29703 59 After failure of re- treatment 2017 Ndola/CB 
N459 29703 59 After failure of re- treatment 2016 Mpika/MP 
N425 29746 59 New 2016 Ndola/CB 
N356 29746 59 After failure of re- treatment 2016 Samfya/LP 
N358 29664 20 After failure of re- treatment 2016 Samfya/LP 
N400 29664 20 After failure of 1
st
  treatment 2016 Ndola/CB 
Abbreviations: CB, Copperbelt province; ID, identification; LP, Luapula province; MP, 
Muchinga province, SIT, spoligo international type; TB, tuberculosis. 
 
 
4.6 Conclusion 
Over half of the cases included in the study were either retreatment failure cases (WHO 
category 2) (25%), or first line treatment failures (26%) (Table 4.1). These findings point to 
an inefficient TB control program. There is a need to implement routine phenotypic DST or 
nucleic acid tests such as Xpert assay or the line probe assay for all confirmed TB cases for 
early case detection of drug resistance and to enable appropriate treatment. These findings 
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further support WHO recommendations of discontinuing with the category 2 retreatment 
regimen in settings with the capacity to perform routine DST, it has been demonstrated that 
adding one drug to a failing regimen promotes selection of resistance (7). Twenty four 
percent of patients were categorised as “new”, that is patients that have not received prior TB 
treatment for longer than one month. Together with clustering of strains, this implies that 
drug resistant TB is being transmitted in the study population. The gaps in demographic and 
clinical data such as HIV status, and the inadequate specimen banking system at TB referral 
level is of great concern as analysis of these data and isolates could lead to misrepresentation 
of the transmission dynamics and evolutionary events of drug resistant TB in the study 
population and Zambia as a whole (8). 
A high level of genotype diversity of drug resistant M. tuberculosis clinical strains has been 
observed within parts of Zambia. This suggests that multiple strains are responsible for drug 
resistant TB, and that acquisition is at least partially driving the burden of drug resistant TB 
in Zambia. It is however worth noting that drug resistant TB strains were possibly missed 
during sample collection due to the poor case detection rate reported for MDR/RR-TB in 
Zambia. Further, identical fingerprinting patterns have been observed amongst these isolates 
suggesting that there is a level of recent transmission of drug resistant TB, 84% and 28% of 
isolates share identical patterns according to spoligotyping and IS6110-RFLP, respectively.  
A previous molecular study which focused largely on drug susceptible TB strains in Ndola 
district revealed that the predominant genotypes belonged to LAM, (specifically 
LAM11_ZWE), T1, X2, and CAS (2). The current study demonstrates that these genotypes 
are further driving drug resistant TB in Ndola district and the surrounding region. This 
implies that the current TB control program is not efficient in preventing the emergence and 
transmission of drug resistant TB in the study population.  
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There are however genotypes that were previously not described in this population group 
such as the lineage 2 Beijing genotype (which has been associated with MDR- and XDR-TB 
outbreaks across the world) and the non-Beijing SIT 955 (3, 9). The presence of Beijing 
genotypes in the study population suggests that migration from high Beijing prevalent areas, 
for example cross border movement between South Africa and Zimbabwe and Zambia, could 
possibly be playing a role in transmission of drug resistant TB strains. A further explanation 
for the identification of lineage 2 genotypes in the study population could be the high influx 
of Chinese workforce involved in road and other construction works in Zambia and the 
surrounding region, with an estimate of up to 18,000 Chinese in Zambia in 2015 (10). The 
LAM11_ZWE, T and X clades, on the other hand, have been demonstrated to be widespread 
in the sampled provinces, in the current study and previously (1, 11). These genotypes have 
further been described to be prevalent in neighbouring countries including Tanzania and 
Zimbabwe (11). There is however need to further evaluate the degree of strain relatedness 
amongst clustered strains which have been observed in the current study, and in so doing 
determine the extent of transmission in the study population and the surrounding region. 
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Chapter 5: Molecular analysis of transmission of drug resistant 
tuberculosis from the Copperbelt province and Northern regions of Zambia 
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5.1 Introduction 
In this chapter, whole genome sequence (WGS) analysis was applied to further investigate the 
degree of strain relatedness amongst clustered strains. Whole genome sequencing has been 
demonstrated to have a higher discriminatory power compared to traditional genotyping 
methods in molecular epidemiological studies of Mycobacterium tuberculosis (M.tb) (1). 
WGS has been used to classify outbreaks which conventional genotyping methods are 
unlikely to discriminate accurately as these techniques mostly probe less than 1% of the 
genome (1). It has further been demonstrated to be useful in understanding evolutionary 
events in M.tb to identify drug resistance through analysis of known drug resistance-
conferring mutations (2, 3). The use of WGS in M.tb molecular investigations is rapidly 
becoming available across the world due to decreased cost, increased throughput and 
advancement of the technology. However, the lack of expertise and financial constraints mean 
that is has not been fully applied in low to middle income countries such as Zambia. 
The usefulness of WGS for understanding transmission dynamics and as a rapid TB screening 
tool has been demonstrated in two studies in Zambia (4, 5). In one study, WGS data was used 
to differentiate relapses and re-infection through single nucleotide variant (SNV) analysis; 
this study identified low SNV differences in serial patient samples which was suggestive of 
relapse (4). In another study, WGS analysis was used to screen for M.tb in paediatric 
pneumonia patients from University Teaching Hospital (UTH) in Lusaka, highlighting the 
diagnostic value of WGS (5). To date, the current study provides the most extensive use of 
WGS to describe strain relatedness and drug resistance-conferring mutations in M.tb clinical 
isolates from Zambia. 
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5.2 Analysis of whole genome sequencing data 
WGS was performed on 91 out of 170 clinical isolates (54%) with purified DNA (section 
3.3). Genomic DNA was sequenced either at the Centers for Disease Control and Prevention 
(CDC) Atlanta Georgia (90 strains) or Beijing Genomics Institute (BGI) Tech Solutions Hong 
Kong (12 strains) using the Illumina HiSeq next generation sequencing (NGS) platform as per 
routine. For validation and quality control (QC) purposes 11 strains were sequenced both at 
CDC and BGI. Targeted Sanger sequencing was done on the remainder of strains to identify 
resistance-conferring mutations to first and second line drugs (described in chapter 6). Five 
samples failed initial QC due to low depth of coverage (less than 20x). Therefore WGS data 
for 86 (51%) strains were analysed and are described in this chapter.  
The FASTQ data files generated from WGS were analysed using the customised in-house 
WGS analysis pipeline, Universal Sequence Analysis Pipeline (USAP), as described in 
section 3.7. The resulting high confidence variant files generated from USAP were used here 
to describe the transmission and evolutionary events in the genomes of drug resistant TB 
isolates diagnosed at the TDRC TB reference laboratory in Ndola district, Zambia. Thereby 
addressing Objectives 2, 3 and 4 (section 1.5.3). 
 
5.3 Summary of whole genome sequencing data 
Eighty-six clinical strains showed coverage of more than 20x therefore passing WGS QC 
(Table 5.1). The depth of coverage for the sequenced genomes ranged from 24x to 758x and 
for these isolates, over 96% of the sequencing reads aligned to the M.tb H37Rv (GenBank 
NC000962.2) reference genome.  
The USAP pipeline includes a feature which uses lineage-defining SNVs to assign lineages 
based on WGS data (6). Similar to spoligotyping and RFLP-IS6110 findings (supplementary 
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Table 1, https://tinyurl.com/Zambia-DRTB), the majority of strains belonged to lineage 4.3 
(LAM; 42 strains). Other strains belonged to lineage 4.9 (H37Rv like; 18 strains), 4.1.1.3 
(Haarlem; 6 strains), 4.6.1 (Uganda; 5 strains), lineage 2.2 (Beijing; 5 strains), lineage 3 
(CAS; 2 strains), lineage 4.3.2 (LAM3; 2 strains), and an undefined sub-lineage 4 (6 strains) 
(Table 5.1).  
A further feature of the USAP pipeline is an automated drug resistance classification, based 
on mutations known to confer drug resistance; application of this tool revealed that 16 of the 
sequenced strains were wild type (WT) in known drug resistance conferring genes. These 
were retained in the subsequent analyses for comparative purposes. A total of 58 MDR-TB 
strains were identified amongst the sequenced strains and a further 12 drug resistant strains 
(either mono- or poly-resistant) were identified.  
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Table 5.1: Summary of WGS data for 86 clinical strains sequenced at the CDC and BGI 
Tech solutions.  
Sample 
ID 
Date of 
Culture 
Average 
Coverage 
Mapped 
reads 
Lineage Family  DR 
classification 
Spolpred octal 
code 
N003 2015 122 99.04% 4.3 
Euro-American 
(LAM) MDR 407777607760771 
N011 2015 60 98.68% 4.3 
Euro-American 
(LAM) DS 675556606060371 
N024 2015 50 98.57% 4.9 
Euro-American 
H37Rv like MDR 337756677720601 
N025 2016 55 98.15% 2.2 
East-Asian 
(Beijing) MDR 000000000003551 
N026 2016 58 99.08% 2.2 
East-Asian 
(Beijing) MDR 000000000003751 
N037 2015 67 97.97% 4.9 
Euro-American 
H37Rv like DR 777375777640771 
N038 2015 70 98.25% 2.2 
East-Asian 
(Beijing) MDR 000000000003731 
N039 2015 50 98.94% 4.3 
Euro-American 
(LAM) MDR 406777607660651 
N040 2015 59 99.02% 4.3 
Euro-American 
(LAM) MDR 407737407620711 
N041 2015 59 99.09% 4.9 H37Rv like DS 737377137420671 
N042 2015 50 98.94% 4.3 
Euro-American 
(LAM) MDR 633677406040771 
N043 2015 62 98.61% 2.2 
East-Asian 
(Beijing) MDR 000000000003251 
N050 2014 65 99.62% 3 
East-African-
Indian (CAS) MDR 301335400001571 
N052 2014 82 99.25% 4.3 
Euro-American 
(LAM) MDR 323756606060751 
N053 2015 54 99.16% 4.6.1 
Euro-American 
(Uganda) MDR 452307637720531 
N054 2014 86 99.06% 4.3 
Euro-American 
(LAM) MDR 377777406060771 
N055 2014 67 99.02% 4.9 
Euro-American 
H37Rv like DR 477772777760601 
N056 2015 60 99.29% 4.3 
Euro-American 
(LAM) MDR 777767606060131 
N057 2015 79 99.04% 4.3 
Euro-American 
(LAM) DS 777337406060771 
N059 2015 56 98.10% 2.2 
East-Asian 
(Beijing) DR 000000000003451 
N060 2016 57 99.46% 4.9 
Euro-American 
H37Rv like MDR 673572203460751 
N061 2016 62 98.72% 4.3 
Euro-American 
(LAM) MDR 377755606060570 
N062 2014 61 99.10% 4.6.1 
Euro-American 
(Uganda) MDR 676561737640731 
N064 2016 101 96.02% 4.3 
Euro-American 
(LAM) MDR 777777606060331 
N065 2016 76 97.27% 4.9 
Euro-American 
H37Rv like DS 774000017640731 
N066 2016 42 99.12% 4.9 
Euro-American 
H37Rv like MDR 725102416720201 
N067 2014 61 98.90% 4.9 
Euro-American 
H37Rv like MDR 763766776760601 
N070 2016 74 98.96% 4.3 
Euro-American 
(LAM) MDR 777773606060651 
N071 2016 63 99.37% 4 Euro-American MDR 777773677760770 
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(UNSP) H37Rv like 
N074 2016 89 98.54% 4.1.1.3 
Euro-American 
Haarlem DR 777776737740701 
N075 2016 84 99.29% 4.3 
Euro-American 
(LAM) MDR 777777606060331 
N076 2016 71 99.18% 4.3 
Euro-American 
(LAM) DS 733177606000771 
N083 2016 24 97.48% 4.3 
Euro-American 
(LAM) MDR 401200204000000 
N089 2014 103 98.52% 4.9 
Euro-American 
H37Rv like DR 777776777760401 
N101 2016 39 98.77% 4.3 
Euro-American 
(LAM) MDR 674573406500671 
N105 2016 46 99.18% 
4 
(UNSP) 
Euro-American 
H37Rv like MDR 527125214500150 
N110 2016 66 98.23% 
4 
(UNSP) 
Euro-American 
H37Rv like MDR 761737737560571 
N113 2016 87 98.85% 4.9 
Euro-American 
H37Rv like DR 577776577760601 
N119 2014 110 98.68% 4.3 
Euro-American 
(LAM) MDR 777773606060731 
N133 2016 60 98.53% 4.9 
Euro-American 
H37Rv like DR 767572657760401 
N139 2016 82 99.21% 4.3 
Euro-American 
(LAM) MDR 777777204060531 
N140 2016 47 99.18% 4.3 
Euro-American 
(LAM) MDR 633705004060701 
N176 2016 63 99.16% 4.6.1 
Euro-American 
(Uganda) MDR 777635377620710 
N192 2016 96 98.91% 4.3 
Euro-American 
(LAM) MDR 777777606060771 
N199 2016 79 99.08% 4.3 
Euro-American 
(LAM) MDR 737777606060731 
N227 2016 50 98.70% 4.1.1.3 
Euro-American 
Haarlem DS 737362616000001 
N240 2016 58 99.12% 4.3 
Euro-American 
(LAM) DS 753573206040571 
N262 2016 40 99.06% 4.3 
Euro-American 
(LAM) DS 377304406020530 
N271 2016 44 98.98% 4.9 
Euro-American 
H37Rv like DS 573702615400600 
N283 2016 45 99.00% 4.9 
Euro-American 
H37Rv like DS 573426637240000 
N292 2016 38 79.82% 3 
East-African-
Indian (CAS) MDR 702322400001001 
N296 2016 36 99.26% 4.3 
Euro-American 
(LAM) DS 226171406060111 
N311 2016 50 98.85% 4.3.2 
Euro-American 
(LAM3) DR 132005407500311 
N332 2016 78 98.52% 4.9 
Euro-American 
H37Rv like MDR 777776737740601 
N338 2016 67 98.37% 4.9 
Euro-American 
H37Rv like MDR 577676737500601 
N339 2016 53 99.15% 4.6.1 
Euro-American 
(Uganda) MDR 657417677700321 
N341 2016 53 98.31% 4.1.1.3 
Euro-American 
Haarlem MDR 736716375300401 
N346 2016 56 99.76% 4.3 
Euro-American 
(LAM) DS 656217206060311 
N352 2016 56 98.66% 4.9 Euro-American MDR 077636757760601 
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H37Rv like 
N354 2016 62 96.33% 4.9 
Euro-American 
H37Rv like MDR 467752777560600 
N356 2016 59 99.19% 4.3 
Euro-American 
(LAM) MDR 573135606040551 
N357 2016 90 98.88% 4.3 
Euro-American 
(LAM) MDR 777777606060731 
N358 2016 48 98.61% 4.3 
Euro-American 
(LAM) MDR 061715407620550 
N359 2016 48 98.13% 4.1.1.3 
Euro-American 
Haarlem MDR 071416036400001 
N360 2016 47 99.55% 
4 
(UNSP) 
Euro-American 
H37Rv like MDR 633313637420770 
N365 2016 51 88.56% 4.6.1 
Euro-American 
(Uganda) DR 723737456060711 
N368 2016 62 98.66% 4.3 
Euro-American 
(LAM) DR 777753603540071 
N369 2016 68 98.86% 4.3 
Euro-American 
(LAM) MDR 774637606060731 
N370 2016 56 98.81% 4.3 
Euro-American 
(LAM) MDR 765373406060730 
N373 2016 59 99.21% 4.3 
Euro-American 
(LAM) DR 776007606040610 
N374 2016 39 99.26% 4.3 
Euro-American 
(LAM) MDR 775111006040431 
N375 2016 50 99.37% 4.3 
Euro-American 
(LAM) MDR 761037406040531 
N392 2016 51 99.28% 4.3 
Euro-American 
(LAM) MDR 675543206060551 
N400 2016 45 99.17% 4.3 
Euro-American 
(LAM) MDR 657340607420540 
N412A 2015 56 98.94% 4.3 
Euro-American 
(LAM) DS 236572406040741 
N416 2016 66 98.75 4.3 
Euro-American 
(LAM) MDR 757747607160330 
N420 2016 49 98.94% 4.9 
Euro-American 
H37Rv like MDR 175742117040001 
N422 2016 52 98.78% 4.1.1.3 
Euro-American 
Haarlem MDR 473156517320101 
N423 2016 56 98.99% 
4 
(UNSP) 
Euro-American 
H37Rv like MDR 575565716620111 
N425 2016 63 90.90% 4.3 
Euro-American 
(LAM) MDR 737633606040740 
N426 2016 67 98.60% 4.3 
Euro-American 
(LAM) MDR 677373407640671 
N427 2016 758 97.93% 4.3 
Euro-American 
(LAM) DS 777417606060731 
N429 2017 67 98.73% 4.3.2 
Euro-American 
(LAM3) DR 426137007740770 
N430 2016 92 98.85% 4.3 
Euro-American 
(LAM) MDR 777777606060531 
N431 2016 79 99.05% 
4 
(UNSP) 
Euro-American 
H37Rv like DS 777771777760761 
N446 2014 88 98.63% 4.1.1.3 
Euro-American 
Haarlem DS 777576777720771 
Abbreviations: DR, drug resistant; DS, drug susceptible; ID, identification; MDR, multidrug 
resistant; UNSP, unspecified. 
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5.4 Validation of whole genome sequencing data 
Eleven isolates, from the same DNA stock, were independently resequenced for validation 
purposes at the CDC and BGI Tech solutions. All strains passed QC with an average depth of 
coverage of over 38x and more than 98% of the reads aligned to the M.tb H37Rv reference 
genome (Table 5.2). USAP analysis of the resulting independent sequences yielded 
corresponding SNV results. Crucially, there were no unique SNVs identified between 
duplicate samples sequenced at the CDC and BGI. 
Table 5.2: Comparison of sequencing data for 11 strains resequenced at the CDC and 
BGI Tech solutions.  
Patient ID Average coverage Mapped read (%) Lineage 
 CDC BGI CDC BGI CDC BGI 
N038 70 89 98.57 89 2.2 2.2 
N043 70 103 98.61 97.65 2.2 2.2 
N059 56 104 98.80 95.20 2.2 2.2 
N369 68 105 98.86 98.11 4.3 4.3 
N370 56 116 98.81 99.06 4.3 4.3 
N373 59 100 99.21 96.45 4.3 4.3 
N374 39 102 99.26 95.03 4.3 4.3 
N375 50 101 99.37 96.40 4.3 4.3 
N392 51 101 99.28 96.54 4.3 4.3 
N412A 56 115 98.94 98.93 4.3 4.3 
N430 92 115 98.85 98.90 4.3 4.3 
Abbreviations: BGI, Beijing Genomics Institute; CDC, Centers for Disease Control and 
Prevention; ID, identification. 
 
5.5 Phylogenetic analysis of whole genomes 
To determine the phylogenetic relationship between the 86 sequenced isolates, high 
confidence variable coding and non-coding SNV sites were used to construct a maximum 
likelihood phylogeny with Randomized Axelerated Maximum Likelihood (RaxML), and the 
resulting phylogeny was viewed and edited in FigTree (7). Previously described M.tb isolates, 
representative of lineages 2, 3 and 4 of the M.tb complex, were included in the phylogenetic 
tree for reference purposes (appendix 2). Strains without known resistance-conferring 
mutations (as identified by USAP) were included for comparative purposes. In agreement 
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with the lineage assignments described above, the resulting tree shows that 42 (92%) of the 
sequenced isolates belong to lineage 4, predominantly LAM, while other genotypes belong to 
lineage 2 and 3 (Figure 5.1). There were no isolates from lineages 1, 5, 6 and 7 identified in 
this study population.  
Similar to spoligotyping and IS6110-RFLP findings, WGS suggested that there is a high 
degree of genetic diversity amongst drug resistant TB strains from this study population. 
Furthermore, initial phylogenetic analysis (Figure 5.1) demonstrates a level of clustering. To 
determine how closely related strains were, pairwise comparisons were made (described 
further in section 5.6).  
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Figure 5.1: Genome-wide single nucleotide variant (SNV) based phylogenetic analysis of 
86 M.tb clinical isolates collected from the TDRC TB reference laboratory. To determine 
the phylogenetic relationship between the sequenced isolates, high confidence variable 
coding and non-coding SNV sites were used with Randomized Axelerated Maximum 
Likelihood (RaxML) (7). The replicate tree percentage for clustered taxa in the bootstrap test 
(1000 replicates) is shown next to the nodes. Sample codes from this study begin with N 
followed by the isolate ID (starting with N26). Published M.tb genomes (Appendix 2; M. 
canettii, M. africanum, M. bovis, M. tuberculosis T92, T17, 95_=545, K21, K67, Mt257, 
T67, HN878-27, T85, 00-1695, 98_1833, M4100A, K49, 91_0079, K37, H37Rv, GM_1503) 
are included for reference purposes. The * after the sample ID represent strains genotypically 
identified as having no resistance conferring mutations. Serial isolates from the same patient 
(N025 and N026) are highlighted in red. CDC after the sample ID denotes samples sequenced 
at the CDC while BGI denotes samples sequenced at BGI. Abbreviations: BGI, Beijing 
Genomics Institute; CDC, Centers for Disease Control and Prevention; ID, identification; TB, 
tuberculosis; TDRC, Tropical Diseases Research Centre; UNSP, unspecified. 
 
5.6 Single nucleotide variant (SNV) analysis of clustered strains 
Following alignment to the M.tb H37Rv reference genome, an annotated variant file for the 
individual strains (86 strains) was generated for SNVs and used for pairwise comparison, to 
identify unique nucleotide variances between strains of the same lineage. Filters were applied 
to identity only SNVs identified in all 3 alignment tools by Genome Analysis Tool Kit 
(GATK). Low quality variants (depth of coverage less than 20x) and variants identified in 
repetitive regions, including the pe/ppe and pe_pgrs genes, were excluded. 
To assess strain relatedness, phylogenetic tree-based clusters (hereafter referred to as 
“clusters”) were defined as strains within the same terminal branches (Figure 5.1). The 
number of unique SNVs between clustered strains was determined through pairwise analysis 
of clustered strains. Upon pairwise comparison of strains sharing the same terminal branches, 
genomic clusters were defined as strains separated by 12 or fewer SNVs which is suggestive 
of recent transmission, as previously described (8, 9). 
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5.6.1 Lineage 2.2 cluster analysis 
In total there were 5 sequenced strains in lineage 2.2 (N025, N026, N038, N43and N059), 
Two strains however were serial isolates collected from the same patient (N025 and N026, at 
diagnosis and follow up, respectively) and as expected, the two isolates had low SNV 
differences between them (Table 5.3), one SNV in N025 (a deletion in Rv3479). Cluster 
analysis of the remaining lineage 2.2 strains identified a genomic cluster of two strains (N026 
and N43). Analysis of the two clustered strains (N026 and N43) revealed low SNV 
differences (two unique non-synonymous SNVs) relative to M.tb H37Rv (Table 5.3). Both 
SNVs were found in N043, in Rv1747 (presumed to be involved in cell processes) and 
Rv2630 (a hypothetical protein of unknown function) (10). The two strains shared identical 
drug resistance-conferring mutations in rpoB (codon position 531, TCG-TTG), katG (codon 
position 315, AGC-ACC), embB (codon position 497, CAG-CGG; 1082, ACC-GCC) and 
rpsL (codon position 43, AAG-AGG), further validating how closely related the two strains 
were. The remaining two strains from lineage 2.2 (N038 and N059) were not clustered 
(Figure 5.1) 
Patients N026 and N043 were diagnosed in 2016 and 2015, respectively, and both were 
receiving second line treatment at the time of data collection in 2016. Whereas spoligotyping 
data provided an indication of relatedness between these strains (both strains were assigned 
as belonging to the Beijing clade, SIT 1), IS6110-RFLP showed a level of differentiation; 
both strains were assigned to family 29, but strains had different IS6110 cluster numbers 
(section 4.4). WGS provides a level of detail that supports very recent transmission between 
these patients. The low SNV differences identified in these two clustered strains and the 
similarities in drug resistance-conferring mutations is highly suggestive that lineage 2 strains 
are being transmitted in the study population. Both patients were residents of the Copperbelt 
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province, although in different districts, namely Mufulira district (N043) and Ndola district 
(N026). This further implies that drug resistant TB strains are possibly wide spread across 
parts of Zambia; alternatively nosocomial transmission is occurring during quarantine at the 
NTH MDR-TB ward. However, there is need for epidemiological data linking the patients to 
confidently draw any conclusions on transmission. 
 
5.6.2 Lineage 3.3 cluster analysis 
WGS data was obtained for two lineage 3.3 strains (N050 and N292; Figure 5.1); these 
strains had 30 SNVs differences between them (Table 5.3). Although they had the same 
resistance-conferring mutations in katG (codon position 315, AGC-ACC) (supplementary 
Table 1, https://tinyurl.com/Zambia-DRTB), the strains had additional, differing drug 
resistance-conferring mutations. For strain N050 these added mutations occurred in rpoB 
(codon position 516, GAC-GTC), rpsL (codon position 43, AAG-AGG) and embB (codon 
position 306, ATG-ATA). Strain N292 had added mutations in rpoB (codon position 526, 
CAC-GAC) and embB (codon position 306, ATG-TTG). The patients were admitted to the 
NTH MDR-TB ward in 2014 (N050) and in 2016 (N292). Treatment was completed in one 
(N050) while patient N292 died while on second line treatment. Patient N292 was a resident 
of Kitwe district on the Copperbelt province while patient N050 was a resident of 
Mwinilunga district in North-western province (Supplementary Table 1). Together, the 
available data suggests independent transmission events, with strains possibly evolving 
independently. However, more complete sampling would be required to accurately define the 
transmission and evolution of these strains. 
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5.6.3 Lineage 4 cluster analysis 
There were two clusters of drug resistant strains belonging to lineage 4 (unspecified sub-
lineage) which had two strains (N071 and N110) and three strains (N105, N423 and N360) 
per cluster (Figure 5.1). Two clustered strains (N041 and N065) were drug susceptible 
according to WGS and were therefore not included in the analysis. All clustered drug 
resistant strains in this unclassified sub-lineage shared the same mutations in rpoB (codon 
position 531, TCG-TTG), katG (codon position 315, AGC-ACC), pncA (codon position 35, 
CTG-CGG).  
The two strains from the same cluster (N71 and N110) had added mutations in embB (codon 
position 306, ATG-GTG; codon position 406, GGC-GCC) (Supplementary Table 1, 
https://tinyurl.com/Zambia-DRTB). These strains had 3 SNV differences between them, 
suggestive of very recent transmission events (Table 5.3). The nucleotide variant identified in 
N110 was in Rv1165 (probable GTP binding protein) and two SNVs were identified in N071 
in Rv0358 and Rv0486 (10). Both patients were from the Copperbelt province, patient N071 
from Ndola district and patient N110 from Mufulira district were diagnosed in 2016. One 
patient was admitted to the NTH MDR-TB ward while the other (N110) was not admitted at 
the time of data collection, raising concerns over MDR-TB patient enrolment to treatment. 
The low SNV difference identified between the two patient strains (3 SNVs) and the 
similarities in resistance conferring mutations is suggestive of recent transmission and 
implies that the sub-lineage is being transmitted in the study population. 
The second cluster consisted of 3 strains N105, N423 and N360 with added mutations in 
rpoB (codon 633, CGC-TGC) and one strain (N360) had a mutation in embB (codon position 
306, ATG-GTG). Nucleotide variance analysis revealed high SNV differences, compared to 
the genomic cluster described above, ranging from 22 to 43 SNV differences between strains 
Stellenbosch University  https://scholar.sun.ac.za
116 | P a g e  
 
(Table 5.3). This data is suggestive of isolates evolving independently and is supported by 
spoligotyping and the IS6110-RFLP data which demonstrated that strains were not clustered 
(section 4.4). According to spoligotyping, all 5 sequenced strains from this lineage belonged 
to the T1 clade 3 strains belonged to the SIT 53 (N071, N110 and N423) while the other two 
strains belonged to SIT 926 (N360) and SIT 291 (N105) (section 4.4). IS6110-RFLP data was 
available for 4 strains out of the 5 with two families identified, family 18 (N071 and N423) 
and family 19 (N105 and N110), none of the strains were clustered according to IS6110-
RFLP (section 4.4).  
The data provided here demonstrates the presence of one genomic cluster in this lineage 
(N071 and N110), implying that drug resistant TB strains from this lineage are being 
transmitted in Zambia.  
 
5.6.4 Lineage 4.3 
In the current study, lineage 4.3 has been demonstrated to be the predominant genotype 
associated with drug resistant TB. From the sequenced strains, 42 (49%) belonged to lineage 
4.3, and 11 clusters with 2 strains per cluster were identified and analysed further for strain 
relatedness (Figure 5.1).  
Five genomic clusters were identified from the 11 clustered strains (Table 5.3), that is strains 
with 12 or fewer SNV differences between them (8, 9). The most closely related strains had 4 
SNV differences between them N003 (3 SNVs) and N039 (1 SNV) (Table 5.3). Strains N003 
and N039 shared similar resistance-conferring mutations in rpoB (codon position 526, CAC-
AAC), katG (codon position 315, AGC-ACC) and kasA (codon position 269, GGT-AGT) 
(Supplementary Table 1, https://tinyurl.com/Zambia-DRTB). Both patients were diagnosed in 
2015, one patient (N039) was admitted to the NTH MDR-TB ward while the second was not 
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admitted, however the treatment status for both patients is unknown. Both patients were from 
the Copperbelt province, Ndola district (N039) and Kitwe district (N003). Spoligotyping 
assigned both strains to LAM1, SIT 961, and IS6110-RFLP assigned both strains to family 
14, indicating strain relatedness (section 4.4).  
Strains N042 (2 SNVs) and N083 (3 SNVs) had low nucleotide variance differences between 
them and it was further demonstrated that strains shared similar mutations in rpoB (codon 
position 531, TCG-TTG) and katG (codon position 315, AGC-ACC). Both patients were 
admitted to the NTH MDR-TB ward in 2015 (N042) and 2016 (N083), treatment was 
ongoing for patient N083 at the time of data collection while patient N042 was lost to follow 
up. One patient was from Kitwe district on the Copperbelt province while the other was from 
Mpulungu district in Northern Province. 
In the third genomic cluster strains had 7 SNV differences between them, N358 (4 SNVs) and 
N400 (3 SNVs), both patients had similar resistance-conferring mutations in rpoB (codon 
position 531, TCG-TTG) and katG (codon position 315, AGC-ACC). One patient (N358) 
was admitted to the NTH MDR-TB ward and was receiving second line treatment while the 
second patient (N400) was not admitted at the time of data collection. Patient N358 was from 
Samfya district in Luapula province while patient N400 was from Ndola district.  
Strains N056 (2 SNVs) and N075 (7 SNVs) had 9 SNV differences between them and shared 
similar resistance-conferring mutations in rpoB (codon position 531, TCG-TTG), katG 
(codon position 315, AGC-ACC), embB (codon position 306, ATG-GTG) and in pncA 
(codon 58, TTC-TCC). One patient (N075) was defined as a relapse after completing second 
line treatment, while the second (N056) was not admitted to the NTH MDR-TB ward 
following diagnosis in 2015. Both patients were from the Copperbelt province, Kitwe district 
(N075) and Masaiti district (N056). 
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There were 12 SNV differences between strains N425 (4 SNVs) and N192 (8 SNVs), 
suggestive of recent transmission. These strains shared similar resistance-conferring 
mutations in rpoB (codon position 511, CTG-CGG; 516, GAC-TAC), katG (codon position 
315, AGC-ACC), embB (codon position 306, ATG-ATA) and in pncA (codon 119, TGG-
TGT). Both patients were admitted to the NTH MDR-TB ward in 2016, one patient (N192) 
was receiving treatment at the time of data collection while the treatment status for the 
second patient was unknown (not recorded in the register). Patient N192 was from Luapula 
province while patient N425 was from Ndola district on the Copperbelt province. Other 
genomic clusters identified in lineage 4.3 belonged to N374 (2 SNVs) and N375 (3 SNVs) 
(further discussed in section 5.7 below).  
Genomic clusters with low SNV differences have been identified in lineage 4.3 using WGS 
analysis, these findings are complemented by spoligotyping and IS6110-RFLP data which 
suggests a level of strain relatedness amongst the clustered strains from lineage 4.3. The 
genomic clusters have been demonstrated to share similar resistance-conferring mutations. 
These findings are suggestive of recent transmission of these drug resistant strains in the 
study population. It is concerning that a proportion of MDR-TB patients were not admitted 
for second line treatment. 
 
5.6.5 Lineage 4.6.1 cluster analysis 
In total, 4 drug resistant strains were identified as belonging to sub-lineage 4.6.1 by WGS 
(Figure 5.1). Analysis of 3 clustered strains (N062, N176 and N339) from lineage 4.6.1 
revealed that strains had low SNVs between them (Table 5.3). Comparison of N176 with 
N339 revealed that there were 12 SNV differences between them, 6 unique SNVs were 
identified in each strain. Comparisons between N062 and N176 revealed 13 SNV differences 
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between the strains, and comparisons between N062 and N339 identified 14 SNV 
differences, suggestive of some level of recent transmission of these strains (Table 5.3). 
Further analysis revealed that isolates from this cluster shared similar resistance-conferring 
mutations in gyrA (codon position 80, ACC-GCC), katG (codon position 315, AGC-ACC), 
rpoB (codon position 526, CAC-GAC) and one strain (N062) had a further insertion of G at 
position 450 in the pncA gene. Demographic data showed that all 3 patients from this cluster 
were from Ndola district and had previously been admitted to the NTH MDR-TB ward, in 
2016 (N176 and N339) and 2014 (N062). One patient (N176) was receiving second line 
treatment during data collection, one had completed treatment (N062) and the other (N339) 
died while on treatment. 
One strain (N053) was clustered with a strain (N365) identified as drug susceptible through 
WGS (Figure 5.1). The drug resistant strain (N053) had resistance-conferring mutations in 
gyrA (codon position 80, ACC-GCC), katG (codon position 337, TAC-TGC) and a double 
mutation in rpoB (codon position 516, GAC-GTC; 526, CAC-CAG). The patient (N053) was 
from Samfya district in Luapula province, and was diagnosed in 2015, however the patient 
died while receiving second line treatment. 
The data presented here demonstrates that there is a level of recent transmission amongst 
strains from sub-lineage 4.6.1 in the study population with low SNV differences identified. 
The WGS findings are similar to IS6110-RFLP and spoligotyping findings which assigned 
the strains to respective clusters (section 4.4). Spoligotyping however assigned all 3 strains 
(N062, N176 and N339) as belonging to T2, SIT 52, N053 was assigned to T3T2, SIT 73 
(Supplementary Table 1, https://tinyurl.com/Zambia-DRTB). 
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5.6.6 Lineage 4.9 cluster analysis 
In lineage 4.9, two strains (N352 and N420) had low SNV differences (3 unique SNVs 
between the two strains), characteristic of a genomic cluster (8, 9). Both patients were 
diagnosed with MDR-TB in 2016 and were from the Copperbelt province, N352 was from 
Ndola district and N420 was from Mpongwe district. One patient (N352) died while 
receiving second line treatment while the second had an unknown treatment status. The 
findings of WGS analysis for these strains are similar to findings for IS6110-RFLP (low copy 
clade with 2 bands each) and spoligotyping (both strains were assigned to the clade T1, SIT 
244), indicative of recent transmission of these strains in the study population. 
Other clustered strains from this lineage had between 14 and 28 SNV differences between 
strains, possibly suggesting ongoing transmission of these drug resistant strains of TB (Table 
5.3). 
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Table 5.3: Single nucleotide variant analysis and characteristics of patients with clustered 
strains identified through WGS analysis. This analysis determines the number of unique SNVs 
between each strain (column 2) and M.tb H37Rv (column 3), with the total number of SNV 
differences between strains shown in column 4 (bold indicates the number of SNVs in genomic 
clusters; that is strains separated by 12 or fewer SNV differences). 
Cluster Strain 
ID 
Unique SNVs/strain 
in cluster 
Total 
SNVs 
Lineage Treatment status TB history 
1  N025 
N026 
1 
0 
1  
2.2 
 2nd line on going  1st line re-Tx failure 
N026 
N043 
0 
2 
2  2nd line on going 
 2nd line on going 
 1st line re-Tx failure 
 1st line Tx failure 
2 N050 
N292 
14 
16 
30 3.3  Completed 
 Died 
 New 
 Relapse  
3 N071 
N110 
2 
1 
3 4  Completed  
 Unknown 
 New  
 Unknown  
4 N105 
N423 
10 
12 
22  
4 
 Unknown (TO) 
 2nd line ongoing  
 New  
 1st line re-Tx failure 
N423 
N360 
16 
11 
27  2nd line ongoing 
 2nd line ongoing 
 1st line re-Tx failure 
 1st line re-Tx failure 
5 N054 
N061 
11 
3 
14 4.3  Unknown 
 Completed 
 Unknown 
 1st line re-Tx failure 
6 N374 
N375 
2 
3 
5 4.3  2nd line ongoing 
 2nd line ongoing 
 1st line re-Tx failure 
 1st line re-Tx failure 
7 N199 
N370 
8 
12 
20 4.3  Completed 
 Died 
 1st line re-Tx failure 
 1st line re-Tx failure 
8 N056 
N075 
2 
7 
9 4.3  Unknown 
 Completed 
 1st line Tx failure 
 Relapse  
9 N358 
N400 
4 
3 
7 
 
4.3  2nd line ongoing 
 Unknown  
 1st line re-Tx failure 
 1st line Tx failure 
10 N003 
N039 
3 
1 
4 4.3  Completed 
 Unknown 
 1st line Tx failure 
 Relapse  
11 N416 
N426 
7 
11 
18 4.3  2nd line ongoing 
 2nd line ongoing 
 1st line Tx failure 
 1st line re-Tx failure 
12 N369 
N430 
8 
10 
18 4.3  Died 
 Died 
 1st line re-Tx failure 
 1st line Tx failure 
13 N042 
N083 
2 
3 
5 4.3  Defaulter 
 2nd line ongoing 
 Relapse 
 1st line re-Tx failure 
14 N139 
N140 
4 
10 
14 
 
4.3  2nd line ongoing 
 2nd line ongoing 
 Relapse 
 1st line re-Tx failure 
15 N311 
N429 
105 
112 
117 4.3.2  Unknown 
 2nd line ongoing 
 Unknown 
 New  
16 N176 
N339 
6 
6 
12  
4.6.1 
 
 2nd line ongoing 
 Died  
 Relapse 
 New  
N062 
N339 
7 
7 
14  Completed 
 Died 
 New 
 New 
17 N053 
N365 
20 
15 
35 4.6.1  Died 
 Unknown 
 New  
 Relapse  
18 N066 
N067 
7 
7 
14 4.9  Died 
 Completed 
 Unknown 
 Relapse  
19 N089 
N133 
11 
7 
18 4.9  Unknown 
 2nd line ongoing 
 1st line Tx failure 
 1st line re-Tx failure 
20 N352 
N420 
1 
2 
3 4.9  Died 
 Unknown 
 New 
 1st line Tx failure 
21 N359 
N422 
10 
18 
28 4.9  2nd line ongoing 
 2nd line ongoing 
 1st line re-Tx failure 
 1st line re-Tx failure 
Abbreviation: ID, identification; SNV, single nucleotide variant; TO, transfer out; Tx, treatment. 
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5.6.7 Summary of cluster analysis 
In total, 9 genomic clusters were identified, that is strains with 12 or fewer SNV differences 
between them (8, 9). Isolates from the 9 clusters accounted for 21% of the sequenced isolates 
(18/86). There were ten strains belonging to LAM and two of each strain belonging to 
Beijing, H37Rv-like strain, an unspecified sub-lineage and Uganda lineage (Table 5.3; 
Supplementary Table 1, https://tinyurl.com/Zambia-DRTB). The presence of clustered drug 
resistant TB strains with low SNV differences between them (as low as 2 SNVs) supports the 
hypothesis that drug resistant TB is being transmitted in Zambia. Of concern is that the 
majority of the genomic clusters are MDR-TB cases. Whole genome sequencing in 
combination with IS6110-RFLP and spoligotyping has demonstrated a high level of genetic 
diversity amongst drug resistant TB clinical strains diagnosed at the TDRC TB reference 
laboratory. This implies that diverse genotypes are driving drug resistant TB in parts of 
Zambia and that transmission of these strains is occurring. 
Patients with clustered strains have been demonstrated to originate from different districts, 
implying that drug resistant strains are endemic in Zambia. Other possibilities that could 
explain clustered strains with low SNV differences are nosocomial transmission during 
quarantine at the NTH MDR-TB ward and social factors such as intercity travel for trading 
and social gatherings. To gain a better insight into the transmission of these drug resistant TB 
strains, detailed epidemiological investigations would be required. 
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5.7 Household transmission of MDR-TB 
It has been demonstrated that TB is frequently transmitted outside the household with 
members of the same household being infected with different strains (11). In the current 
study, 2 strains (N374 and N375) were characterised from two members of the same 
household (father and daughter living in the same house) that were diagnosed with MDR-TB 
and admitted to the NTH MDR-TB ward for part of second line treatment in 2016. Initial 
typing revealed that both patient strains belonged to LAM11_ZWE (SIT 815) and strains 
shared identical IS6110-RFLP patterns (section 4.4). Whole genome sequence analysis was 
performed to investigate strain relatedness.  
Whole genome sequence analysis revealed that the strains shared identical drug resistance-
conferring mutations in rpoB (position 526, CAC-GAC), katG (codon position 315, AGC-
ACC) and embB (codon position 1000, ATG-AGG) (Table 5.4). WGS data further revealed 
that the two strains were closely related with low SNV differences identified between them (5 
unique nonsynonymous SNV). The 2 unique SNV identified in strain N374 were in genes 
Rv3198A (possible glutaredoxin protein with an unknown function) and Rv1699 (putative 
function in pyrimidine biosynthesis) (10). The unique SNVs identified in patient N375 were 
in genes Rv0001 (plays an important role in regulation of chromosomal replication), 
Rv2043c (whose product pyrazinamidase/nicotinamidase convert amides to corresponding 
acids) and Rv2173 (whose product is involved in lipid biosynthesis) (10). The presence of a 
SNV in Rv2043c confers resistance to pyrazinamide and therefore implies that this particular 
strain is developing resistance to pyrazinamide. Variation seen in the SNVs between the two 
strains could be suggestive of mutations that arose independently within the host. 
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Table 5.4: Genetic characteristics of strains from two household contacts. 
Strain 
ID 
Resistance-conferring 
mutations (WGS) 
Number 
of SNVs 
SNV position Gene Lineage 
 
N374 embB (pos 1000: ATG-AGG); 
katG (pos 315: AGC-ACC); 
rpoB (pos 445: CAC-GAC). 
2 
(nonSyn) 
Codon 112, Position 1, CAC-TAC Rv3198A 
 
 
4.3 
Codon 283, Position 1: AAT-CAT Rv1699 
 
N375 embB (pos 1000: ATG-AGG); 
katG (pos 315: AGC-ACC); 
rpoB (pos 445: CAC-GAC). 
3 
(nonSyn) 
Codon 1253, Position 2: GCT-GTT Rv0001 
 
 
 
4.3 Codon 512, Position 2: GCG-GGG Rv2043c 
 
Codon 896, Position 2: CTG-CAG Rv2173 
 
Abbreviations: ID, identification; SNV, single nucleotide variant; WGS, whole genome 
sequencing. 
 
5.8 Molecular comparison of isolates from Cape Town and Ndola district 
To determine how closely related isolates from Ndola district were to isolates from Cape 
Town, WGS data conveniently available at Stellenbosch University for strains that have 
previously been described in Cape Town was compared to WGS data for strains of the same 
lineage from the current study. The Beijing genotype which is prevalent in Cape Town and 
has been associated with MDR- and XDR-TB was compared to the Beijing strains from 
Ndola district. There was a high SNV difference between the Beijing strains with 210 SNVs 
between the most closely related strains. The findings suggest that the Beijing genotypes in 
circulation in the study population are genetically unrelated to genotypes in circulation in part 
of Cape Town South Africa.  
It is however worth noting that the Beijing genotype makes up a small proportion of 
sequenced strains in the current study (5%), therefore extensive investigations would be 
required to identify further Beijing genotypes in the study population and in Zambia as a 
whole. It would be more significant to compare these genotypes to similar strains from 
closely neighbouring countries were high migration rates have been reported, such as 
Zimbabwe and Malawi. 
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5.9 Conclusion 
There is very limited data on the transmission dynamics of TB in Zambia with no published 
data on drug resistant TB. Genotyping data available for Zambia from previous studies has 
been generated mostly from spoligotyping and MIRU-VNTR and based on these studies, 
clustering has been observed (14-17).  
In this study, 86 out of 170 strains (51%) were analysed using whole genome sequencing. 
Even though not all strains were sequenced, the level of detail provided by WGS has 
demonstrated a likelihood of recent transmission amongst patients with drug resistant TB 
diagnosed at the TDRC TB reference laboratory. However to confidently conclude that 
transmission has occurred, there is a need for epidemiological data linking patients. Low 
SNV differences have been identified between strains from patients resident in different 
regions, implying that drug resistant TB is endemic in Zambia. Nosocomial transmission and 
intercity travel are possible reasons why clustered strains have been identified amongst 
patients from different regions. However there is need for more detailed epidemiological 
investigations. It has further been demonstrated that transmission of drug resistant TB is 
occurring amongst household contacts placing emphasis on the need for routine screening of 
MDR-TB contacts in Zambia, which is currently not implemented despite recommendations 
by the Ministry of Health (MoH) and the National TB and Leprosy Control Program (NTLP) 
in Zambia (12). 
It is concerning that a significant proportion of patients with MDR-TB died while receiving 
second line anti TB treatment. These deaths raise concerns over treatment adherence, co-
infection with HIV and co-morbidity with diabetes mellitus, which have been demonstrated 
to impact the progression of disease (18). It has been demonstrated that the majority of 
patients with clustered strains had failed first line treatment (first treatment or re-treatment), 
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this implies that the TB control program is not efficient in managing TB and as a result drug 
resistant TB is being acquired and transmitted in the study population. 
Migration has been demonstrated to be a driver of the transmission of drug resistant TB and 
TB in general (13). In the current study, comparison of drug resistant strains belonging to 
lineage 2, which is prevalent in parts of South Africa and is further associated with XDR-TB 
(19), has revealed a high SNV difference (210 SNV differences between the most closely 
related strains). With the currently available data, we were not able to identify any suspected 
recent transmission events. However, we acknowledge the limitation of incomplete sampling. 
Extensive surveillance will be required to fully understand the role of migration in the 
transmission of drug resistant TB within the region. 
The usefulness and application of genotyping tools in understanding M.tb transmission events 
has been demonstrated in the current study. Overall WGS provides a superior level of 
understanding strain relatedness and investigating resistance-conferring mutations in M.tb 
(discussed further in chapter 6), compared to IS6110-RFLP and spoligotyping. Spoligotyping 
has been demonstrated to be important in differentiating LCCs while IS6110-RFLP provides 
a good resolution of a particular subset of strains. In the current study, WGS has been 
demonstrated to provide the best resolution of M.tb strains, giving detailed insight into the 
level of nucleotide differences between strains. There is a need to implement the use of more 
rapid and accurate techniques alongside phenotypic culture based methods in order to fully 
understand the molecular epidemiology of drug resistant TB in Zambia and the surrounding 
region, for informed and targeted intervention measures. Data presented here represent a first 
step towards an improved understanding of the drug resistant TB endemic in Zambia. 
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Chapter 6: Genetic mechanisms of drug resistance in Mycobacterium 
tuberculosis isolates from the Copperbelt province and Northern regions of 
Zambia 
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6.1 Introduction 
In Zambia national guidelines recommend culture-based first and second line drug 
susceptibility testing (DST) for the diagnosis of drug resistant tuberculosis (TB) (1). 
However, in practice, first line DST is not readily available to all confirmed TB cases due to 
the lack of capacity, and therefore the Ministry of Health (MoH) and the National TB and 
Leprosy Control Program (NTLP) diagnostic algorithm prioritises high risk MDR-TB 
suspects for receiving first line DST (Figure 1.3) (1). The national TB reference laboratory at 
Chest Diseases Laboratory (CDL) has the capacity to perform DST on some second line 
drugs (kanamycin, capreomycin and ofloxacin) (1), however second line DST is not routinely 
performed for MDR-TB patients in Zambia. Overall, this has resulted in low multidrug 
resistant (MDR)-TB case detection rates and very limited knowledge on the efficacy of the 
current standardised MDR-TB treatment regimen used in Zambia. There is also very little to 
no information on the incidence of extensively drug resistant (XDR)-TB in the country with 
one study describing a case of pre-XDR-TB (gyrA mutation) and one case of XDR-TB (2). In 
addition, little is known regarding the transmission of these strains. 
In this chapter, known mutations conferring drug resistance to any of the first and second line 
drugs are described for 170 clinical isolates collected over a period of 15 months from the 
Tropical Diseases Reference Centre (TDRC) TB reference laboratory in Ndola district. 
Further, a first insight is given into the genotypes associated with pre-XDR-TB in the study 
population. 
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6.2 Known resistance-conferring mutations in Mycobacterium tuberculosis 
Several mutations in Mycobacterium tuberculosis (M.tb) have been demonstrated to be 
associated with drug resistance (Table 6.1) (3). For one of the core first line drugs, rifampicin 
(RIF),  mutations in the rpoB rifampicin resistance determining region (RRDR), an 81bp 
region of the gene (spanning from codon 507 to 533), are most commonly associated with 
resistance to this drug (3). The rapid diagnostic tool GeneXpert MTB/RIF assay has exploited 
the RRDR by simultaneous identification of M.tb and mutations in this region which confer 
rifampicin resistance (4). While for isoniazid, the most common mutations associated with 
resistance are found in the katG gene and inhA promoter. For katG, mutations in codon 315 
confer high level resistance, defined as a minimum inhibitory concentration (MIC) >1 μg/mL, 
while inhA promoter mutations (-15) confer low level resistance, defined as an MIC <1 
μg/mL (3). Mutations commonly associated with resistance to the other first line drugs 
include those conferring resistance to streptomycin, (found in rpsL, codon 43 and rrs, codon 
514), to ethambutol (embB, codon 306) and to pyrazinamide (pncA; mutations occur 
throughout the gene) (3).  
In terms of second line drugs, specific resistance-conferring mutations to fluoroquinolones 
(FQs) have been described in gyrA and the most common mutations are seen in the 
quinolone-resistance-determining region (QRDR) in codon 90 and 94 (3). While the most 
common mutations associated with resistance to the second line injectable drugs kanamycin, 
capreomycin and amikacin are found in rrs (at position 1401, 1402 and 1484 in the gene), 
cross resistance is however not complete as mutations in eis gene and the eis promoter 
(position -10 and -35) have been demonstrated to confer resistance to kanamycin and not 
capreomycin or amikacin (3). There is full cross resistance in mutations associated with drug 
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resistance in capreomycin and viomycin, mutations throughout the open reading frame (ORF) 
are associated with drug resistance in tlyA (3, 4). 
Conventional culture-based phenotypic DST is a laborious and time consuming approach to 
diagnosis of drug resistant TB (5, 6). Recommendations by the World Health Organisation 
(WHO) on the use of molecular line probe assays (LPA) and GeneXpert MTB/RIF assay 
have allowed rapid and simultaneous identification of M.tb and drug resistance in clinical 
samples (6). The use of DNA sequencing methods for known drug resistance-conferring 
mutations in M.tb , such as targeted gene sequencing (TGS) and whole genome sequencing 
(WGS) have been demonstrated to be superior in investigating genetic mechanisms of drug 
resistance (7, 8). The impediments to these DNA sequencing based techniques in low to 
middle income countries such as Zambia include the lack of expertise and the high costs 
associated with equipment purchase as well as running and maintenance costs. It is possibly 
due to these constraints that there are very limited molecular investigations occurring in 
Zambia and Africa as a whole. 
Only a few studies have used molecular tools to elucidate the mechanisms of drug resistant 
TB in Zambia. One study used LPA to evaluate 113 MDR-TB strains (2). Another study used 
targeted gene sequencing to identify mutations conferring resistance to first and second line 
drugs, 13 out of 16 strains in the study had a Ser>Thr substitution at codon 88 (9). Two 
studies have demonstrated the usefulness of WGS as a rapid diagnostic tool and in 
understanding the transmission dynamics (differentiating relapse from reinfection) of TB in 
Zambia (10, 11). However one study had a small cohort size, 36 patients from 4 countries in 
Southern Africa including Zambia. Further, these studies were not centred on characterising 
genotypes of drug resistant TB. The current study has a particular focus on the genotypes of 
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drug resistant TB and included a larger cohort of patient isolates collected from routine 
diagnosis. 
 
Table 6.1: The most frequently identified high confidence mutations conferring drug 
resistance in M.tb (3). 
Drug First/ 
Second line 
Locus Frequently mutated codon position 
Streptomycin First line rpsL 43 
  rrs (388-1084) 514 
Isoniazid First line katG 315 (high level resistance) 
  inhA promoter -15 (low level resistance) 
Rifampicin First line rpoB 531, 526, 516 
Ethambutol First line embB 306 
Pyrazinamide First line pncA throughout gene  
Fluoroquinolone Second line gyrA 94, 90 
Kanamycin, Capreomycin, 
amikacin  
Second line rrs (1158-1674) 1401, 1402, 1484 
Kanamycin  Second line eis -10, -35 
Capreomycin, viomycin Second line tlyA throughout ORF 
Abbreviations: ORF, open reading frame. 
 
6.3 Analysis of Sanger sequencing and whole genome sequencing data 
To investigate the genetic mechanisms of drug resistance and the presence of XDR-TB in the 
study population, we performed targeted Sanger sequencing for 84 isolates (described in 3.8), 
extracted information from WGS data for 80 isolates, and applied both approaches to a 
further 6 strains (N024, N041, N064, N133, N139, N199). Similar mutations conferring 
resistance were identified in 5 of these strains by both WGS and TGS, there were no 
mutations identified in one strain (N041) (Supplementary Table 1, 
https://tinyurl.com/Zambia-DRTB). 
Targeted gene sequencing for 8 genes (rpoB, katG, inhA, embB, pncA, rrs, gyrA, and tlyA) 
commonly associated with drug resistance in M.tb (Table 6.1) was performed at the Central 
Analytical Facilities (CAF), Stellenbosch University (as described in section 3.8). ABI 
Sanger sequence data was aligned to the M.tb H37Rv (GenBank NC000962.2) reference 
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genome in BioEdit and chromatograms were analysed for the presence of single nucleotide 
variants (SNVs) in relation to the reference genome.  
The FASTQ data files generated from WGS were analysed using the customised in-house 
WGS analysis pipeline, Universal Sequence Analysis Pipeline (USAP), as described in 
section 3.7. The resulting WGS summary report, which included known mutations conferring 
drug resistance identified by USAP, was used to identify mutations conferring resistance to 
first and second line drugs. Mutations identified as resistance-conferring through sequencing 
were validated by comparing with mutations listed on the TBdream database 
(https://tbdreamdb.ki.se/Info/Default.aspx). The findings are used here to describe the genetic 
mechanisms of resistance and the relationship to phenotype as well as to describe the 
genotypes associated with XDR-TB in the study population, thereby addressing objectives 5 
and 6 (section 1.5.3). 
 
6.4 Overall profile of drug resistance-conferring mutations in study strains 
In this chapter, TGS and WGS analysis was applied to profile drug resistance-conferring 
mutations in drug resistant M.tb isolates diagnosed at the TDRC TB reference laboratory 
during the study period. Among 170 isolates, nucleotide sequence analysis identified 23 
(14%) strains which did not have any drug resistance-conferring mutations despite being 
classified as drug resistant through routine culture based phenotypic DST at the TDRC TB 
reference laboratory; this will be discussed further in section 6.5. One serial strain from the 
same patient (N025) was removed from analysis. In the remaining 146 strains, we did 
however identify high confidence mutations in genes associated with resistance to the first-
line drugs rifampicin (rpoB), isoniazid (katG, kasA), ethambutol (embB), streptomycin (rpsL, 
rrs) and pyrazinamide (pncA), as well as to the second-line FQs (gyrA), kanamycin (eis), and 
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amikacin (rrs), there were no mutations identified in tlyA (Table 6.2, Figure 6.1, 
Supplementary Table 1, https://tinyurl.com/Zambia-DRTB). Further, the most common 
resistance-conferring high confidence mutations identified in this study are in keeping with 
previous studies (3, 5, 7). 
Out of the 146 strains identified with drug resistance-conferring mutations 48 (33%) mono-
resistant strains were identified. Of the 48 mono-resistant strains, 26 (54%) were resistant to 
rifampicin, 17 (35%) to isoniazid, 3 (6%) to streptomycin and one each (2%) to ethambutol 
and FQ (Supplementary Table 1). The high rate of mono-resistance is alarming and could 
point towards an inadequate TB control program and low treatment adherence (12). 
Genotyping identified 93 MDR-TB strains (64%), 53 of these had added resistance to one or 
more anti TB drugs (Supplementary Table 1). Eight (9%) pre-XDR TB cases were identified 
out of the 93 MDR-TB cases, comparable to WHO global estimate of 9.5% MDR-TB cases 
being XDR-TB (12). These are further discussed in section 6.6. 
Of the 93 MDR-TB cases identified through genotyping, almost half of the patients were HIV 
positive (48%) while 18 (19%) had an unknown HIV status. Over half of the patients had 
failed first line treatment (20 (22%) failed first treatment while 27 (29%) failed retreatment), 
and 11 (12%) were defined as relapse cases, highlighting deficiencies in the TB control 
program. Of concern is that a further 27 (29%) were new TB patients, suggesting that MDR-
TB is possibly being transmitted in the study population (Supplementary Table 1). With 
regards to the treatment status of MDR-TB patients identified in the current study, 39 (42%) 
were receiving second line treatment at the time of data collection, while 14 (15%) had 
completed treatment and 12 (13%) had died. Of concern is that a proportion of MDR-TB 
patients were lost to follow-up 3 (3%), had an unknown treatment status 19 (20%) and 7 (7%) 
were not enrolled on second line treatment at the time of data collection, similar to trends 
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observed in a previous study in Zambia (13). Therefore, there is a high risk that MDR-TB is 
being spread in the community by patients that are poorly managed by the TB control 
program. 
One hundred and nineteen strains out of 170 (70%) had mutations identified in rpoB and in 
keeping with other studies (3, 5), the most commonly identified mutation in rpoB (63 strains) 
was in codon 531 (Table 6.2, Figure 6.1, Supplementary Table 1). Seven strains had double 
mutations in rpoB; codons 511 and 516 (3 strains), codons 516 and 526 (1 strain), codons 531 
and 633 (3 strains) (Supplementary Table 1). Mutations conferring resistance to isoniazid 
were identified in 113 (66%) strains. Mutations in katG were the most common (103 strains), 
with kasA mutations only identified in 6 strains; 5 strains had multiple resistance-conferring 
mutations (katG and kasA), while 1 isoniazid mono-resistant strain had a mutation in kasA 
only which has been associated with drug resistance in previous studies (3). A deletion 
identified in codon 1737 of katG (N70) has previously not been identified as resistance-
conferring (Table 6.2, Supplementary Table 1). There were no mutations identified in the 
inhA promoter region. In the other first line anti-TB drugs, mutations were identified in embB 
conferring resistance to ethambutol (55 strains; 4 strains had multiple resistance conferring 
mutations), while in rrs 15 strains were identified as having mutations, however only 5 of 
these mutations have previously been defined as conferring resistance to streptomycin, a 
further 4 strains had mutations in rpsL (Table 6.2). Targeted sequencing did not include the 
rpsL gene, data for this gene was only extracted from WGS data of 85 strains. Therefore, the 
incidence of mutations in rpsL is possibly underestimated. Seventeen strains had mutations in 
pncA, however only 10 mutations have previously been described as conferring resistance to 
pyrazinamide (Table 6.2). These findings are in keeping with other studies (3) describing the 
most commonly associated mutations conferring drug resistance to first line drugs to be 
found in rpoB (codons 531, 516 and 526), katG (315), embB (306), rrs (514), and rpsL (43).  
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Analysis of mutations associated with second line drug resistance identified 9 strains with 
mutations in gyrA conferring resistance to fluoroquinolones, 2 of these strains (N026 and 
N043) had multiple resistance-conferring mutations (Supplementary Table 1). One strain 
(N038) with a mutation in rrs (517, C-T) had a further mutation in the eis promoter region, 
which confers resistance to kanamycin, a core second line injectable drug which is part of the 
standard first choice MDR/RR-TB regimen recommended by the NTLP in Zambia (1). The 
most common mutation identified in 5 strains was in codon 80 (ACC-GCC) (Table 6.2, 
Figure 6.1). The characteristics of patients with resistance-conferring mutations to second 
line drugs are described in section 6.6. A mutation in ethA was identified at codon 1291, 
however resistance to ethionamide has not been confirmed. 
The current findings demonstrate a high rate of rifampicin resistance amongst drug resistant 
TB strains (70%) highlighting the usefulness of the GeneXpert MTB/RIF assay in the rapid 
diagnosis of these drug resistant TB strains. Furthermore, all rifampicin resistant strains had 
mutations within the RRDR which the GeneXpert MTB/RIF assay detects, highlighting the 
usefulness of the technique in the study population. However a substantial number of strains 
that were not resistant to rifampicin were resistant to other drugs (27 strains), and could be 
missed by the GeneXpert MTB/RIF assay. The presence of pyrazinamide resistance amongst 
MDR-TB patients (approximately 11%; 10 out of 93 patients) is concerning as pyrazinamide 
is a key drug in treatment of MDR-TB in Zambia (1) and currently routine DST for this drug 
is not conducted in Zambia. 
This data demonstrates the presence of mutations conferring drug resistance to core first and 
second line anti-TB drugs, placing emphasises on the need to implement routine first and 
second line DST for all TB patients in Zambia for early case detection. 
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Table 6.2: Mutations identified in genes associated with drug resistance in clinical 
strains of M.tb diagnosed at the TDRC TB reference laboratory, using WGS and TGS 
data. Complete data set available at: https://tinyurl.com/Zambia-DRTB 
Drug (number of 
strains) 
Gene(s) Codon position,  nucleotide 
change 
Number 
of strains 
Confidence 
mutation confers 
resistance 
Ref  
Rifampicin 
(119 strains; 7 strains 
with multiple 
mutations) 
rpoB Codon 511, CTG-CCG 5 Yes 14 
Codon 511, CTG-CGG 4 Yes 14 
Codon 516, GAC-GTC 20 Yes 15 
Codon 516, GAC-TAC 6 Yes 15 
Codon 526, CAC-GAC 8 Yes 15 
Codon 526, CAC-AAC 5 Yes 15 
Codon 526, CAC-TAC 5 Yes 15 
Codon 526, CAC-CTC 3 Yes 15 
Codon 526, CAC-CAG 1 Yes 15 
Codon 531, TCG-TTG 63 Yes 15 
Codon 533, CTG-CCG 3 Yes 15 
Codon 633, CGC-TGC 3 Yes  16 
Isoniazid (113 strains; 
5 strains with multiple 
mutations) 
katG Codon 141, TTG-TTC 2 Yes 17 
Codon 299, GGC-AGC 2 Yes 17 
Codon 315, AGC-ACC 103 Yes 17 
Codon 315, AGC-AAC 1 Yes 17 
Codon 315, AGC-CGC 1 Yes 17 
Codon 337, TAC-TGC 2 Yes 17 
Deletion 1737, CGGTTT-C 1 ND  
kasA Codon 269, GGT-AGT 6 Yes 18 
Ethambutol 
(55 strains; 4 strains 
with multiple 
mutations) 
embB Codon 306,  ATG-GTG 28 Yes 17 
Codon 306, ATG-ATA 18 Yes 17 
Codon 306, ATG-ATT 1 Yes 17 
Codon 306, ATG-TTG 1 Yes 17 
Codon 406, GGC-GCC 2 Yes 19 
Codon 497, CAG-CGG 3 Yes 19 
Codon 1000, ATG-AGG 2 Yes 19 
Codon 1024, GAC-AAC 2 Yes 19 
Codon 1082, ACC-GCC 2 Yes 20 
Streptomycin (19 
strains) 
rpsL Codon 43, AAG-AGG 4 Yes 21 
rrs Codon 431, CGG-CGT 1 ND  
Codon 432, GGT-AGT 1 ND  
Codon 438, CCC-TAC 1 ND  
Codon 468, CGT-AGT 1 ND  
Codon 469, CAT-CAC 2 ND  
Codon 477, CCA-CCG 2 ND  
Codon 482, TCG-TTG 2 ND  
INS Codon 483, T 3 Yes 21 
Codon 486, TGT-CGT 2 ND  
Codon 492, C-T 2 ND  
Codon 514, A-C 1 Yes 3 
Codon 517 C-T 1 Yes  3 
Pyrazinamide (17 
strains) 
pncA Codon 35, CTG-CGG 6 No  22 
Codon 47, ACC-GCC 1 Yes 23 
Codon 58, TTC-TCC 3 Yes 17 
Codon 68, TGG-TGA 1 Yes 17 
Codon 102, GCG-GTG 1 Yes 23 
Codon 119, TGG-TGT 2 Yes 17 
Codon 120, CTG-CCG 2 Yes 23 
Insertion codon 450, G-GC 1 ND  
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Table 6.2 continued. 
Drug (number of 
strains) 
Gene(s) Codon position,  
nucleotide change 
Number of 
strains 
Confidence 
mutation confers 
resistance 
Ref  
Fluoroquinolone 
(10 strains) 
gyrA Codon 79,  AGA-AGG 1 ND  
Codon 80, ACC-GCC 5 Yes 24 
Codon 88,  GGC-TGC 1 Yes 17 
Codon 90,  GCG-GTG 2 Yes 17 
Codon 91,  TCG-CCG 2 Yes 17 
Kanamycin (1 
strain) 
eis 
promoter 
Codon -10, C-T 1 Yes 3 
Ethionamide (1 
strain) 
ethA Codon 1291, AG-A 1 ND  
Abbreviations: ND, not defined; ref, reference; TB, tuberculosis; TDRC, Tropical Diseases 
Research Centre. 
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Figure 6.1: The most common mutations identified in genes associated with drug 
resistance in clinical strains of M.tb diagnosed at the TDRC TB reference laboratory. 
The arrows represent the codon positions (in bold) while the number of strains with a specific 
mutation are represented in brackets. Black arrows have previously been associated with 
resistance while red arrows have not been defined as resistance-conferring mutations.  
 
 
6.5 Comparison of genotype and phenotype data 
To assess the level of agreement between genotype and phenotype data, comparisons of 
phenotypic DST findings and genotype data were made. Phenotypic data was only available 
for the first line drugs, streptomycin, isoniazid, rifampicin and ethambutol and therefore 
comparisons could only be made for these data. In total, phenotypic data for 120/170 (71%) 
samples were in agreement with sequence data (Supplementary Table 1, 
https://tinyurl.com/Zambia-DRTB). Of the 50 (29%) samples that were not in agreement, 23 
(46%) were scored as phenotypically resistant at the TDRC TB reference laboratory, however 
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no drug resistance-conferring mutations were identified according to sequence data. Repeat 
phenotypic DST was performed for 5 isolates out of the 23 at the Division of Molecular 
Biology and Human Genetics, Stellenbosch University and they were all scored as drug 
susceptible (Table 5.3, Supplementary Table 1). 
Of the 23 isolates with no known drug resistance-conferring mutations identified the majority 
(96%) belonged to lineage 4, one strain belonged to lineage 3 (Table 6.3). Most patients in 
this group had failed first line treatment (13 out of 23) and a proportion (6 out of 23) had 
received second line treatment, either completed or treatment was ongoing during the study 
period (Table 6.3). 
In the remaining 146 isolates, additional phenotypic resistance was identified in 15 strains 
(10%) compared to genotyping results. Further, 12 strains (8%) were over-scored by 
genotyping compared to phenotypic DST findings. Analysis revealed that WGS under-scored 
8 phenotypically resistant strains while TGS under-scored 7 strains (Supplementary Table 1). 
Furthermore, WGS over-scored 7 strains while TGS over-scored 5 phenotypically resistant 
strains. Comparison of phenotype and genotype data for individual drugs revealed that 
phenotypic DST identified 5 fewer rifampicin resistant strains and over-scored 1 compared 
with genotyping. Phenotyping under-scored 1 and over-scored 2 isoniazid resistant strains 
than genotyping (Supplementary Table 1). For ethambutol and streptomycin genotyping 
under-scored 6 and 12 strains with resistant phenotypes, respectively (Supplementary Table 
1). Furthermore, genotyping over-scored 3 streptomycin resistant strains and 7 ethambutol 
resistant strains compared with phenotypic DST findings (Supplementary Table 1) 
The discrepancies identified could be attributed to a number of factors. For example, 
operational errors during sample processing (due to inadequate laboratory staff training 
and/or insufficient QC) could result in errors in data capture and sample mix ups. Biological 
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factors could include mixed infections or genetic heterogeneity (25); indeed analysis of TGS 
data identified 3 strains (N068, N094 and N452) with heterogeneous variants in rpoB and one 
(N094) had added variants in katG and embB (Supplementary Table 1). Other biological 
possibilities include unidentified gene targets which could be involved in the phenotypic 
resistance profiles identified.  Furthermore, not all genetic resistance markers are included in 
the USAP and therefore resistance-conferring mutations could have been missed during 
analysis of sequence data. 
Phenotypic DST for certain anti TB drugs has been demonstrated to be highly varied and 
challenging and discordant results have been demonstrated between phenotype and genotype 
(26, 27). For instance, phenotypic DST for ethambutol has been shown to be discordant with 
genotypic testing, with as high as 91% of ethambutol resistant strains being phenotypically 
undetected in one study (26), highlighting the need for more sensitive and accurate diagnostic 
tools for this drug. However, other studies have described ethambutol susceptible strains that 
harbour mutations in embB306 (28, 29), similar to findings in the current study for 9 isolates 
(N050, N068, N292, N332, N354, N392, N420, N459, N477). The embB306 mutation has 
further been associated with strains harbouring a wide range of drug resistance patterns and is 
associated with an increased ability of transmission of these strains (28, 29). These findings 
demonstrate the importance of complementing phenotypic DST with genotyping methods 
(25, 27, 30). 
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Table 6.3: Phenotypic characteristics of strains identified as having no known 
resistance-conferring mutations by WGS and TGS analysis. Complete data set available 
at: https://tinyurl.com/Zambia-DRTB 
Isolate ID Phenotypic DST 
SIRE (TDRC) 
Phenotypic DST 
SIRE (SU) 
Lineage Treatment received 
N011 SSRS Not done 4.3 First line treatment completed 
N041 SRSS Not done 4.9 After failure of 1
st
 line retreatment 
N057 RSRR Not done 4.3 After failure of 1
st
 line treatment 
N065 SRRR Not done 4.9 2
nd 
line treatment completed 
N076 RSSS Not done 4.3 After failure of 1
st
 line treatment 
N181 SSRS SSSS 4 Not enrolled on second line treatment 
N227 SRSS Not done 4.1.1.3 After failure of 1
st
 line retreatment 
N240 SSRS Not done 4.3 After failure of 1
st
 line treatment 
N246 SRSS SSSS 4.9 After failure of 1
st
 line treatment 
N262 RSRS Not done 4.3 After failure of 1
st
 line treatment 
N271 SRRS Not done 4.9 2
nd
 line treatment on going 
N283 SSRS Not done 4.9 After failure of 1
st
 line treatment 
N296 RSRS Not done 4.3 After failure of 1
st
 line treatment 
N318 SRRS SSSS 4 Not enrolled on second line treatment 
N325 SSRS Not done 4.3 2
nd
 line treatment defaulter 
N331 SSRS SSSS 4.3 After failure of 1
st
 line retreatment 
N346 SSRS Not done 4.3 2
nd
 line treatment on going 
N412A SSRS Not done 4.3 2
nd
 line treatment completed 
N424 SSRS SSSS 3 After failure of treatment 
N427 RSSR Not done 4.3 After failure of 1
st
 line treatment 
N431 SRRS Not done 4.3 2
nd
 line treatment on going 
N446 RSSR Not done 4.1.1.3 After failure of 1
st
 line treatment 
N465 SSRS SSSS 4.3 After failure of retreatment 
Abbreviations: DST, drug susceptibility testing, TGS, targeted gene sequencing; WGS, whole 
genome sequencing. Drug resistance (SIRE) order; S, streptomycin; I, isoniazid; R, 
rifampicin; E, ethambutol. 
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6.6 A first insight into the genetics of pre-XDR in Zambia 
Here we use sequencing data captured from the more sensitive techniques of targeted gene 
sequencing and WGS to describe the molecular characteristics of pre-XDR-TB identified 
from isolates collected from the TDRC TB reference laboratory in Ndola district, giving a 
first insight into the genotypes associated with XDR-TB in Zambia. 
 
6.6.1 Pre-XDR-TB genotypes identified from drug resistant isolates diagnosed at the 
TDRC TB reference laboratory 
From the sequenced strains, 8 were identified as genotypically pre-XDR-TB cases (MDR-TB 
with added genotypic resistance to a second line injectable drug or a FQ) with mutations 
either in gyrA (7 strains) or in rrs and the eis promoter (1 strain) and not both (Table 6.4). In 
total 4 out of the 8 strains (50%) belonged to lineage 4.6.1, there were 3 strains belonging to 
lineage 2.2 (37.5%), and 1 strain belonged to lineage 4.3 (N054). One strain (N063) had a 
mutation in codon 79 (AGA-AGG) of gyrA, which has not been described as conferring 
resistance to FQ. Four pre-XDR-TB strains from lineage 4.6.1 (N053, N062, N176 and 
N339) shared a similar mutation in codon 80 (ACC-GCC) of the gyrA locus. Furthermore, 
strains from this lineage shared similar mutations in rpoB (526, CAC-GAC) and katG (315, 
AGC-ACC), one strain (N062) had an added mutation in pncA (insertion codon 450, G-GC) 
which has not been associated with pyrazinamide resistance. One strain (N053) had 
mutations in rpoB (526, CAC-CAG; 516, GAC-GTC) and in katG (337, TAC-TGC). 
The other predominant pre-XDR-TB strains belonging to lineage 2.2 (N026, N038 and N043) 
have previously not been described in Zambia. Two strains (N026 and N043) from this 
lineage shared similar mutations in gyrA (90 GCG-GTG; 91, TCG-CCG), rpoB (531, TCG-
TTG) katG (315, AGC-ACC), embB (497, CAG-CGG), embB (1082, ACC-GCC) and rpsL 
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(43, AAG-AGG), Table 6.4. Overall, there was concordance between phenotype and 
genotype data for the pre-XDR-TB strains identified in the study (Supplementary Table 1). 
Only one pre-XDR TB strain (N054) belonging to lineage 4.3 was identified. This lineage is 
the predominant genotype associated with drug resistance in the current study and has been 
associated with drug susceptible TB in previous studies in Zambia and the surrounding region 
(31, 32). Of interest is that the lineage represents a small proportion of pre-XDR TB cases 
identified in the study (11%), this could however be due to the low case detection reported 
for Zambia or additional unknown resistance-conferring gene targets. 
From the eight pre-XDR-TB cases identified in the current study, 3 (37.5%) were receiving 
second line treatment at the time of data collection, 2 (25%) had completed treatment and a 
further 2 (25%) had died while on treatment. Of concern is that the treatment status for one 
patient was unknown, lost to follow up (Table 6.4). The pre-XDR TB genotypes have been 
detected in 4 districts and 2 provinces implying that these strains could be widespread across 
the country. 
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Table 6.4: Characteristics of pre-XDR-TB cases and strains with gyrA mutations 
identified amongst drug resistant TB patients diagnosed at the TDRC TB reference 
laboratory 
Patient  
ID 
Lineage Locus Mutations  
conferring 
resistance to 2
nd
 
line anti-TB 
drugs 
Other SNVs Treatment 
status 
Residential 
address 
N026 2.2 gyrA Codon 90,  GCG-
GTG; codon 91, 
TCG-CCG 
rpoB 531, TCG-TTG; 
katG 315, AGC-ACC; 
embB 497,  CAG-CGG; 
embB 1082, ACC-GCC;  
rpsL 43, AAG-AGG 
Treatment 
ongoing 
Ndola, 
Copperbelt 
N038 2.2 rrs Codon 517, C-T rpoB 531, TCG-TTG; 
katG 315, AGC-ACC; 
ethA 1291, AG-A: pncA 
120, CTG-CCG; 
Completed Mansa, 
Luapula 
eis_pr
omoter 
 
-10, C-T 
N043 2.2 gyrA Codon 90,  GCG-
GTG;  
91, TCG-CCG 
rpoB 531, TCG-TTG; 
katG 315, AGC-ACC; 
embB 497, CAG-CGG; 
embB 1082, ACC-GCC; 
rpsL 43, AAG-AGG 
Treatment 
ongoing 
Mufulira, 
Copperbelt 
N053 4.6.1 gyrA Codon 80, ACC-
GCC 
rpoB 516, GAC-GTC; 
rpoB 526, CAC-CAG; 
katG 337, TAC-TGC; 
Died Samfya, 
Luapula 
N054 4.3 gyrA Codon 88,  GGC-
TGC 
rpoB 526, CAC-CTC; 
katG 141, TTG-TTC; 
embB 1024, GAC-AAC; 
pncA 68, TGG-TGA 
Unknown Ndola, 
Copperbelt 
N062 4.6.1 gyrA Codon 80, ACC-
GCC 
rpoB 526, CAC-GAC; 
katG 315, AGC-ACC; 
pncA Indel codon 450, G-
GC 
Completed Ndola, 
Copperbelt 
N063 4.6.1 gyrA Codon 79,  AGA-
AGG 
rpoB 526, CAC-GAC; 
katG 315, AGC-ACC 
Completed Kitwe, 
Copperbelt 
N176 4.6.1 gyrA Codon 80, ACC-
GCC 
rpoB 526, CAC-GAC; 
katG 315, AGC-ACC 
Treatment 
ongoing 
Ndola, 
Copperbelt 
N339 4.6.1 gyrA Codon 80, ACC-
GCC 
rpoB 526, CAC-GAC; 
katG 315, AGC-ACC 
Died Ndola, 
Copperbelt 
N365 4.6.1 gyrA Codon 80, ACC-
GCC 
None  Unknown Ndola, 
Copperbelt 
Abbreviations: ID, identification; SNV, single nucleotide variant; TB, tuberculosis. 
 
6.6.2 Transmission of pre-XDR TB in the study population  
In the preceding chapter (section 4.4) molecular typing using spoligotyping and IS6110-
RFLP demonstrated clustering amongst pre-XDR TB strains, which could be suggestive of 
recent transmission. However, the low discriminatory power of these tools limits the ability 
to conclusively determine whether transmission has taken place. To address this, we 
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examined WGS data. This revealed low nucleotide variant differences amongst these 
clustered strains (section 5.6). For instance, cluster analysis of strains belonging to lineage 
4.6.1 showed that strains N62, N176 and N339 were genomic clusters with 12 SNVs between 
them (discussed in the previous chapter), indicative of recent transmission (33, 34). 
Furthermore, these strains share similar drug resistance-conferring mutations, discussed 
above. Two pre-XDR-TB strains (N026 and N043) from lineage 2.2 were clustered with a 
low SNV difference (2 unique non-synonymous SNVs). This is suggestive of recent 
transmission of these strains in the study population and calls for urgent action towards active 
case detection and treatment. Since sample collection was not comprehensive, there could be 
underestimation of transmission of XDR TB in the study population. 
All 8 pre-XDR-TB patients and one MDR-TB patient (N063) with a  gyrA mutation that has 
not been confirmed as resistance conferring had previously been admitted to the Ndola 
Teaching Hospital (NTH) MDR-TB ward for part of second line treatment; however patients 
had varying residential addresses (Figure 6.2). One patient that was not admitted to the NTH 
MDR-TB ward had a streptomycin resistant strain according to phenotypic DST, genotyping 
however only identified a mutation in gyrA. A possible explanation for the presence of a 
fluoroquinolone mono resistant strain could be the use of fluoroquinolones, which is rampant 
in Zambia, in the treatment of other bacterial infections (35). 
Five out of the eight patients were residents of Ndola district on the Copperbelt province; 
there was a single patient each from Mansa district (Luapula province), Samfya district 
(Luapula province) and Mufulira district (Copperbelt province) (Figure 6.2). Two lineage 2.2 
strains (0N26 and N043) shared very low SNVs (2 SNVs), even though patients originated 
from different districts. This could be explained by the high rate of intercity travel that is seen 
on the Copperbelt province and Zambia as a whole. 
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The incidence of pre-XDR-TB in the sampled patients (9%; 8 out 93 MDR-TB cases) is 
comparable with WHO global estimate of 9.5% MDR-TB cases being XDR-TB (12). The 
incidence of XDR- and pre-XDR-TB in the study population could be higher than identified 
in the current study, since gyrA is not the only gene target that confers resistance to FQs (3) 
and the USAP does not identify all resistance markers. Routine phenotypic DST would be 
essential to confirm the incidence of XDR-TB in Zambia. The presence of pre-XDR-TB in 
the study population is concerning as it implies that strains are developing added resistance to 
the current MDR-TB treatment regimen. 
 
 
Figure 6.2: Geographical distribution of pre-XDR-TB cases for strains collected from 
the TDRC TB reference laboratory. 6 cases were identified on the Copperbelt province (5 
in Ndola district and 1 in Mufulira district) and 2 cases were identified in Luapula province (1 
in Mansa district and 1 in Samfya district).  
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6.7 Conclusion 
In the current study, the prevalence of pre-XDR TB amongst drug resistant isolates was 5.5% 
(8 out 146 genotypically drug resistant TB strains). The incidence of pre-XDR-TB in MDR-
TB patients (9%; 8 out of 93) is comparable to WHO estimates for the incidence of XDR-TB 
amongst MDR-TB cases (9.5%) (12). Of interest, the predominant genotype in the current 
study, LAM (lineage 4), is only accounting for 12.5% of pre-XDR, with the majority of pre-
XDR isolates belonging to lineage 4.6.1 (Uganda) (62.5%) and lineage 2.2 (Beijing) (25%). 
This could be due to strains from these lineages (4.6.1 and 2.2) having a higher ability to 
develop resistance compared to strains from lineage 4.3. Other factors that could be attributed 
to the low rate of pre-XDR strains belonging to sub-lineage LAM11_ZWE are incomplete 
sampling and the current MDR-TB regimen is possibly successful in preventing development 
of added resistance in this sub-lineage. 
Further, isolates belonging to lineage 4.6.1 and lineage 2.2 have been demonstrated to be in 
genomic clusters with low SNV differences (section 5.4), implying that these genotypes are 
being transmitted within the study population. Transmission of these lineages is not only 
limited to one district but appears to occur across multiple districts and provinces (Figure 6.1; 
Figure 6.2A and B), implying that drug resistant TB strains are endemic across the country. 
However, there is need for further evaluation to investigate the extent of transmission of these 
strains in Zambia. The Beijing genotype (lineage 2.2) has been associated with diverse drug 
resistance profiles including XDR-TB and what is termed as “Totally Drug Resistant” 
(TDR)-TB in parts of the world including South Africa (36-39). This genotype has previously 
not been described in Zambia. In the current study, we have demonstrated that the Beijing 
genotype is associated with drug resistant TB in Zambia and of great concern is that the 
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lineage is associated with pre-XDR-TB and is further being transmitted in the study 
population. 
The lack of strains with mutations in the tlyA locus and the low level of rrs mutations in loci 
associated with second line resistance is encouraging as it demonstrates the usefulness of 
these second line drugs in the management of MDR-TB in the sampled patients. However, 
more extensive investigations are required to determine the extent of resistance to these 
critical second line anti TB drugs. Resistance to core anti TB drugs including rifampicin has 
been demonstrated to be high, raising concerns over the efficacy of the TB control program in 
managing both drug resistant and drug susceptible TB in Zambia. Mono-resistance to 
fluoroquinolones and streptomycin has been identified suggesting that the use of these key 
anti TB drugs in the treatment of other bacterial infections could possibly play a role in 
development of drug resistance in M.tb (40). 
Discordant phenotype and genotype findings are concerning as this would lead to 
inappropriate treatment regimens. Although biological factors may play a role in the 
discordant samples (e.g. underlying genetic heterogeneity), operational factors should be 
strongly considered. There is an urgent need to implement quality assurance measures such as 
the use of genotyping techniques alongside phenotypic DST and inter-laboratory quality 
assurance checks. For instance, 5 out of the 23 isolates scored as drug resistant at the TDRC 
TB reference laboratory were scored as susceptible at the Division of Molecular Biology and 
Human Genetics, Stellenbosch University, demonstrating a level of phenotypic over-scoring 
at the TDRC TB reference laboratory. However, heterogeneous variants have been identified 
through targeted gene sequencing in 3 strains (N068, N094 and N452) in the current study, 
providing a possible explanation for some of the discordant strains (25). A further 
Stellenbosch University  https://scholar.sun.ac.za
152 | P a g e  
 
consideration is not all drug resistance markers are identified by USAP, therefore some 
resistance-conferring mutations could have been missed. 
The high rate of rifampicin resistant cases observed in this study (82%; 119 strains with 
confirmed SNV out of 146 drug resistant strains) highlights the need for early case detection 
through the use of rapid diagnostic tools such as the GeneXpert MTB/RIF assay, whose 
usefulness in diagnosis of rifampicin resistance in a high HIV prevalence setting has been 
demonstrated (40). However, the observation of drug resistant strains with no phenotypic or 
genotypic rifampicin resistance suggests the need for some caution moving forward. Further, 
there is a need for specialised training and QC in the various centres offering the service in 
order to minimise on false positive and negative results. The high rate of mono-resistant 
strains (33%) is alarming and is possibly due to deficiencies in the TB control program; such 
as inadequate chemotherapy, poor adherence to treatment (12). The resistance-conferring 
mutations identified in the current study are in keeping with previous studies (3, 4, 7). There 
is a need to conduct extensive molecular typing studies to acquire further knowledge of how 
widespread drug resistant strains identified in the current study are across Zambia. This 
would be made feasible in cooperation with national drug resistance surveillance. 
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Chapter 7: Occupational risk of transmission of drug resistant TB in 
healthcare workers: knowledge, attitudes and practices. 
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7.1 Introduction 
Healthcare workers (HCWs) play a critical role in the management and control of nosocomial 
transmission of tuberculosis (TB) (1, 2). At the same time, working in TB health care 
facilities such as hospital wards, diagnostic and treatment facilities increases the risk of 
acquiring TB due to occupational exposure in HWCs (3, 4, 5). The risk is further heightened 
in high TB prevalence populations as HCWs are exposed both occupationally and in the 
community (6, 7). The prevalence of TB in HCWs has been demonstrated to be higher than 
that of the general population (3, 8). Globally, it is estimated that HCWs are three times more 
likely to acquire TB, while in high TB burden countries such as South Africa, estimates are as 
high as six times more than the general population (3, 8). There is however very scarce data 
on the occupational transmission of multidrug resistant (MDR)-TB and associated risk factors 
in health care facilities in Africa as a whole, mainly due to poor surveillance and reporting 
(1). Furthermore occupational exposure to MDR-TB is likely to be minimal in African 
countries that have not been treating MDR-TB or have recently begun treating MDR-TB (9), 
resulting in fewer cases of MDR-TB in HCWs. In Zambia for instance, there are no reliable 
estimates of the incidence of MDR-TB in HCWs. However in one study aiming to assess the 
feasibility of TB screening in HCWs at TB diagnostic and treatment facilities in Ndola 
district, the incidence of TB was estimated to be 1% in HCWs (10), lower than the estimated 
incidence of 6.5% in the general population for Ndola (personal communication with the 
Ndola district TB focal person). Furthermore, the study recommended establishing screening 
algorithms for HCWs in Zambia (10). 
The highest burden of MDR- and extensively drug resistant (XDR)-TB has been noted in 
resource-constrained countries, regions also experiencing a TB/HIV co-epidemic (11, 12). 
Infection with HIV has been associated with an increased risk of nosocomial transmission in 
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both HCWs and patients (3, 5, 13, 14). The increase in lifestyle diseases in Africa, such as 
diabetes mellitus, has also been demonstrated to be a further driver in progression of drug 
resistant TB in the general population and in HCWs (4, 14, 15). 
Critical knowledge gaps on infection control measures have been demonstrated in HCWs (14, 
15, 16). Infection control practices have been described to be influenced by staffing levels 
and patient load in TB health care facilities, with HCWs in high burden facilities being less 
likely to adhere to infection control practices (17, 18). 
The usefulness of molecular epidemiological tools in investigating nosocomial transmission 
of TB in HCWs and patients has been described (6, 7). For instance, in South Africa an 
endemic XDR-TB strain (designated F15/LAM4/KZN) has been described in patients and 
HCWs, placing emphasis on the transmission of these highly resistant strains in health care 
facilities (19, 20). The genotype was further associated with high mortality rates amongst 
HIV infected patients and HCWs (20). These investigations have demonstrated that both 
patients and HCWs are at an increased risk of acquiring TB in the health care facility more 
especially in the absence of infection control and prevention (IPC) measures (6, 7). While no 
such examples were identified in the current study, the lack of routine screening and lack of 
data on nosocomial transmission of drug resistant TB in health care workers warrants further 
studies. 
This chapter describes the knowledge, attitudes and practices (KAPs) of health care workers, 
towards IPC measures, at the Ndola Teaching Hospital (NTH) MDR-TB ward and the 
Tropical Diseases Research Centre (TDRC) TB reference laboratory in Ndola district. A self-
administered KAPs questionnaire which included 34 questions based on demographics (age, 
gender, profession and highest education level), knowledge of TB transmission, attitude 
towards IPC policies and IPC practices was developed in consultations with an IPC specialist. 
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7.2 National TB and Leprosy Control Program (NTLP) Zambia: TB infection 
prevention and control (IPC) guidelines 
The National TB and Leprosy Control Program (NTLP) in Zambia has prescribed guidelines 
to prevent the transmission of TB in the general population and in health care facilities (21). 
The guidelines define three core TB IPC measures centred on administration, environmental 
controls and the use of personal protective equipment (PPE) for all HCWs working in TB 
health care facilities (21). Administrative controls include the provision of up to date IPC 
policies, continuous staff training, patient education and community awareness as well as 
integration of HIV/TB care programs (21). Environmental control measures include safe 
sputum collection practices such as establishing designated sputum collection points 
preferably outdoors, increasing natural ventilation in congregate areas and the provision of 
high efficiency particulate air (HEPA) filters as well as ultraviolet germicidal irradiation (21). 
(21). The PPE recommended to be important in minimising exposure to aerosols containing 
bacilli consists of N95 masks/respirators, water proof laboratory gowns, disposable overshoes 
and gloves (21). 
Despite these clear guidelines, personal observations during sample collection and initial 
processing for this study however suggested deficiencies in IPC practices at the TDRC TB 
reference laboratory and the NTH MDR-TB ward. Improper IPC practices observed included 
lack of full PPE during sample processing and patient consultation. In some cases, HCWs 
were observed using surgical masks instead of N95 masks. It is in this light that the study was 
developed with the aim of providing some preliminary knowledge on barriers to adhering to 
TB IPC recommendations. The information gathered in this study will guide larger future 
studies. 
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7.3 Data capture and analysis 
The study assessed the knowledge, attitudes and practices of HCWs through a self-
administered questionnaire which was designed in consultation with an IPC specialist, Dr 
Dramowski, Department of Paediatrics and Child Health Stellenbosch University. The survey 
questions were developed using previously described methods from published studies and 
based on guidelines from the World Health Organisation (WHO) and the NTLP guidelines (1, 
17, 18, 21). The questionnaire included 32 multiple choice questions and 2 open ended 
questions based on demographics (age, gender, profession, service length in current 
employment and highest education level), knowledge of TB transmission, attitude towards 
IPC policies and IPC practices (appendix 3). 
Six out of nine HCWs at the TDRC TB reference laboratory were available to participate in 
the survey, one was on study leave and two were out of station at the time of data collection. 
Five out of eight HCWs participated in the survey at the NTH MDR-TB ward, two HCWs 
were not willing to participate and one was unavailable at the time of data collection. Eight 
HCWs preferred to answer the questionnaire privately and gave a date for collection of 
answered questionnaires, while three participants required assistance with entry and 
descriptions. The captured data was entered and analysed in Microsoft excel. 
 
7.4 Characteristics of health care workers that participated in the survey 
Eleven out of 17 health care workers, 5 from the NTH MDR-TB ward and 6 from the TDRC 
TB reference laboratory, gave consent to participate in the survey in September 2017. The 
participants included 3 scientists, 3 nurses, 1 laboratory assistant, 1 data entry clerk and 3 
cleaners (Table 7.1). The highest levels of education were 1 postgraduate degree (scientist) 
and 2 undergraduate degrees (scientists) and 4 diploma holders (3 nurses and 1 data entry 
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clerk), while the lowest level of education was grade 12 secondary school education (1 
laboratory assistant and 3 cleaners). All participants at the NTH MDR-TB were female while 
there were 67% males and 33% females at the TDRC TB reference laboratory. The age range 
for participants was between 25 and 63 years and the longest serving HCW had served for 26 
years at the TDRC TB reference laboratory. At the time of the study, there were no students 
on attachment at the two institutions. The laboratory manager of the TDRC TB reference 
laboratory and the clinician in charge of the NTH MDR-TB ward were unavailable to 
participate in the survey. 
Table 7.1: Characteristics of health care workers that participated in the IPC 
knowledge, attitudes and practices survey. 
 TDRC TB reference laboratory 
(%) 
NTH MDR-TB ward (%) 
Gender: 
Male 
female 
 
4 (67%) 
2 (33%) 
 
- 
5 (100%) 
Age: 
25-35 
36-45 
46-55 
56-65 
 
2 (33%) 
3 (50%) 
1 (17%) 
- 
 
- 
1 (20%) 
2 (40%) 
2 (40%) 
Highest level of education: 
Postgraduate degree 
Undergraduate degree 
Diploma 
Secondary education (G12) 
 
1 (17%) 
2 (33%) 
1 (17%) 
2 (33%) 
 
- 
- 
3 (60%) 
2 (40%) 
Profession: 
Scientist 
Nurse 
Laboratory assistant 
Data clerk 
Cleaner  
 
3 (50%) 
- 
1 (17%) 
1 (17%) 
1 (17%) 
 
- 
3 (60%) 
- 
- 
2 (40%) 
Number of years in service: 
>5 
6 – 10 years 
11 – 20 years 
21 – 30 years 
 
- 
4 (66.6%) 
1 (16.7%) 
1 (16.7%) 
 
1(20%) 
2 (40%) 
2 (40%) 
- 
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7.5 Knowledge, attitudes and practices of healthcare workers towards IPC practices 
7.5.1 Knowledge of TB and symptoms 
Assessment of TB knowledge indicates that all participants identified chronic cough and 
night sweats as symptoms suggestive of TB (Table 7.2). Eighty-two percent associated 
weight loss as a symptom suggestive of TB while 73% identified coughing up blood and 
fever as symptoms suggestive of TB. A further 64% identified weakness and chest pains as 
symptoms suggestive of TB. HIV was identified as a predisposing factor for TB by all 
participants while only 18% (MDR-TB ward nurses) identified both HIV and diabetes as 
predisposing factors. At birth M. bovis Bacillus Calmette–Guérin (BCG) vaccination was 
reported as not protective in adult TB by 73% of participants, 27% indicated that at birth 
BCG vaccination was protective against adult TB. 
The knowledge of treatment length for drug susceptible and MDR/RR-TB was generally high 
amongst HCWs, 82% and 73% respectively, and 91% for knowledge of whether both forms 
of TB have similar routes of transmission. Two HCWs (cleaners) had not heard of XDR-TB 
and one indicated that MDR-TB was not as infectious as drug susceptible TB. Most gaps in 
knowledge were seen in cleaners, and this could be due to the lack of formal training in 
health sciences and TB IPC practices. This highlights the need to provide TB IPC training for 
all HCWs, including cleaners, that are in direct contact with patients or working in laboratory 
facilities. 
 
7.5.2 Infection prevention and control training 
All participants reported to have received TB IPC training with the majority (73%) stating 
that TB IPC training was conducted during induction at the start of the current employment 
(Table 7.2). Only three participants, scientists from the TDRC TB reference laboratory, 
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reported to have received TB IPC training after induction, two participants on the 5
th
 of May 
2017 and one in 2015. It is concerning that HCWs from the NTH MDR-TB ward and non-
scientists at the TDRC TB reference laboratory did not participate in TB IPC training 
subsequent to that provided at induction. 
7.5.3 TB screening and use of personal protective equipment (PPE) 
All participants from the TDRC TB reference laboratory were screened for TB at the start of 
employment while three participants (one nurse and two cleaners) from the NTH MDR-TB 
ward were not screened at the start of the current employment (Table 7.2). All participants 
reported that they had not received annual TB screening due to the service not being provided 
for by their institution, although all were willing to receive annual TB screening. 
Participants were further assessed on the use of PPE, 82% of participants reported that their 
institution provided N95 masks while 18% were unsure (Table 7.2). The majority of 
participants (64%) reported that they always used N95 masks during sample processing and 
patient consultation, while 36%, from the NTH MDR-TB ward, reported periodic use of N95 
masks. The lack of ongoing TB IPC training at the NTH MDR-TB ward could explain the 
inconsistencies observed in the use of PPE by the HCWs at the MDR-TB ward and calls for 
frequent IPC training for HCWs. All participants reported not having received any fit testing 
for N95 masks. Assessment of HCWs attitudes towards TB IPC measures revealed that all 
participants were willing to receive TB and HIV screening if they had symptoms suggestive 
of TB. All participants indicated that they would be willing to disclose to their family and 
work colleagues if they were diagnosed with TB. 
All HCWs that participated in the study indicated that indoor sputum collection areas were 
high risk areas for TB transmission and outdoor sputum collection areas were low risk 
transmission areas, this implies that the assessed HCWs have adequate knowledge on the 
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need for good ventilation as a TB IPC measure. A high proportion of HCWs (82%) showed 
knowledge that wards and consultation rooms were high risk areas for transmission of TB, 
this is possibly due to the ongoing campaign using “Stop TB keep doors open” stickers which 
encourages keeping doors and windows open at all times to allow for adequate air circulation. 
There are lessons to be learned from the efficiency of this campaign which has translated 
noticeable stickers in both English and vernacular languages at the various TB diagnostic and 
treatment facilities in Zambia. 
Close to half of the participants indicated that the specimen processing laboratory was not a 
high risk area for transmission of TB (Table 7.2). An explanation for this could be 
complacency on the part of HCWs with the lack of direct contact with patients being deemed 
safer. 
In conclusion, 82% of HCWs indicated that TB IPC practices were well implemented in their 
workplace, despite observed practices. Response bias is a possible limitation to the study. 
When asked about factors which make their work place unsafe 67% of laboratory personnel 
indicated that manipulation of live cultures made their work place unsafe and 40% of 
personnel at the MDR-TB ward (nurses) indicated that lack of staff rotation and low staffing 
levels made their work place unsafe as other nursing staff were unwilling to work at the 
MDR-TB ward in preference for lower risk hospital departments and wards. 
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Table 7.2: Knowledge, attitude and practices of HCWs at the NTH MDR-TB ward and 
the TDRC TB reference laboratory. 
 Yes 
Number of 
participants 
(%) 
No 
Number of 
participants 
(%) 
Not sure 
Number of 
participants 
(%) 
Prior TB diagnosis:  - 11 (100%) - 
Most recent TB IPC training in current job: 
Less than 6 months ago 
2 years ago 
At induction 
None received 
- 
2 (18%) 
1 (9%) 
8 (73%) 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Knowledge of symptoms suggestive of TB: 
Chronic cough 
Fever 
Weight loss 
Chest pains 
Night sweats 
Weakness 
Coughing up blood 
 
11 (100%) 
8 (73%) 
9 (82%) 
7 (64%) 
11 (100%) 
7 (64%) 
8 (73%) 
 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
Predisposing factors for TB: 
HIV 
Diabetes 
Not sure 
 
11 (100%) 
2 (18%) 
- 
 
- 
- 
- 
 
- 
- 
- 
Does birth BCG vaccine prevent TB in adults? 3 (27%) 8 (73%) - 
High risk areas for TB transmission: 
Wards 
Sputum collection rooms 
Specimen processing laboratory 
Consultation office 
Outdoor sputum collection area 
 
9 (82%) 
11 (100%) 
5 (45%) 
9 (82%) 
- 
 
2 (18%) 
- 
5 (45%) 
2 (18%) 
11 (100%) 
 
- 
- 
1 (9%) 
- 
- 
Are N95 masks provided for by institution? 9 (82%) - 2 (18%) 
Use of N95 masks when in contact with patients 
or during sample processing: 
Always 
Sometimes  
Has fit testing been done for current N95 mask? 
 
 
7 (64%) 
4 (36%) 
- 
 
 
- 
- 
11 (100%) 
 
 
- 
- 
- 
TB Screening: 
At the start of employment 
Annual screening 
Annual screening not done due to service not 
being offered by employer 
 
8 (73%) 
- 
11 (100%) 
 
3 (27%) 
11 (100%) 
- 
 
- 
- 
- 
Elective screening if TB suspected 
Elective HIV testing if TB suspected 
Willing to inform family, colleagues and manager 
if diagnosed with TB 
 
11 (100%) 
11 (100%) 
11 (100%) 
 
- 
- 
- 
 
- 
- 
- 
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Table 7.2 (Continued) 
 Yes 
Number of 
participants 
(%) 
No 
Number of 
participants 
(%) 
Not sure 
Number of 
participants 
(%) 
Knowledge of treatment length for drug sensitive 
TB 
Knowledge of treatment length for MDR/RR-TB 
Is MDR-TB as infectious as drug susceptible TB? 
Does MDR-TB spread the same way as drug 
susceptible TB? 
Are MDR-TB symptoms similar with drug 
susceptible TB symptoms? 
Knowledge of XDR-TB 
9 (82%) 
 
8 (73%) 
10 (91%) 
11 (100%) 
 
10 (91%) 
 
9 (82%) 
- 
 
1 (9%) 
1 (9%) 
- 
 
1 (9%) 
 
2 (18%) 
2 (18%) 
 
2 (18%) 
- 
- 
 
- 
 
- 
Abbreviations: BCG, M. bovis Bacillus Calmette–Guérin; IPC, Infection Prevention Control; 
MDR, multidrug resistant; NTH, Ndola Teaching Hospital; TB, tuberculosis; TDRC, 
Tropical Diseases Research Centre; XDR, extensively drug resistant. 
 
7.6 Conclusion 
Transmission of drug resistant TB strains in healthcare facilities is driven by several factors 
centred on lack of adherence to TB IPC practices, and in some cases the lack of existing IPC 
policies (1, 11). This is reflective of a poor TB national control program (1, 11). Effective 
administrative IPC measures require the development of policies and administrative support 
to ensure adherence to the established policies (1, 2). These administrative support measures 
include staff training and retraining, patient and community education, provision of 
mandatory PPE to staff and affected patients, and annual TB screening of HCWs (1, 2, 10). 
These measures together with environmental measures have been described as being effective 
in the management and control of TB (1).  
In the current study, all HCWs indicated that they received TB IPC training with most (73%) 
reporting that training was received only during induction at the beginning of employment. 
This is concerning since most HCWs that participated in this study have served in their 
current employment for more than 5 years. Further, HCWs that reported training within the 
past 6 months were all scientists implying that HCWs with lower qualifications do not 
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receive ongoing IPC training. It is therefore recommended that HCWs at all levels be 
included in annual TB IPC trainings including cleaners (22), who are less knowledgeable but 
play a critical role in management of drug resistant TB. 
There is strong evidence that additional administrative support is required to implement TB 
IPC policies in the management of drug resistant TB (1, 2, 23, 24). For instance, all HCWs 
had not received prior fit testing for N95 masks that were in use. This means that there is an 
increased risk of acquiring TB in the work place as HCWs are not adequately protected due 
to poorly fitting masks (25, 26). Variation in knowledge has been demonstrated which can be 
attributed to the different levels of education. There was a low level of knowledge of diabetes 
being a predisposing factor for TB, with only nurses indicating this point. This could be 
suggestive of the differences in training curriculum and patient exposure. This highlights the 
need to incorporate these gaps in curriculum into TB IPC training modules (27).   
The absence of routine monitoring of these critical personnel has serious implications for 
transmission of drug resistant TB. There is a need to implement annual screening and routine 
TB IPC training. In the current study, it has been demonstrated that barriers for adhering to 
TB IPC practices in this group of HCWs are mainly due to the lack of administrative support. 
The HCWs that participated in this study have demonstrated willingness to implement TB 
IPC practices with the necessary administrative support in place. Overall HCWs had a good 
attitude towards participating in the survey and knowledge of TB symptoms was generally 
high. Key areas of improvement are the lack of administrative support mainly centred on 
provision of fit testing for N95 masks and annual TB screening for all HCWs. Transmission 
of MDR-TB and pre-XDR-TB has been identified in the study population (discussed in 
section 6.4.2) and these patients have received care and continue to receive care from HCWs 
at the NTH MDR-TB ward and the TDRC TB reference laboratory. The risk of transmission 
Stellenbosch University  https://scholar.sun.ac.za
171 | P a g e  
 
of these drug resistant strains to HCWs is heightened in the absence of adequate IPC 
measures. 
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Chapter 8: General conclusion 
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8.1 Summary of findings 
The current study used molecular strain typing tools, including spoligotyping, IS6110-RFLP, 
whole genome sequencing (WGS) and Sanger (targeted gene) sequencing to describe the 
genetic characteristics of drug resistant Mycobacterium tuberculosis (M.tb) isolates diagnosed 
at the Tropical Diseases Research Centre (TDRC) TB reference laboratory in Ndola district, 
Zambia. The centre provides culture based phenotypic drug susceptibility testing (DST) to 
the first line drugs streptomycin, isoniazid, rifampicin and ethambutol (SIRE) to patients 
from the catchment area; Copperbelt, Luapula and North-Western provinces. Furthermore, an 
assessment of the knowledge, attitudes and practices (KAPs) of health care workers (HCWs) 
at the TDRC TB reference laboratory and the Ndola Teaching Hospital (NTH) multidrug 
resistant (MDR)-TB ward was conducted with the aim of identifying barriers in adhering to 
TB infection prevention and control (IPC) measures. 
The current study identified a high level of genetic diversity amongst drug resistant TB 
strains diagnosed at the TDRC TB reference laboratory. The majority of strains belong to 
lineage 4 (LAM11_ZWE, T and X), discussed in section 4.3, which have previously been 
associated with drug susceptible TB in Ndola district and the surrounding region (1, 2). This 
implies that drug susceptible strains are probably evolving to become resistant in the study 
population. Other lineages associated with drug resistant TB were lineage 2 (Beijing and non-
Beijing SIT 955) and lineage 3 (CAS1-Kili and Manu3), section 4.3. The lineage 2 genotype, 
which has previously not been described in Zambia, has been associated with MDR- and 
extensively drug resistant (XDR)-TB across the world and transmission of these strains has 
been documented in parts of Africa (3, 4, 5). There is a need for further investigations to 
determine the extent of transmission of these lineage 2 strains in Zambia and the surrounding 
region. 
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The current study demonstrated that genotypes that are driving drug resistant TB are 
widespread across the sampled districts in Zambia (section 4.2). A high degree of clustering 
amongst drug resistant TB strains was demonstrated using spoligotyping and IS6110-RFLP 
suggestive of recent transmission (section 4.4). Whole genome sequence analysis further 
demonstrates the level of strain relatedness with some clustered strains sharing low single 
nucleotide variant (SNV) differences, as low two SNVs in some genomic clusters (section 
5.6). Patients with clustered strains have been demonstrated to originate from the same 
districts and in some cases from different districts, highlighting how widespread these drug 
resistant strains and their transmission could be in Zambia.  
Alarmingly, transmission of pre-XDR-TB was identified in the current study, which provides 
a first preliminary insight into the genotypes associated with pre-XDR-TB in Zambia (section 
6.6). The predominant genotypes associated with pre-XDR-TB in the study population are 
lineage 4.6.1 (Uganda), lineage 2.2 (Beijing clade) and lineage 4.3 (LAM). Household 
transmission was also demonstrated, placing emphasis on the need for routine contact tracing 
and screening of MDR-TB/rifampicin resistant TB contacts (section 5.7). Contact tracing 
would improve MDR/RR-TB case detection and allow for early quarantine; this should be 
de-centralised to district or provincial level allowing patients easier access to health care. The 
current MDR/RR-TB quarantine does not protect the community well enough as MDR/RR-
TB patients are usually expected to travel long distances (over 900 km in some cases) for 
admission and review at the NTH MDR-TB ward and in most instances patients rely on 
public transport, placing unknowing passengers at risk of TB infection.  
Quarantine of MDR/RR-TB patients in the absence of IPC measures poses a serious risk of 
nosocomial transmission to patients and HCWs (6). Previous studies have demonstrated that 
lack of adherence to TB IPC practices is a major driver of nosocomial transmission of drug 
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resistant TB and TB in general (6, 7). Low adherence to TB IPC practices, such as improper 
use of personal protective equipment, low knowledge of TB IPC measures and lack of 
continuous IPC training has been observed amongst health care workers at the MDR-TB 
facilities in Ndola district (section 7.5). Knowledge gaps have been observed to be higher in 
HCWs with informal training such as cleaners. And it has further been demonstrated that IPC 
trainings are not inclusive to all HCWs with laboratory scientists having more opportunities 
to attend trainings than nurses and other groups of health care workers. This calls for changes 
to the current TB IPC policy in Zambia to enable frequent IPC trainings that are inclusive of 
all HCWs. Improved administrative support, such as provision of annual TB screening and fit 
testing for N95 masks, is required to prevent transmission of drug resistant TB strains in 
HCWs at the MDR-TB facilities. 
Weaknesses have been identified in the TB control program which could be impacting on TB 
IPC and transmission in Zambia. For instance, a large proportion of patients in the current 
study had failed treatment (47%), 22% of these patients failed retreatment raising concerns 
that patients are being provided with an inappropriate treatment regimen or patients are not 
adhering to treatment, resulting in resistance (section 4.2, Supplementary Table 1). Patients 
should therefore be subjected to routine DST before commencement of treatment. 
In the current study, the incidence of pre-XDR-TB amongst MDR-TB patients (9%) is 
comparable with WHO estimates (9.5%) suggesting that the current MDR-TB regimen is not 
entirely efficient in treating MDR-TB in Zambia, section 6.6.2, (8). This places further 
emphasis on the need for routine second line drug susceptibility testing to monitor treatment 
response and trends in drug resistance. From the eight pre-XDR-TB cases identified, 37.5% 
were receiving second line treatment at the time of data collection, 25% had completed 
treatment, and a further 25% had died while on treatment. Of concern is that 12.5% of these 
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cases had an unknown treatment status and were lost to follow up by the NTLP (section 
6.6.1). 
High rates of resistance to other first line drugs pyrazinamide and ethambutol have been 
demonstrated in the current study. Of great concern is the drug resistance rate (11%) to 
pyrazinamide which plays an important role in management of MDR-TB in Zambia (9). 
Currently there is no routine DST for pyrazinamide in Zambia; therefore patients are likely to 
be placed on an inappropriate treatment regimen (10, 11). 
Concerns have arisen over the management of MDR-TB patients with a proportion of 
patients being lost to follow up (3%) and not being enrolled on second line treatment (7%), 
similar to trends observed in a previous study in Zambia (12). The current patient clinical 
records archiving system, which is paper based, poses a high risk of loss of data and does not 
allow adequate transfer of records between health care facilities. Furthermore, there are gaps 
in knowledge with registers not being completely filled. In the current study, there were gaps 
in all variables that were assessed, for instance the HIV status for 26% of patients was not 
recorded (section 4.2). There is a pressing need to implement an isolate and record banking 
system for all drug resistant TB strains at referral level. This would allow for future 
molecular studies to be conducted and provide a better insight into the transmission dynamics 
of drug resistant TB in Zambia. The current study has demonstrated that drug resistant strains 
of TB are being transmitted in Zambia. This places emphasis on the need for routine 
surveillance to monitor drug resistance trends which will inform treatment and management 
of drug resistant TB in Zambia. 
 The usefulness of genotyping tools in understanding M.tb transmission events has been 
demonstrated in the current study. Overall WGS provides a superior level of understanding 
strain relatedness and investigating resistance-conferring mutations in M.tb, compared to 
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IS6110-RFLP and spoligotyping. Spoligotyping has been demonstrated to be important in 
differentiating LCCs while RFLP provides a good resolution of strains, other than LCCs. 
These techniques are therefore recommended for future studies in Zambia. There is an urgent 
need to build in-country capacity to enable molecular investigations to be conducted locally. 
This would require laboratory capacity and training of laboratory and research personnel and 
would be achieved through local and international funding. 
 
8.2 Limitations 
The case detection rate for MDR-TB is low in Zambia, 13% according to WHO (8). This 
means that there is a high proportion of undetected MDR-TB in the country and a possible 
underestimation of transmission of drug resistant TB in the current study. In order to improve 
case detection, there is need for the National TB and Leprosy Control Program (NTLP) in 
Zambia to initiate active case finding through universal DST for all TB patients, and an 
integration of HIV and TB care services which would encourage early case detection. 
Universal DST would however require increasing diagnostic capacity at the three TB 
reference laboratories that are currently offering first line DST. 
Several operational errors were observed during sample processing, data capture and analysis 
which could impact the findings in the current study. For instance, discordant phenotypes and 
genotypes could lead to some drug resistant genotypes being missed since the sampling 
process relied up phenotypic DST findings to select only samples that were phenotypically 
resistant. Discordant phenotype and genotype findings (described in section 6.5) are 
concerning and could imply that patients are being over treated. However, the Universal 
Sequence Analysis Pipeline (USAP) used for WGS analysis in this study does not identify all 
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resistance-conferring mutations, therefore it is highly likely that some resistance-conferring 
mutations were missed. 
Gaps in data were observed in the TB registers at the TDRC TB reference laboratory and the 
NTH MDR-TB ward, a challenge which stems from clinic level with clinicians and nurses 
not always completely filling in patient request forms. This calls for an electronic medical 
records system accessible by all TB diagnostic and treatment centres, similar to the 
“SmartCard care” system currently available for HIV management in Zambia (13). There is 
also a need to collect epidemiological data in order to strengthen molecular findings.  
A poor specimen banking system at the TDRC TB reference laboratory meant that only a few 
strains with corresponding clinical records were revived for genotyping. This means that a 
wealth of genotype information has been lost for strains that have been associated with drug 
resistant TB in the past for the study population resulting in underestimation of transmission 
and genetic variability. There is a need to implement a reliable specimen backing system for 
drug resistant strains diagnosed at the TDRC TB reference laboratory which will allow future 
molecular studies to provide a better understanding of the transmission dynamics of drug 
resistant TB and TB in general in Zambia. 
 
8.3 Future research 
To address the operational errors observed in the current study, we aim to compare culture-
based phenotypic findings with genotype over a prolonged period of time at the TDRC TB 
reference laboratory and inter-laboratory comparisons will be made with standard operating 
procedures. Further, recommendations will be made for retraining and quality control 
measures such as equipment calibration and assessment of contamination will be emphasised. 
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In order to get a better understanding of the transmission dynamics of drug resistant TB in 
Zambia as a whole, countrywide molecular typing of drug resistant M. tuberculosis strains 
will need to be conducted. However to provide a better representation of the transmission 
dynamics of drug resistant TB in Zambia, there is a need for active case finding. A pilot study 
is therefore proposed to screen contacts of MDR-TB patients in Zambia and from there 
determine the incidence of MDR-TB amongst contacts, in relation to strain relatedness. 
An expansion on the findings reported in the current study (chapter 7) aiming to investigate 
the knowledge, attitudes and practices of health care workers towards TB infection 
prevention and control measures is recommended. It is envisioned that such a study will 
sample a larger cohort of health care workers and will be inclusive of diagnostic and 
treatment centres offering services to patients with drug susceptible TB. Furthermore, 
nosocomial transmission of TB should be investigated with a particular focus on health care 
workers. The study will also aim to estimate the incidence of latent TB infection amongst 
health care workers. 
Currently, there is little to no information on the role of migration on transmission of drug 
resistant TB strains in Zambia. The current study was unable to identify strain relatedness 
between drug resistant strains belonging to lineage 2.2 (Beijing genotype) identified in the 
study with strains of the same lineage from Cape Town, South Africa (section 5.8).  
Therefore we aim to assess the role of migration in transmission of drug resistant M. 
tuberculosis strains, through collaborative studies with neighbouring countries in the region. 
Molecular typing methods will be used to assess strain relatedness amongst drug resistant M. 
tuberculosis strains identified in neighbouring countries and Zambia. 
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8.4 Conclusion 
In the current study we have demonstrated that diverse genotypes are associated with drug 
resistant TB in parts of Zambia. Genotypes previously associated with drug susceptible TB 
have been identified to be driving drug resistant TB implying that these genotypes are 
evolving to become resistant. This is reflective of a weak national TB control program. Pre-
XDR-TB has been identified in the current study with an incidence of 9% amongst MDR-TB 
patients, comparable to WHO estimates of 9.5%. The presence of pre-XDR TB in the study 
population is concerning as it suggests that the current MDR-TB regimen and management is 
not efficient in the treatment of MDR-TB.  
Alarmingly, these forms of drug resistant TB are being transmitted in the study population 
with molecular typing techniques demonstrating clustering of these strains. Furthermore, 
WGS analysis has revealed low single nucleotide variant differences, as low as 2 in some 
clustered strains. Sanger (targeted gene) sequencing of genes associated with drug resistance 
has further revealed that some clustered strains have similar drug resistance conferring 
mutations, implying transmission of these strains. The current study has provided a first 
insight into the genetics of drug resistant TB strains in circulation in Zambia. These findings 
add to the gaps in knowledge for Zambia and Africa as a whole. 
 
8.5 Summary of contributions 
My contributions to this study included: 
1. Protocol development  
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2. Obtaining necessary ethical approval from the TDRC ethics committee, the Health 
Research Ethics Committee Stellenbosch University and the National Health Research 
Authority at the Ministry of Health Zambia; 
3. Obtaining approval to collect samples and access clinical data from the Ministry of 
Community Development Mother and Child Health, the Ndola District Medical Office 
and the Ndola Teaching Hospital management; 
4. Study design and proposal development; 
5. Development of a TB infection, prevention and control (IPC) questionnaire; 
6. Sample and clinical data collection; 
7. Experimental work: M. tuberculosis culturing, DNA isolation, spoligotyping, IS6110 
typing and targeted gene sequencing; 
8. Data analysis and interpretation; 
9. Thesis write up and editing 
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Appendices 
Appendix 1: PCR primers and melting temperatures for the amplification of genetic 
elements 
Primer name Primer sequence Tm (ºC) Target Product size (bp) 
DRa (reverse) GGTTTTGGGTCTGACGAC  
55 
Direct repeat 
(DR) sequence 
Varied 35 to 41 
DRb (Forward) CCGAGAGGGGACGGAAAC 
RTB 59 TGGCCGCGGCGGTCGACATT 78  
rpoB 
 
437 RTB 38 GGTCAGTGGCCAGCATCGTC 76 
inhA P5 CGCAGCCAGGGCCTCGCTG  
55 
 
inhA promoter 
 
246 inhA P3 CTCCGGTAACCAGGACTGA 
emb 151 TCCACAGACTGGCGTCGCTG  
64 
 
embB 
 
260 emb 131 TCCACAGACTGGCGTCGCTG 
rrs290F TGCTACAATGGCCGGTACAA  
62 
 
rrs 
 
290 rrs290R CTTCCGGTACGGCTACCTTG 
pncAF GGCGTCATGGACCCTATA  
60 
 
pncA 
 
700 pncAR GTGAACAACCCGACCCAG 
gyrA For TGACATCGAGCAGGAGATGC  
62 
 
gyrA 
 
344 gyrA REV GGGCTTCGGTGTACCTCATC 
rrs290 F TGCTACAATGGCCGGTACAA  
62 
 
rrs 
 
290 rrs290 R CTTCCGGTACGGCTACCTTG 
tlyA F CTGGAGTCGGCGGAGAAG  
62 
 
tlyA 
 
871 tlyA R GGACGACCAGCAGAACACTG 
Abbreviations: DR, direct repeat; Tm, melting temperature. 
Appendix 2: M. tuberculosis genomes included in phylogenetic analysis 
Isolate name Accession number Original study 
T92 SRX003589 1 
T17 SRX005394 1 
95_0545 SRX007721 1 
K21 SRX002001 1 
K67 SRX002004 1 
K93 SRX002005 1 
T67 SRX007715 1 
T85 SRX003590 1 
00_1695 SRX007716 1 
98_1833 SRX007718 1 
M4100A SRX007719 1 
91_0079 SRX007720 1 
K49 SRX002002 1 
GM_1503 SRX012272 1 
4783_04 SRX007723 1 
K37 SRX002003 1 
M. canetti SRX002429 1 
HN878_27 PRJNA242362 2 
M.bovis (ravenel) SRR022532 SRA EBI Animal 
Mt257 ERR181435 3 
H37Rv ERS153830 4 
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Appendix 3: Knowledge, attitudes and practices questionnaire: occupational 
transmission of MDR-TB in health care workers. 
The following questionnaire aims to determine the knowledge, attitudes and practices of 
health care workers at the Ndola Teaching Hospital (NTH) MDR-TB ward and the Tropical 
Diseases Research Centre (TDRC) TB reference laboratory towards drug resistant TB 
infection prevention and control (IPC) measures. The study has been cleared by the TDRC 
ethics committee (ethics number: TDRC STC 2015/9) as part of a larger study which aims to 
characterise the genetics of drug resistant tuberculosis in Ndola. If you have any further 
queries concerning ethical approval of this study please contact the ethics secretary at TDRC 
on the 6
th
 floor of the NTH.  
Attached is a self-administered questionnaire which will take approximately 15 minutes to 
complete. Should you require assistance with filling in this questionnaire, please feel free to 
ask the researcher/assistant. You are required to answer the questions fully and with sincerity. 
There will be no personal identifying information used. By filling in this questionnaire you 
have demonstrated your willingness to take part in this study. Findings from this study will be 
disseminated to IPC policy makers and recommendations will be made for key areas of 
training and safety measures.  
 
 
Questionnaire 
Gender: Male  Female   Age: 
Profession: Doctor  Scientist Laboratory technologist  Nurse  
  Data entry clerk Cleaner Other (specify) 
Stellenbosch University  https://scholar.sun.ac.za
189 | P a g e  
 
Highest level of education:  
Secondary education (up to G9)    Secondary education (G12)  Diploma 
Undergraduate degree  Postgraduate degree 
Number of years in service:  
Have you been diagnosed with active TB disease in the past?  Yes  No 
Have you received training on TB infection prevention and control in your current job? 
Yes  No 
If yes, how long ago was the training?  
What type of training was received? In-service  Lecture Course 
Induction at start of employment  Other (specify)  
Which of the following would you consider to be symptoms suggestive of active TB? 
Chronic cough Fever  Weight loss  Chest pains   
Night sweats  Weakness  Coughing up blood  Not sure 
Which of the following would you consider to be predisposing factors for TB disease? 
HIV  Diabetes  Not sure  Other (specify) 
 
Does birth vaccination with BCG prevent TB in adults? 
Yes  No  Not sure 
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Which of the following do you consider to be high risk areas for transmission of TB: 
Wards  Sputum collection rooms  Specimen processing laboratory 
Consultation office/station  Outdoor sputum collection area  
Other (specify)  
Are N95 respirators (masks) provided by your institution? (Refer to attachment for 
pictures of a surgical mask & N95 mask)   Yes  No  Sometimes 
Do you use N95 respirators (masks) when in contact with TB patients and/or when 
processing specimens?  
 Always     Sometimes  No  I use surgical masks 
If no, what are your reasons? 
If yes, have you received fit testing for the mask type you are currently using?  
Yes  No 
If yes, how long ago? Less than 2 years  2-5 years  5 years + 
Were you screened (x-ray, smear microscopy, culture, tuberculin skin test) for TB at the 
start of your current job? Yes  No 
Do you receive annual TB screening?     Yes  No     sometimes 
If no, why not? I do not want to be screened  service is not offered         
 Other (specify)  
Would you receive screening if you had symptoms suggestive of TB?  
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Yes  No  Not sure 
If diagnosed with TB, would you be willing to test for HIV?  
Yes  No  Not sure 
Would you tell your family if you were diagnosed with TB?   
Yes  No  Not sure 
Would you tell your manager/supervisor if you were diagnosed with TB?   
Yes  No  Not sure 
Would you tell your work colleagues if you were diagnosed with TB?   
Yes  No  Not sure 
If no, why not?  
What is the recommended treatment length for drug sensitive TB in Zambia? 
1 month  3 months  6 months   until a patient is culture 
or/and smear negative  Until a patient feels better  Not sure  
Which of the following is the recommended treatment length for MDR-TB in Zambia? 
6 months  12 months  20 months +  until a patient is culture 
or/and smear negative  Until a patient feels better  Not sure  
Do you think MDR-TB is as infectious as drug sensitive TB?  
Yes  No  Not sure 
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Dose MDR-TB spread the same way as drug sensitive TB? 
Yes  No  Not sure 
Are MDR-TB symptoms similar to drug sensitive TB symptoms? 
Yes  No  Not sure 
Have you heard of extensively drug resistant (XDR)-TB? 
Yes  No 
How well do you feel TB-IPC is implemented at your workplace?  
What are the factors that make your workplace an unsafe working environment for TB 
transmission?  
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